

Original research by: Doug Henderson, J.D.

TITLE	DESCRIPTION	YEAR	Settlement or verdict amount
Pfizer Inc. (PFE) (JOBS) to Pay \$2.3 Billion to Settle Marketing Charges	Pfizer have agreed to pay \$2.3 billion, the largest health care fraud settlement in the history of the Department of Justice, to resolve criminal and civil liability arising from the illegal promotion of certain pharmaceutical products, the Justice Department announced today.	2009	2,300,000,000.000
Polio Vaccine Victim Wins Lawsuit Against Big Pharma	A New York jury has concluded that pharmaceutical company Lederle Laboratories was responsible for the injury to a man who contracted polio from a vaccine 30 years ago, and ordered it to pay him \$22.5 million.	2009	22,500,000.000
Pfizer Pays \$60 Million to Settle Unlawful Marketing of Drugs	A settlement has been reached between Pfizer and 34 states over the unlawful marketing of 2 prescription pain medicines - Bextra and Celebrex. The settlement, according to media reports, includes a \$60 million pay out, and the stipulation that the drug company submit all 'direct to consumer' TV ads to the FDA for review, prior to the advertisement launching.	2009	60,000,000.000
Pfizer, Pharmacia Found Guilty of Medicaid Fraud	Pharmacia, a subsidiary of the pharmaceutical company Pfizer, was found guilty by a Wisconsin jury yesterday of repeatedly committing Medicaid fraud with the state.	2009	153,000,000.000

Pfizer Reaches Tentative Bextra and Celebrex Settlements of \$894 Million	Pfizer Inc announced today that it has reached agreements in principle to resolve substantially all of the personal injury cases, consumer fraud cases and state attorneys general claims involving its non-steroidal anti-inflammatory (NSAID) pain medication Bextra, which Pfizer voluntarily withdrew from the U.S. market in 2005.	2009	894,000,000.000
Pfizer Inc. (PFE) (JOBS) Pays \$17 Million to Resolve Venezuela Tax Claim	Drug maker Pfizer's Venezuelan unit paid 36.59 million bolivars (\$17 million) in back taxes after auditors questioned its transfer pricing methodology, Venezuela's tax service said in a statement on Tuesday. Drug maker Pfizer's Venezuelan unit paid 36.59 million bolivars (\$17 million) in back taxes after auditors questioned its transfer pricing methodology, Venezuela's tax service said in a statement on Tuesday.	2009	17,000,000.000
Pfizer Inc. (PFE) (JOBS) To Pay \$75 Million In Trovan Settlement With Nigeria's Kano State	U.S. drugmaker Pfizer (PFE.N) has agreed to pay \$75 million in a court settlement with Nigeria's Kano State related to a study of its Trovan meningitis drug, according to a source close to the proposed deal.	2009	75,000,000.000

Former Astra head found guilty on most counts	<p>A jury on Thursday sided largely with Astra USA in a complex civil court dispute over its messy split with Lars Bildman, the former head of pharmaceutical company Astra AB's American operations. Bildman was fired in 1996 amid allegations that he ran a "fraternity-like" atmosphere and spent company cash on home repairs, family vacations and high-priced prostitutes. A 13-member Suffolk County jury ruled against Bildman on 24 of 25 counts and he was ordered to pay his former employer more than \$1 million after the jury ruled he defrauded the Westboro-based pharmaceutical company, sexually harassed employees and spent corporate funds for his own benefit.</p>	2002	1,000,000.000
Merck, Schering Settle Vytarin Zetia Class Action	<p>Merck and Schering Plough have entered into \$41.5 million settlement of class action lawsuits related to claims against their shared cholesterol medication Vytarin and Zetia.</p>	2009	41,500,000.000
Hendelson v. Johnson & Johnson; Alza Corp. (USDC 05-81116)	<p>This wrongful death action was brought after a female died when she was provided the wrong dosage of medication by the defendant pharmacy where her prescription was filled. The plaintiff contended that the defendant's nonparty pharmacist negligently filled the decedent's prescription with a dosage ten times stronger than prescribed. The defendant admitted liability but denied causing her death. The plaintiff was awarded \$25,800,000.</p>	2009	25,800,000.000

U.S. Judge OKs Bristol-Myers Squibb Company (BMY) (JOBS) \$125 Million Plavix Settlement	A federal judge has granted preliminary approval for Bristol-Myers Squibb Co to pay \$125 million to resolve a shareholder lawsuit accusing it of hiding information related to a case involving its anti-blood clotting medication Plavix.	2009	125,000,000.000
Insurers Reach \$80 Million Settlement with Merck over Vioxx	Third party payers, unions and other private groups have reached an \$80 million settlement in their class action against Merck, the maker of Vioxx. The suit alleged that they parties would not have covered the cost of the drug had they known about the associated health risks specifically cardiovascular events.	2009	80,000,000.000
Schering Plough, Merck Settle Cholesterol Study Probes for \$5.4 Million	A multi-state investigation into Merck and Schering Plough's supposed delayed release of test results for two blockbuster cholesterol drugs has been settled.	2009	5,400,000.000
Ky. gets \$16 million judgment from drug company	Kentucky Attorney General Jack Conway says a Franklin County jury has handed down a \$16 million judgment against Sandoz, the generic-drugs division of pharmaceutical giant Novartis. Conway said Wednesday's judgment was from a lawsuit claiming the company had defrauded the Medicaid program and Kentucky consumers by inflating the prices of prescription drugs.	2009	16,000,000.000
Eli Lilly Settles Zyprexa Investigations for \$62 Million	Eli Lilly has settled Zyprexa lawsuits with 32 states and Washington DC, for a reported \$62 million, putting an end to investigations into the company's marketing practices of the antipsychotic medication.	2009	62,000,000.000
Verdict in MVH case sets mark; \$31M malpractice award against hospital could be largest single case in state history	He suffered "permanent, irreversible brain damage," during his birth, according to the complaint his family filed in 2006.	2009	31,000,000.000

Verdicts & Settlements July 20, 2009: Pharmacy gives wrong dosage to blind customer; Sleep apnea condition is worsened by error	The plaintiff, who is blind and uses a seeing-eye dog, brought a prescription for two boxes of 25 microgram Fentanyl patches to the defendant pharmacy.	2009	200,000.000
Glaxo to Pay \$40 Million in Paxil Settlement with Insurers	The pharmacy dispensed to the plaintiff two boxes of 50 microgram Fentanyl patches. Because of the plaintiff's visual impairment, of which the pharmacy was aware, the plaintiff was unable to detect the dosage error before using the medication.	2009	40,000,000.000
Lilly Settles Zyprexa Lawsuits with 8 of 12 Remaining States	GlaxoSmithKline (GSK) has agreed to \$40 million to settle a long-running lawsuit over Paxil, its beleaguered antidepressant. The settlement will go to insurers to reimburse health plans that covered the use of the drug in children and adolescents.	2009	1,400,000,000.000
Ambrilia Biopharma Inc. Settles its Arbitration With Merck & Co., Inc. (MRK) (JOBS)	Lilly will pay a reported \$1.4 billion to settle the claims, and plead guilty to a misdemeanor violation of the Food, Drug and Cosmetic Act. The settlement of criminal charges will use approximately \$615 million of the settlement monies.	2009	2,000,000.000
Schell, Estate of v. Smithkline Beecham Pharmacy (USDC 00CV-025Bea)	Ambrilia (Toronto:AMB.TO - News) today announced that it has settled with Merck Sharp and Dohme Research Limited and Merck & Co. ("Merck")	2009	8,000,000.000
Wheatley v. Walgreen Drug Store (Circuit 99CI 7397)	The two largest universities in West Virginia will receive nearly \$8 million in unclaimed funds from a class action suit settled with Warner-Lambert Co. and Parke-Davis. The suit was over the companies diabetes drug Rezulin, which can have severe side effects.	2009	43,000,000.000
	Products Liability: Prescription \$43,000,000 Verdict: Death	2009	8,000,000.000

UTAH GETS \$3.5 MILLION FROM
PFIZER

IN FRAUD SETTLEMENT 2009 35,000,000.000

Merck to Pay \$42.5 Million to Settle
Lawsuits Against Its Pharmacy-
Benefit Unit

Merck & Company yesterday agreed to pay
\$42.5 million to settle long-running class-
action lawsuits against its pharmacy-benefit
unit, Medco Health Solutions.

2002 42,500,000.000

Bristol-Myers paying \$150 million in
settlement of SEC fraud charges

Bristol-Myers Squibb Co. is paying \$150
million to settle a major alleged accounting
fraud as federal regulators accused the
company Wednesday of manipulating its
inventory of drugs to inflate earnings and
meet Wall Street targets.
The pharmaceutical giant, which also
recently settled a lawsuit by shareholders for
\$300 million, still faces a criminal
investigation by the Justice Department.

2004 150,000,000.000

Bristol-Myers

Settles dispute with shareholders.

300,000,000.000

Lilly agrees to pay nearly \$700
million to settle Zyprexa claims

Eli Lilly & Co. has agreed to pay as much as
\$690 million to settle lawsuits involving an
estimated 8,000 people who claim the
company did not properly list risks
associated with its anti-psychosis drug
Zyprexa.
Lilly said late Thursday it had agreed in
principle with plaintiffs' attorneys involved
in the Zyprexa claims. The settlement, when
finalized, will resolve about 75 percent of
the Zyprexa claims pending in the United
States, according to a Lilly news release.

2005 700,000,000.000

Bayer Corp. to pay \$14 million to settle Medicaid allegations	Bayer Corp. agreed Tuesday to pay \$11 million to the federal government and 45 states to settle allegations it caused doctors and other health care providers to submit inflated reimbursement claims to the Medicaid health insurance program, the Justice Department said.	2001	14,000,000.000
Merck CEO got \$17.3M compensation package in 2008	Merck & Co.'s chief executive, Richard T. Clark, received a compensation package valued at \$17.3 million in 2008, up 20 percent from a year earlier, according to an Associated Press calculation of figures disclosed in a regulatory filing made late Wednesday.	2009	17,300,000.000
Medco to Pay \$29.3 Million to Settle Complaints of Drug Switching	Medco Health Solutions, the largest pharmacy benefits management company in the nation, said yesterday that it had agreed to start telling patients, doctors and employers about billions of dollars in annual rebates that it has received from drug manufacturers for promoting their products. A U.S. federal jury returned a \$1.67 billion verdict against Abbott Laboratories (ABT.N) in a patent suit brought by Johnson & Johnson (JNJ.N) related to arthritis treatments, the drug companies said on Monday.	2004	29,300,000.000
Jury returns \$1.67 billion drug verdict against Abbott		2009	1,670,000,000.000
Proposed Settlement In Abbott's Norvir Class Action	Preliminary approval of a Proposed Settlement related to the average wholesale prices of certain prescription drugs has been granted by the District Court for the District of Massachusetts. In the lawsuit, plaintiffs claimed that drug manufacturers unlawfully inflated the published average wholesale price of certain drugs, increasing what certain consumers and others paid. The defendants deny any wrongdoing.	2009	21,800,000.000

Amerigroup Settles with Medicaid for \$225 Million	Abbott Laboratories has agreed to pay a \$10 million and \$27.5 million, depending on pending court rulings, to settle nationwide consumer claims of being overcharged for Abbott's HIV/AIDS drug Norvir	2009	27,500,000.000
Amerigroup Settles with Medicaid for \$225 Million	to settle allegations by federal and Illinois state authorities that Amerigroup's health plans denied coverage to pregnant women and people with health ailments in the	2009	225,000,000.000
Advanced Bionics Settles with FDA	Gary Charbonneau has been awarded \$8.2 million in damages stemming from claims that Mirapex, a drug used to treat Parkinson's Disease, caused him to gamble compulsively	2009	8,200,000.000
Aventis Pharmaceuticals, Inc. (AVE) to Pay U.S. \$95.5 Million to Settle False Claims Act Allegations	Aventis Pharmaceutical Inc., a wholly owned subsidiary of sanofi-aventis U.S. LLC, has agreed to pay the United States \$95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations, the Justice Department announced today.	2009	95,500,000.000
Luminex Corporation (LMNX) Settles Legal Dispute	Luminex Corporation settled the pending litigation with The Research Foundation for the State University of New York and the Board of Trustees of the University of Illinois ("Plaintiffs"). As part of the settlement, the Plaintiffs received a one time cash payment of \$4.35 million with no admission of fault. T	2009	4,350,000.000

82 Year Old Awarded \$6 Million in SJS Lawsuit	A jury in Pasadena, California has awarded over \$6 million to an 82 year-old Chinese female immigrant who suffered Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TENS) after being prescribed Allopurinol for allegedly having gout. The woman reportedly maintained that she did not have gout but took the drug anyway which resulted in her developing SJS.		6,000,000.000
Novo Nordisk A/S (NVO) to Pay \$18 Million to Settle US Probes	Denmark-based Novo Nordisk, a leading maker of diabetes care products, said on Monday it has agreed to pay \$18 million to settle U.S. investigations into the company's sales to Iraq as part of the United Nations' oil for food program.	2009	18,000,000.000
Pfizer Inc. (PFE) (JOBS) District Sales Manager Guilty of Altering Off-Label Celebrex Documents .	Thomas Farina, a former district sales manager at Pfizer, <u>was found guilty of obstruction of justice</u> after he was found altering documents on his computer during a federal investigation of off-label sales of Bextra and Celebrex. He faces a possible 20 years in prison and a \$250,000 fine	2009	250,000.000
McKesson Corporation Pays \$350 Million in Settlement That Lowers Drug Prices 4 Percent	The prices of about 1,400 branded drugs are about to get a little cheaper because of a \$352.7 million class action settlement with wholesale drug distributor McKesson.	2009	350,000,000.000
AstraZeneca loses price inflation lawsuit appeal	An appeals court on Wednesday upheld a lower court's ruling that AstraZeneca inflated the price of expensive drugs in Massachusetts. London-based AstraZeneca was ordered to pay \$12.9 million in damages in that original decision. New York-based Bristol-Myers was ordered to pay \$695,594 in damages.	2009	12,900,000.000

	Pharmaceutical manufacturer, Bristol-Myers Squibb Co. has announced it will pay \$403 million in settlements of lawsuits brought against it by 44 states regarding prescription drug pricing fraud through state-run Medicaid programs.		
BMS Settles with States for \$403 Million in Prescription Drug Pricing Suits	BMS was accused of reporting inflated prices for various prescription drugs, as well as paying healthcare providers and pharmacies incentives to purchase Squibb and Apothecon products. BMS was also alleged to have promoted the unapproved use of its antipsychotic drug Abilify.	2008	403,000,000.000
Advanced Bionics	The U.S. Food and Drug Administration (FDA) has reached a settlement with California hearing device manufacturer Advanced Bionics LLC and its president and CEO Jeffrey Greiner over alleged violations of federal law. The alleged violations involved the failure to notify the FDA of a change of outside supplier or vendor, which may have exposed patients to unnecessary health risks, such as device failure and surgery.	2009	1,175,000.000
Vioxx Advertising	Officials on both sides said that the parties had reached a settlement agreement, in which the company will pay \$13.25 million to resolve all claims.	2009	13,250,000.000
Biovail Pharmaceuticals Inc	As part of a settlement reached in the suit, the company agreed to pay \$58 million to resolve the multistate allegations.	2009	58,000,000.000
Biovail Corporation (BVF) Settles Cardizem Case	A U.S. unit of Canadian drugmaker Biovail Corp has pleaded guilty to conspiracy and kickback charges, ending a case over its Cardizem hypertension drug, the U.S. Justice Department said on Monday.	2007	22,200,000.000

Biovail pays \$138-million to settle class action	US Attorney Michael Sullivan's office brought a lawsuit against Biovail Pharmaceuticals Inc., a NJ, based subsidiary of Biovail Corp., alleging that the company illegally paid doctors so that they would prescribe Cardizem LA, a blood pressure drug. The suit alleged that Biovail Corp. paid thousands of physicians and others up to \$1,000 each, to induce them to either prescribe or recommend Cardizem LA. Biovail pays \$138-million to settle class action	2008	138,000,000.000
Leiner Health Products Inc	Federal officials brought a lawsuit against Leiner Health Products Inc., over the production, control and distribution of certain over-the-counter drug products at the company's now defunct South Carolina facility.	2008	24,600,000.000
Eli Lilly and Co., Drug Warnings Omitted	The suit, filed in March 2006, claimed that the State and healthcare providers were not sufficiently warned about probable side effects relating to weight gain, high blood sugar and diabetes, causing injury to the recipients and subsequently increased costs to the State. The suit sought reimbursements to pay the State for those costs and pay civil penalties under the Alaska Unfair Trade Practices and Consumer Protection Act. class action lawsuit was brought against OSI Pharmaceuticals Inc., over its lung-cancer drug, Tarceva. The class action was filed in December 2004, accusing OSI of making false and misleading statements about Tarceva's potential to increase survival from lung cancer.	2008	10,000,000.000
OSI Pharmaceuticals Inc.,		2008	15,000,000.000
Wyeth Pharmaceuticals and Upjohn		2008	9,000,000.000

U.S. Department of Justice Investigation of Bristol-Myers Squibb in Proposed Plavix Patent Settlement Is Resolved	Bristol-Myers Squibb today pleaded guilty to two counts of violating 18 U.S.C. Sec. 1001 in U.S. District Court for the District of Columbia. This guilty plea resolved as to the company the previously disclosed investigation by the Antitrust Division of the U.S. Department of Justice into the proposed settlement of the Plavix patent litigation with Apotex Inc., and Apotex Corp. (Apotex). As a result of the plea, the company will pay a fine of \$1 million.	2007	1,000,000.000
Drug Makers Pay	A lawsuit was filed by consumers and insurance companies against nine leading pharmaceutical companies, including healthcare companies Abbott Laboratories (ABT) and Watson Pharmaceuticals (WPI), over the Average Wholesale Price or AWC of certain prescription drugs. As part of a settlement agreement reached in the case, sources stated that healthcare companies Abbott Laboratories (ABT) and Watson Pharmaceuticals (WPI), and the other nine leading pharmaceutical companies, agreed to pay nationwide damages of \$125 million to resolve allegations.	2008	125,000,000.000
Mitsubishi Tanabe Pharma Corp	Five lawsuits were brought against Mitsubishi Tanabe Pharma Corp., a Japanese pharmaceutical company, alleging that customers who used Fibrinogen, which is used to stop bleeding, ended up victims of hepatitis virus-tainted blood products. As part of the settlement agreement, the company agreed to pay 2.1 billion yen (\$18.17 million) to resolve the case.	2008	425,000,000.000
J&J Paid \$68 Million to Settle Birth-Control Cases	million to settle hundreds of lawsuits filed by women who suffered blood clots, heart attacks or strokes after using the company's Ortho Evra birth-control patch, court records show.	2008	68,700,000.000

Ortho Evra Death	The family of Alycia Brown, a resident of Lacrosse, brought a lawsuit against Johnson & Johnson, alleging that the 14-year-old girl died after using the company's Ortho Evra birth control patch. As part of a settlement reached, the company agreed to pay \$1.25 million to resolve the lawsuit.	2008	18,170,000.000
Products Liability: Prescription \$2,000,000 Settlement: Kidney Dysfunction	A 68-year-old unemployed male suffered muscle damage that resulted in kidney dysfunction and dialysis after he ingested Baycol, prescribed by the fifth-named defendant physician and manufactured and distributed by the remaining defendants, as part of a treatment plan to reduce his	2006	2,000,000.000
Biotape Fraud	The Federal Trade Commission brought charges against Smart Inventions, Inc. and Jon Nokes, two marketers of the alleged pain relief product called Biotape, accusing them of deceptively claiming that Biotape, an adhesive tape, provided significant, permanent relief from severe pain and that it was superior to other pain-relief products. As part of a settlement reached, Smart Inventions and Nokes agreed to provide up to \$2.5 million in consumer refunds.	2008	2,590,000.000
Cephalon Inc.	Biotechnology company Cephalon Inc. had a second quarter loss after reserving \$56 million for a settlement over alleged illegal marketing for the anticancer drug Trisenox. The controversy involving the drug had earlier cost the company \$10.5 million in settlements, but company officials have since put that figure at close to \$56 million.	2008	56,000,000.000

Law school establishes Sam Nunn ethics chair with \$2.5 million DuPont settlement	Earlier this year DuPont settled a lawsuit alleging the chemical corporation withheld evidence during a 1993 civil case. U.S. District Court Judge Hugh Lawson of Columbus, seeking to make a statement about the importance of legal ethics, devised an unusual solution. Under the agreement, which also halted a federal criminal investigation, DuPont paid a total of \$11 million--\$2.5 million to each of Georgia's four law schools, plus \$1 million to establish an annual symposium.	1999	2,500,000.000
Walgreen's Pharmacy pays for customer's death.	A 56-year-old male teacher alleged that he suffered rhabdomyolysis, caused by kidney dysfunction, when he ingested a combination of three medications, prescribed by the codefendant physician, during his stay at the defendant hospital for treatment of pneumonia.	2009	1,629,000.000
Walgreen's	FINAL DECREE ENTERED WITH WALGREENS FOR \$24 MILLION IN LANDMARK RACE DISCRIMINATION SUIT BY EEOC The Department of Justice, the US Attorney's Office for the Eastern District of New York, the Office of the Inspector General of the United States Department of Health and Human Services, the United States Office of Personnel Management, and	2008	24,000,000.000
Jazz Pharmaceuticals Inc.	A lawsuit was filed against the two Johnson & Johnson subsidiaries after Adam Hendelson died while wearing the company's Duragesic pain patch. Hendelson was in a automobile accident and was suffering from persistent hip pain.	2008	210,000,000.000
Janssen Pharmaceutica Products and ALZA Corp.	A lawsuit was filed against the two Johnson & Johnson subsidiaries after Adam Hendelson died while wearing the company's Duragesic pain patch. Hendelson was in a automobile accident and was suffering from persistent hip pain.	2008	20,000,000.000

Accutane	Andrew McCarrell, 36, filed a lawsuit against the makers of Accutane, Roche, after undergoing multiple surgeries, including having his colon removed, after taking the drug in 1995. A New Jersey Superior Court jury recently awarded over \$2.5 million to the Alabama man who claimed that the company's acne drug caused his inflammatory bowel disease. The case is the first of the nearly 400 US lawsuits involving Accutane. The jury awarded McCarrell \$2.5 million in damages and \$119,000 to cover medical expenses.	2008	2,600,000.000
GlaxoSmithKline	A settlement has been reached with Britain-based GlaxoSmithKline over a 2004 lawsuit which claimed that the drugmaker promoted the drug, Paxil, to children while withholding information about negative side effects, including increased suicidal behavior. The company agreed to a \$64 million class action deal to settle claims.	2008	64,000,000.000
Purdue Pharma LLC	In a lawsuit filed by the Attorney General Richard Blumenthal and state Consumer Protection Commissioner Jerry Farrell Jr. against Stamford-based Purdue Pharma LLC, the maker of the painkiller OxyContin, they alleged that the company propagated illegal marketing practices that led to greater abuse of the highly addictive painkiller. In a settlement reached with 27 states, Purdue agreed to pay \$19.5 million as well as not to market the drug for off-label purposes, that is uses other than those approved by the US Food and Drug Administration.	2008	19,500,000.000

Medicis Pharmaceutical Corp.	The US Department of Justice filed charges against Medicis Pharmaceutical Corp., alleging that it promoted its anti-fungal cream Loprox for unapproved uses.	2008	9,800,000.000
DuPont Co.	Two lawsuits filed against the DuPont Co. claimed that the fungicide Benlate caused birth defects in children. The company has paid more than \$1 billion in settlements and legal fees on claims of damage from Benlate, including a recent \$30 million settlement with six Hawaii plant nursery operators.	2008	1,000,000,000.000
Cell Therapeutics	The US government filed charges against Seattle biotechnology company, Cell Therapeutics, accusing it of promoting an anti-cancer drug, Trisenox, for uses that were not approved by the Food and Drug Administration.	2008	10,500,000.000
Pfizer Inc.	The Department of Justice began an investigation into the off-label marketing of Pfizer's human-growth hormone brand, Genotropin, alleging that a unit of the company made kickbacks to an outside vendor in order to increase its sales. Pfizer admitted that Pharmacia, one of its acquired companies improperly promoted Genotropin between January 2000 and March 2003 for anti-aging purposes, improved athletic performance, and enhanced appearance. In a settlement reached, Pfizer agreed to pay \$34.7 million to end the investigation.	2008	34,700,000.000

Merck & Co.	Frederick Humeston filed suit against drug-maker Merck after suffering a heart attack while on the arthritis pill Vioxx. The 61-year-old man suffered a heart attack in 2001 while taking Vioxx, several months before Merck put a stronger warning about the drug's cardiovascular risks on the package insert.	2008	2,200,000.000
John DiCosolo, as Administrator of the Estate of Janice V. DiCosolo, deceased v. Janssen Pharmaceutica Inc. and ALZA Corp.	On Feb. 15, 2004, plaintiffs' decedent Janice DiCosolo, 38, disabled, of Cicero, died while using a prescribed Duragesic patch to reduce pain caused by a neurological condition known as reflex sympath... A Pfizer Inc. unit failed to properly warn a New Jersey woman about the cancer risk of its hormone-replacement drug Provera and should pay \$1.5 million in damages, jurors said in the first trial over the menopause treatment.	2008	16,500,000.000
Simon v. Wyeth and Pfizer		2007	1,500,000.000
Hayes v. Wyeth pharmaceuticals	Outcome: 1.4 Million dollar verdict for Plaintiff Description: First Intermediate opt-out case in the nation in Fen-Phen litigation	2003	1,400,000.000
Anonymous Male v. Anonymous Pharmacy	A man who received the wrong medication from a pharmacy, which he took for nearly a year before discovering the error, pursued this malpractice claim against the pharmacy. The case settled for \$350,000.	2008	350,000.000

<p>Donna Scroggin v. Wyeth and its divisions Wyeth Pharmaceuticals Inc. and Esi Lederle, Pharmacia and Upjohn Company Pharmacia Corporation, Pfizer Inc., Greenstone, Ltd., Barr Pharmaceuticals Inc., Barr Laboratories, Duramed Pharmaceuticals, Inc.</p>	<p>In August 2000, plaintiff Donna Scroggin, 58, was diagnosed with invasive hormone positive ductal cancer in both breasts. From 1989 to 2000, she underwent hormonal replacement therapy to treat her men...</p>	<p>2008</p>	<p>29,900,000.000</p>
<p>Accutane IBD Victims Awarded \$13 Million</p>	<p>The maker of Accutane has been ordered to pay nearly \$13 million to three people who said the acne medication caused them to develop inflammatory bowel disease.</p>	<p>2008</p>	<p>13,000,000.000</p>
<p>\$16.6 Million Awarded in Duragesic Case</p>	<p>Three Florida residents who took Accutane as teens and developed inflammatory bowel disease (IBD) have been awarded \$12.89 million by a jury in Atlantic City.</p>	<p>2007</p>	<p>12,900,000.000</p>
<p>InterMune Inc.</p>	<p>Patients with potentially fatal, idiopathic pulmonary fibrosis have been using a drug manufactured by InterMune Inc. The drug, Actimmune, was not approved for the disease, but had been promoted for that use by InterMune Inc.</p>	<p>2007</p>	<p>47,500,000.000</p>
<p>MERCK TO PAY MORE THAN \$650 MILLION TO RESOLVE CLAIMS OF FRAUDULENT PRICE REPORTING AND KICKBACKS</p>	<p>Merck & Company has agreed to pay more than \$650 million to resolve allegations that the pharmaceutical manufacturer failed to pay proper rebates to Medicaid and other government health care programs and paid illegal remuneration to health care providers to induce them to prescribe the company's products, the Justice Department announced today. The allegations were brought in two separate lawsuits filed by whistleblowers under the qui tam, or whistleblower, provisions of the False Claims Act.</p>	<p>2008</p>	<p>650,000,000.000</p>

EMD Serono Inc.	A civil lawsuit was filed against EMD Serono in 2005 for allegedly promoting the company's AIDS drug Serostim for unapproved uses. Serostim treats AIDS wasting, a condition involving serious weight loss in AIDS patients.	2007	24,000,000.000
Wyeth Pharmaceuticals	Jennie Nelson filed a lawsuit against the maker of Prempro after she was diagnosed with breast cancer. Wyeth was ordered to pay \$3 million in damages after a jury found the company's menopause treatment was linked to a woman's breast cancer. Florida Attorney General Bill McCollum announced that Florida and 29 additional states have reached an \$8 million settlement with Bayer Corporation, resolving an investigation into the marketing of a drug to lower cholesterol. The settlement was part of a consumer protection enforcement action	2007	3,000,000.000
Bayer Corporation		2007	8,000,000.000
Medicis Pharmaceutical Pays \$9.8 Million to Settle False Claims Allegations	Medicis Pharmaceutical Corporation of Scottsdale, Ariz., agreed to pay the United States \$9.8 million to settle allegations that the company violated the False Claims Act with respect to claims submitted to Medicaid, according to a Department of Justice announcement earlier this week. The settlement resolves allegations that Medicis promoted the use of a topical skin preparation, Loprox, for use on children under the age of 10, without approval by the Food & Drug Administration (FDA).	2007	9,800,000.000

GlaxoSmithKline	<p>A class action lawsuit was filed against the pharmaceutical company for allegedly promoting its antidepressant drug Paxil for use by children and adolescents while withholding negative information about the medication's safety and effectiveness. The class includes all US residents who bought Paxil or Paxil CR for their children. Madison County Associate Judge Ralph Mendelsohn has approved a \$63.8 million class action settlement. GlaxoSmithKline denies the lawsuit's claims, but has agreed to pay to settle the claims.</p>	2007	63,800,000.000
Prempro	<p>Jennie Nelson took Prempro for six years and developed breast cancer. As a result of the cancer, she underwent a mastectomy and chemotherapy and radiation therapy. She filed a lawsuit against Wyeth claiming it was negligent in the testing, manufacture and marketing of its hormone replacement therapy drug Prempro. A jury awarded Nelson \$1 million and her husband \$500,000 in compensatory damages after finding that Wyeth's Prempro was a cause of her breast cancer. The Philadelphia Court of Common Pleas jury may award additional punitive damages if it finds Wyeth failed to warn of the dangers of Prempro.</p>	2007	1,500,000.000
Novartis AG	<p>Acambis and Novartis were in a dispute over an experimental vaccine for yellow fever. The dispute arose over non-performance from a 1999 deal by predecessor companies acquired by Novartis. Acambis had US sales rights to the Arilvax vaccine and had previously completed Phase 3 clinical trials with a view</p>	2007	19,000,000.000
Merck has agreed to pay \$4.85 billion in a settlement over Vioxx	<p>Merck will pay \$4.85 billion to settle most of the nearly 27,000 pending Vioxx lawsuits nationwide in one of the largest civil agreements ever, the company announced Friday.</p>	2007	4,850,000,000.000

Schering-Plough	<p>According to the government, Schering-Plough engaged in illegal sales and marketing programs for several cancer drugs. It improperly promoted Temodar for use in brain tumors and metastatic cancer, and pushed the drug Intron A for use in superficial bladder cancer and hepatitis C. Schering-Plough has agreed to pay \$435 million in fines and has pleaded guilty to criminal conspiracy charges</p>	2007	435,000,000.000
Merck & Co. Inc.	<p>The jury also found that Merck knowingly misrepresented or failed to disclose information about Vioxx to the doctors of 62-year-old Gerald Barnett. Merck has been ordered to pay Barnett at \$51 million settlement.</p>	2007	51,000,000.000
NVE Pharmaceuticals	<p>A lawsuit was filed against the company claiming it misled consumers by making false and misleading claims about the safety and effectiveness of its products. The lawsuit claimed NVE violated the New Jersey State Consumer Fraud Act through ads that exaggerated the benefits and minimized the risks of Stacker-2 and other Ephedra based supplements. The settlement requires NVE and its president Robert Occhifinto to pay a \$260,000 settlement to the state of New Jersey.</p>	2007	260,000.000
Baxter Healthcare	<p>The Texas attorney general filed a lawsuit against Baxter Healthcare in 2004 for alleged Medicaid fraud. The lawsuit claimed a scheme falsely reported wholesale prices of I-V fluids and injectible medications prescribed for Medicaid patients. Baxter denied any wrongdoing but agreed to pay the state an \$8.5 million settlement.</p>	2007	8,500,000.000

	<p>In November 2005, U.S. regulators warned that the Ortho Evra birth control patch exposes women to 60% more hormones than do oral contraceptives and may cause blood clots.</p>		
Johnson & Johnson	<p>Other users have filed about 140 lawsuits claiming that they suffered strokes or clots in the legs or lungs. The company has not disclosed the settlements or any possible reserves for Ortho Evra sufferers. CONFIDENTIAL.</p>	2007	-
	<p>The U.S. Attorney's office in Missouri filed charges against the pharmaceutical wholesaler for allegedly conspiring to sell millions of dollars in counterfeit, stolen and illegally imported prescription drugs. A former H.D. Smith employee pleaded guilty to accepting kickbacks and undisclosed commissions on sales of counterfeit Lipitor, a cholesterol drug. H.D. Smith Wholesale Drug has agreed to pay a \$2.2 million settlement.</p>		
H.D. Smith Wholesale Drug Co.	<p>In April 2001, within one month of taking Vioxx, Leonel Garza had fatal heart attack. The 71-year-old's family filed a lawsuit against the drug manufacturer alleging wrongful death. A South Texas jury has ordered the company to pay \$7 million in compensatory damages and \$25 million in punitive damages.</p>	2007	2,200,000.000
Merck & Co.		2007	25,000,000.000

Merck & Co.	John McDarby used Vioxx for five years until 2004, when he suffered a heart attack. The 77-year-old man filed a lawsuit against the drug manufacturer for allegedly misleading the U.S. Food and Drug Administration about the painkiller's heart risks. A jury ordered Merck & Co. to pay \$9 million in punitive damages. A New Jersey Superior Court jury also found Merck violated the New Jersey consumer fraud law by failing to properly warn consumers of Vioxx's cardiovascular risks. The jury awarded McDarby \$4.5 million in compensatory damages.	2007	13,500,000.000
Schering Plough KK	SciClone Pharmaceuticals, Inc. filed a lawsuit against Schering regarding a dispute concerning clinical trials conducted in Japan with ZADAXIN, SciClone's lead compound. Schering has agreed to pay SciClone an \$8 million settlement.	2007	8,000,000.000
Merck	A 62-year-old male former FBI agent suffered a vascular reocclusion, which required an angioplasty and stent placement, after taking the prescription drug Vioxx, manufactured by the defendant	2007	9,000,000.000
Talbert v. E'Ola International (Superior)	Pharmacist Negligence: Prescription \$206,005 Verdict: Emotional Distress	2007	206,000.000
Schell, Estate of v. SmithKline Beecham n/k/a GlaxoSmithKline, PLC (USDC)	Products Liability: Weight Loss Products \$13,300,000 Verdict: Mild Brain Injury	2007	13,300,000.000

Wirt v. America Home Products Corp.; Wyeth-Ayerst Laboratories; A. H. Robins Co.; Abbott, M.D. (Circuit 99CV0307)	Products Liability: Prescription \$8,000,000 Verdict: Suicide	2007	8,000,000.000
Scott v. American Home Products Inc.; Giunta, M.D. (Common Pleas 3249)	Products Liability: Prescription \$14,205,000 Verdict: Heart Damage	2007	14,200,000.000
Anonymous Male v. Anonymous Hospital	A settlement was reached under the Federal Tort Claims Act after a pharmacy allegedly gave an 80 year old patient the incorrect dosage of blood clotting medication. Plaintiff was rendered a paraplegic...	2007	1,050,000.000
Deane Hippely, as personal representative of the Estate of Beth Hippely, deceased, on behalf of : the Estate of Beth Hippely; Hosler Lee Wall III, as plenary guardian of the property of Nellie Kay Hippely; Hosler Lee Wall III, as plenary guardian of the property of Kerrienne Hippely; Randy Borden; and Deane Hippely, individually v. Walgreen Co., a foreign corporation, and Elizabeth Partlow	On Jan. 8, 2007, plaintiffs' decedent Beth Hippely, 46, a homemaker, died of metastatic breast cancer. In the summer of 2002, Hippely, who was diagnosed with clinical depression at 18, was dia...	2007	25,850,000.000
Felicia Wrice, et al. v. JC Penney Corporation, Inc., JC Penney Properties d/b/a Eckerds and Eckerds Drugs	A pharmaceutical error reportedly caused plaintiff to suffer a severe allergic reaction after taking an excessive amount of prescription medication. Defendant disputed that the medication caused the r...	2007	131,000.000
Andrew McCarrell v. Hoffmann-La Roche Inc. and Roche Laboratories, Inc.	Between June 1995 to October 1995, plaintiff Andrew McCarrell, a 36-year-old computer manager of St. Clair, Ala., used the drug Accutane. Introduced in 1982, Accutane (also known by its generic name,...	2007	2,600,000.000

Adam W. Mason v. John Doe	In the mid-1990s, plaintiff Adam Mason, 20s, occupation not given, was prescribed Accutane, a drug that is given to patients with severe acne. Accutane is prescribed for patients who suffer from sever...	2007	2,800,000.000
Patricia Sloan v. Eckerd Drug Corporation	On Sept. 11, 2003, plaintiff Patricia Sloan, 55, a school secretary, went to an Eckerd pharmacy to refill her prescription for Clonidine, a drug she had taken for years to treat hypertension. Sloan cl...	2007	250,000.000
Jennie Nelson and Lawrence Nelson v. Wyeth Pharmaceuticals, Inc.	Plaintiff Jennie Nelson, a 67-year-old retiree, took the drug Prempro, a menopausal hormone therapy drug, from 1996 to 2001. In 2001 Nelson was diagnosed with lobular cancer in both her breasts.	2007	3,000,000.000
Barbara A. Gleich v. Thompson Medical Company, Inc.	On Aug. 30, 1998, plaintiff Barbara Gleich, 30s, a sales manager, began taking Dexatrim caplets. She followed the instructions to take one caplet a day. On Sept. 5, she felt nauseous and was stricken ...	2007	700,000.000
Martha Nelly Espinoza and Cesar Espinoza and Nelly Espinoza, as the Executrix of the Estate and Parents of Cesar Espinoza v. Donald J. Filip, M.D., Lakeside Pharmacy, et al.	A patient with a brain tumor died after overdosing on his chemotherapy medicine. A suit was brought against the dispensing pharmacy and the patient's oncologist in Fulton County. A jury awarded decede...	2007	500,000.000
Jensen v. American Home Products Corp. d/b/a Wyeth Ayerst Pharmaceuticals Inc. (Common Pleas 021201202	Products Liability: Prescription \$2,000,000 Settlement: Kidney Dysfunction		2,000,000.000
Moore v. American Home Products Inc.	A female suffered heart damage when she took diet drugs manufactured by the defendant company. The plaintiff contended that the defendant failed to warn of the dangers associated with its product. The defendant settled with the plaintiff for 500,000.	2000	500,000.000

Bayer AG	<p>A class action lawsuit was filed against the German drug maker. Bayer recalled Baycol in 2001 after it was allegedly linked to more than 100 deaths. Major health insurers, employers and unions purchased Baycol before the recall that could not be used after the drug had been withdrawn from the market. A Philadelphia Court of Common Pleas Judge has approved a nationwide class action settlement which may provide class members with as much as \$10 million.</p>	2007	10,000,000.000
Matrixx Corp.	<p>More than 300 people filed a class action lawsuit against the makers of the cold remedy Zicam alleging the zinc nasal spray caused a loss of sense of smell and taste. Millions of people have used the zinc gluconate nasal spray without problems, but hundreds of other users felt an intense burning sensation in their nose, and subsequently lost their sense of smell and/or taste. Only 30% of the latter had some sense of smell return. Matrixx has agreed to pay a \$12 million class action settlement.</p>	2007	12,000,000.000
Diageo PLC	<p>During the 1960s the pharmaceuticals division of the Distillers Company distributed thalidomide throughout the United Kingdom. Pregnant women taking the drug began to produce babies with deformities including stunted arms and legs. The drug was withdrawn in 1961. Diageo has finalized a \$150 million (GBP) financial settlement with Thalidomide Trust's National Advisory Council and Thalidomide UK set up for those affected by the drug.</p>	2007	150,000,000.000

McKesson Corp. to pay \$18.7M to settle lawsuit against St. Louis-based D&K Healthcare Resources.	McKesson Corp., the largest U.S. health-care services company, will pay \$18.7 million to settle a class action securities fraud lawsuit filed against St. Louis-based D&K Healthcare Resources, which McKesson acquired in 2005.	2007	18,700,000.000
Kroger Co.	The Drug Enforcement Agency audited seven King Soopers pharmacies and discovered multiple violations of the Controlled Substances Act. The Drug Enforcement Agency filed charges against the nation's largest retail grocery chain and two of its subsidiaries, King Soopers and City Market. Kroger Co. has agreed to pay a \$7 million settlement as well as start a corporate wide compliance program to improve their pharmaceutical controls.	2007	7,000,000.000
Medirate Professional Pharmacy Inc.	The wholesale closed door pharmacy dba Medicate Long Term Pharmacy distributes controlled substances to customers in nursing homes and prisons. Medirate informed the Drug Enforcement Administration that 300,000 doses of several controlled substances went missing from their pharmacy. Charges were filed against the company for lack of security. Several former employees have been charged with felonies related to diverting controlled substances and Medirate has agreed to pay a \$450,000 settlement.	2007	450,000.000
Serono	The European biotechnology firm has plead guilty to criminal charges over the promotion of its drug Serostim, used to fight physical wasting caused by AIDS. They conspired with a medical device maker to use a diagnosis that was not approved by the U.S. Food and Drug Administration. Serono has also agreed to pay a \$704 million settlement, including a \$137 million criminal fine and \$567 million in civil suits.	2007	704,000,000.000

Merck Settles Clean Water Act Violations at its Montgomery County, Pennsylvania Pharmaceutical Plant	In one of the most comprehensive remediation settlement agreements for the Eastern District of Pennsylvania, Merck will pay \$10 million to put into place systems that will prevent future dangerous discharges at their facility. Merck will spend approximately \$9 million for extensive environmental projects	2007	10,000,000.000
Texas Jury Awards \$253 Million to Widow of Vioxx User	A Texas jury has found one the world's largest pharmaceutical corporations, Merck, liable for the death of a man who once took the Merck painkiller Vioxx and has awarded the widow of the man more than \$253 million in damages	2007	253,000,000.000
Products Liability: Prescription \$51,000,000 Verdict: Heart Condition	On August 17,2006 a federal court jury in New Orleans rendered a \$51,000,000 verdict against Merck, the manufacturer of Vioxx. The Plaintiff, Gerald Barnett	2006	51,000,000.000
Bristol Meyers Squibb Co., Baxter Healthcare and 3M	Canadian women with silicone gel breast implants filed a class action lawsuit over a decade ago against the three companies. Over the term of the suit, the focus shifted from systemic health problems to hardness, scarring, ruptures from the implants.	2006	43,000,000.000
GlaxoSmithKline Antitrust Settlement	With accusations from the U.S. Department of Justice, the pharmaceutical giant GlaxoSmithKline has agreed to pay a \$150 million settlement for allegedly inflating prices of cancer drugs to maximize profits.	2006	150,000,000.000

Tiffany Phillips v. Eckerd Corporation, et al.	A Lancaster County jury rejected defendant's argument that plaintiff should have known better than to take medication without checking the dosage and ordered Eckerd Corporation to pay plaintiff \$8,000,000...	2006	8,000,000.000
Florence Glassman v. The Regents of the University of California and Bishop's Medical Supplies	Glassman, 84, retired, received a prescription for compression stockings from the University of California, Mount Zion Wound Clinic, where she was being treated fo...	2006	1,400,000.000
Patricia Anne Archer v. The Kroger Co. and James Ryder Olfson M.D.	On March 29, 2002, plaintiff Patricia Anne Archer, 65, a part-time housekeeper, was prescribed Zocor by her physician, James Ryder Olfson, to lower her cholesterol. Archer was already taking an antide...	2006	1,590,000.000
Richard Marston, as independent administrator for the estate of Leonard L. Kulisek v. Walgreens Co. and James Wilmes	On Jan. 1, 2001, plaintiff's decedent Leonard L. Kulisek, 77, a retired International Harvester worker who spent time volunteering, ordered a prescription refill over the phone for gout medication fro...	2006	31,350,000.000
Gerald Barnett v. Merck & Co. Inc.	In 1998, plaintiff Gary Barnett, 58, a former FBI agent living in Myrtle Beach, N.C., suffered a heart attack and underwent quintuple bypass surgery. Following the surgery, he again took the prescribe...	2006	51,000,000.000
Martin L. Dunson and Lisa M. Jones administrators of the estate of Marquis Matthew Dunson, deceased v. McNeil-PPC, Inc., and McNeil Consumer Healthcare Division of McNeil-PPC, Inc. and McNeil Consumer & Specialty Pharmaceuticals, a division of Johnson & Johnson, Inc.	On March 16, 2002, plaintiff's decedent Marquis Dunson, a 12-month old boy, developed a cold. During the ensuing three days, his parents administered Tylenol's Infants' Drops formula.	2006	5,000,000.000

Renee and Christopher Mirante, Individually and as the Parents of Madeline Mirante v. Bonneville's Pharmacy	A pharmacy admitted providing the wrong medication to an 11 month old child, who became very ill as a result. A jury awarded \$350,000 to the child and her parents. Defendant disputed the extent of dam...	2006	350,000.000
Walgreen Co.	The Drug Enforcement Administration, the Federal Bureau of Investigation, and others were investigating the retail drugstore chain for allegedly breaking federal laws by failing to monitor sales of cold medicines used to make methamphetamine. A Denton Walgreen store sold more than 53,000 tablets in one day to one person. New legislation requires stores to sell cold medicines behind the pharmacy counter and requires consumers to show a photo ID and sign a log. They are limited to 7.5 grams, or about 250 30-milligram pills, in a 30-day period. Computer tracking will prevent customers from exceeding the limit by shopping at multiple stores. Walgreen has agreed to pay a \$1.3 million settlement.	2005	1,300,000.000
CryoLife Inc.	A class action lawsuit was filed against the biomaterial and biosurgical device company alleging inadequate disclosures. CryoLife's donor tissue was associated with a death of a patient who received a soft tissue implant during reconstructive knee surgery. During its inspection, the FDA found numerous, significant violations of regulations and in August 2002, the FDA recalled the tissue. CryoLife denied any wrongdoing and liability but has agreed to a \$23.3 million settlement.	2006	23,300,000.000
Boston Scientific	The U.S. Justice Department filed a lawsuit against the company claiming it illegally continued to make and sell systems for implanting stents in 1998 even after learning that a significant percentage of them were defective.	2005	74,000,000.000

Eli Lilly & Co.	The pharmaceutical company has agreed to a \$690 million settlement with consumers. The class action lawsuit alleged Eli Lilly did not adequately warn consumers that its antipsychotic drug Zyprexa could cause diabetic symptoms.	2006	69,000,000.000
Wyeth Pharmaceuticals	Four Utah women sued the drug company after they allegedly suffered heart valve damage as a result of taking Pondimin, one of the drugs used in the fen phen slimming cocktail.	2006	2,200,000.000
Wyeth Pharmaceuticals	A Pennsylvania jury has awarded two former fen-phen users \$200 million in damages for heart problems caused by the diet drug. In February, Wyeth offered class action plaintiffs a 'drop claim' settlement option of up to \$100,000. Even though the weight loss medication is still on the market, Margie Paul and Elaine Karician were awarded \$100 million each.	2005	200,000,000.000
Sulzer Medica AG	The company has settled a class action lawsuit in regards to faulty hip and knee surgical implants made by a subsidiary, avoiding bankruptcy for Sulzer. The suit was settled for \$725 million.	2006	725,000,000.000
Wyeth Pharmaceuticals	Two Utah residents had filed a class action lawsuit against the company for cardiovascular damages from the diet drug phen-fen. A jury decided the plaintiffs should be awarded \$5.5 million in damages. Phen-fen has been withdrawn from the market and Wyeth has set aside \$21.1 billion to resolve litigation.	2006	5,500,000.000
Sulzer Medica AG	The company has settled a class action lawsuit in regards to faulty hip and knee surgical implants made by a subsidiary, avoiding bankruptcy for Sulzer.	2005	4,000,000.000

Bayer	A settlement has been reached in the class action lawsuit filed on behalf of Canadians who took Baycol, a cholesterol-lowering drug. The suit alleged that the plaintiffs contracted rhabdomyolysis, a muscle disease, after taking the drug.	2004	9,000,000.000
DuPont Pharmaceuticals Co.	A \$77.5 million settlement has been reached in the class action lawsuit filed on behalf of consumers who purchased the blood-thinning medication, Coumadin. The suit alleged that the company disseminated false court approval in the class action lawsuit filed on behalf of Canadians (excluding those residing in Quebec) who ingested the	2005	12,000,000.000
Servier Canada Inc. et al.		2005	44,500,000.000
TAP Pharmaceutical Products	A \$150 million settlement has been reached in the class action lawsuit filed in May 2001 on behalf of anyone who purchased the drug Lupron after Jan. 1, 1985. The suit alleged that the company artificially inflated the price of the drug, which is primarily used to treat prostate cancer, but is also prescribed for endometriosis in women and premature puberty in children.	2005	150,000,000.000
Organon USA Inc. & Akzo Nobel N.V.	A \$36 million settlement has been reached in the nationwide class action lawsuit filed on behalf of the consumers, state purchasers, and other end payors of the antidepressant drug, Remeron. The suit alleged that the company improperly listed a new "combination therapy" patent with the U.S. Food and Drug Administration in order to unlawfully extend its monopoly.	2005	36,000,000.000
Bristol-Myers Squibb Co., Baxter International Inc.'s healthcare unit, 3M Co., Dow Chemical Co.'s Union Carbide Corp. unit et al.	An \$11.3 million settlement has been reached with the U.S. government as medical reimbursement for women injured by silicone breast implants. The suit was filed four years ago by the Department of Justice.	2005	11,300,000.000

GlaxoSmithKline PLC.	A \$2.5 million settlement has been reached with the State of New York. The lawsuit alleged that the company had misrepresented data on prescribing its antidepressant drug Paxil to children. Almost seven years and \$1 billion later, McKesson Corp. is ready to close the book on a 1999 corporate accounting scandal that led to a \$9 billion loss in the company's market value. While some litigation may	2005	2,500,000.000
McKesson legal saga nears end; \$960 million settlement approved last week.		2005	960,000,000.000
Warner-Lambert	A \$60 million settlement has been reached and is pending approval in the class action lawsuit filed in regards to the company's sale of Warner-Lambert's diabetes drug, Rezulin. The suit was filed on behalf of purchasers of Rezulin who reside in Illinois.	2005	60,000,000.000
Metabolife.	A \$7.4 million verdict has been reached in the lawsuit filed by Rhea McAllister, a 35-year-old woman who suffered a stroke as a result of taking the now banned supplement which contains the drug ephedra.	2005	7,400,000.000
GlaxoSmithKline.	A \$75 million settlement has been reached in the consumer lawsuit filed regarding charges that the company illegally blocked generic versions of its arthritis drug Relafen in the United States.	2005	75,000,000.000

Fen-Phen maker Wyeth-Ayerst Laboratories.	A \$1.3 million verdict has been awarded to Deborah Hayes who alleged that use of the weight-loss drug damaged her heart. Hayes had opted out of a pending class action suit. The company still faces approximately 70,000 similar opt-out lawsuits.	2005	1,300,000.000
Cardizem.	A \$21 million dollar settlement fund has been created as part of the settlement in the class action lawsuit filed on behalf of consumers who took the heart medication Cardizem, CD, or any of its generic equivalents, between 1998 and the present. Class members must file their claims by September 23, 2003 in order to be awarded settlement funds.	2005	21,000,000.000
Bristol-Myers Squibb.	Bristol-Myers Squibb. A \$62.5 million settlement has been reached in the class action lawsuit filed against Bristol-Myers Squibb, the manufacturer of the cancer-fighting medicine Taxol. The suit alleged that the company conspired to keep lower priced generic equivalents of the breast and ovarian cancer medication off the market. The class consists of 400,000 patients who used Taxol between 1999 and 2003, and they are expected to receive \$400 to \$2,600 back.	2005	62,500,000.000
Bristol-Myers Squibb	A \$41.7 million settlement has been reached in the antitrust class action filed against BuSpar maker Bristol-Myers Squibb. The suit claimed that the company had conspired with a potential competitor to prevent the entry into the market of a generic version of the drug, which is used to treat Generalized Anxiety Disorder and other disorders, including Alzheimer's Disease.	2004	41,700,000.000
Dupree v. Wyeth	Jury Awards \$41,195.12 in Compensatory Damages	2004	41,000.000

Dey, Inc.	An \$18.5 million dollar settlement has been reached in the Medicaid fraud settlement filed against Dey Inc. (a California-based subsidiary of Merck KGaA) by the state of Texas and the federal government. The suit claimed that the company falsified price reports to the Texas Medicaid program.	2004	18,500,000.000
Guidant Corp.	A \$92 million dollar settlement has been reached in the lawsuit filed against the Guidant Corp. subsidiary EndoVascular Technologies Inc. The company pled guilty to 10 felony counts for putting a defective product, Ancure Endograft, on the market. Ancure was used to treat abdominal aortic aneurysms.	2004	92,000,000.000
Rexall Sundown, Inc.	Preliminary approval has been granted in the settlement of the class action lawsuit filed against Rexall Sundown, Inc. regarding the sale of the company's anti-cellulite dietary supplement, "Cellasene", which plaintiffs claim violated state and federal laws regarding unfair competition and false advertising. The company will pay \$12 million dollars into a Consumer Redress Fund to compensate those who purchased Cellasene.	2004	12,000,000.000
Cytodyne Technologies	A verdict has been found in the class action lawsuit filed against Cytodyne Technologies on behalf of consumers. The court has ordered the company to pay \$12,536,820, the amount identified as "obtained by means of unlawful practice." The suit alleged that the companies advertisements for its ephedra-based Xenadrine RFA-1 diet	2004	12,500,000.000
Bayer Corporation and GlaxoSmithKline	The companies have agreed to pay settlement amounts totalling more than \$344 million for their fraudulent conduct in a scheme involving the re-labeling of products to an HMO at deeply discounted prices, and then concealing and avoiding their obligation to pay millions of dollars in additional rebates to the Medicaid program.	2004	344,000,000.000

Aventis Pharmaceuticals and the Andrx Corp.	have agreed to pay \$80 million to settle claims of conspiring to prevent a generic version of a popular blood pressure medication, Cardizem CD, from reaching the market.	2004	80,000,000.000
Brochu v. Ortho Pharmaceutical Corp., 642 F.2d 652, Prod. Liab. Rep. (CCH) ¶8914 (1st Cir. N.H. 1981)	Mrs. Brochu used this brand of oral contraceptive until November 14, 1971; the next day she suffered a cerebral thrombosis that initially left her totally paralyzed on her left side.	2004	210,000.000
Skill v. Martinez, 91 F.R.D. 498, 8 Fed. R. Evid. Serv. (Callaghan) 1372 (D.N.J. 1981)	Products liability-medical malpractice action, Mrs. Skill suffered a cerebral vascular accident (CVA), commonly known as a stroke, resulting from her ingestion of an oral contraceptive pill (Ortho Novum), manufactured by the defendant, Ortho Pharmaceutical Corporation (Ortho).	2004	600,000.000
Timm v. Upjohn Co., 624 F.2d 536, Prod. Liab. Rep. (CCH) ¶8753 (5th Cir. La. 1980), cert. denied 449 U.S. 1112, 66 L. Ed. 2d 840, 101 S. Ct. 921	The plaintiffs, Deborah and Robert Timm, filed this diversity action in the district court for personal injuries to Deborah Timm, and consequential damages from those injuries, allegedly caused by her use of defendant The Upjohn Company's drug Cleocin. A jury in the United States District Court for the Eastern District of Louisiana found Upjohn negligent in its marketing of Cleocin ; it further found that the negligence was a proximate cause of Deborah Timm's injuries. Deborah Timm's damages were set at \$195,000 and her husband Robert's damages were set at \$115,000.	1980	250,000.000
Watkins v United States US Dist Ct, D SC, No 81-1029-1 (June 27, 1984) 27 ATLA L Rep 462 (Dec 1984) [\$152,740];		1984	153,000.000
Reyes v. Wyeth Laboratories, 498 F.2d 1264, 19 Fed. R. Serv. 2d (Callaghan) 174 (5th Cir. Tex. 1974)		1974	310,000.000

Stavro v Upjohn ED Mich, No 77-1761 (March 17, 1982) 25 ATLA L Rep 323 (Sept 1982)		2003	200,000.000
Needham v. White Laboratories, Inc., 639 F.2d 394, Prod. Liab. Rep. (CCH) ¶8875, 7 Fed. R. Evid. Serv. (Callaghan) (7th Cir. Ill. 1981)		1981	500,000.000
Sterling Drug, Inc. v. Yarrow, 408 F.2d 978 (8th Cir. S.D. 1969) .	Appellee claimed that her vision had been permanently damaged by use of a prescription drug manufactured and sold by appellant for use in treatment of rheumatoid arthritis and other diseases.	1969	800,000.000
Boutte v United States US Dist Ct, MD Fla, No 79-643 Civ T-H (Dec 6, 1983) 27 ATLA L Rep 462 (Dec 1984)		2003	180,000.000
Stevens v. Parke, Davis & Co., 9 Cal. 3d 51, 107 Cal. Rptr. 45, 507 P.2d 653, 94 A.L.R.3d 1059 (1973)	Liability for overpromoting a drug [jury verdict against both drug manufacturer and <u>prescribing physician</u>	1973	978,000.000
Glass v Phillips Roxane Cal, Los Angeles County Super Ct, No C-270-762 (Dec 12, 1983)		1983	678,000.000
Mahr v. G. D. Searle & Co., 72 Ill. App. 3d 540, 28 Ill. Dec. 624, 390 N.E.2d 1214, Prod. Liab. Rep. (CCH) ¶8636 (1st Dist. 1979)		1979	500,000.000
Wooderson v. Ortho Pharmaceutical Corp., 235 Kan. 387, 681 P.2d 1038, Prod. Liab. Rep. (CCH) ¶10100 (1984),	Carol Wooderson lost both kidneys to a blood disorder caused by birth control pills and underwent two kidney transplants. The jury awarded \$4.75 million. The manufacturers subsequently reduced the level of estrogen in birth control pills and added consumer information to their packaging.	1984	4,750,000.000

Givens v. Lederle, 556 F.2d 1341, 2 Fed. R. Evid. Serv. (Callaghan) 387 (5th Cir. Fla. 1977)	This is a consolidated products liability case, with cross-appeal for additur, involving the Sabin oral polio vaccine. That represents what the company will pay after insurance claims are resolved, with the total settlement worth \$138 million. It is one of the largest amounts paid out by a Canadian company involved in a securities lawsuit.	1977	250,000.000
Pays \$138 million. Class action was filed by U.S. investors			<u>138,000,000.000</u>
Cobalis settles outstanding litigation with Gryphon Master Fund, L.P.	The settlement, which relates to two investments in Cobalis totaling \$1.6 million that were made by Gryphon in September 2003, includes an agreed judgment totaling a maximum of \$1.6 million.	2006	1,600,000.000
\$89 Million Proposed Class Action Settlement Provides Consumers and Insurers With Money Back for Celebrex and Bextra Purchases and Reimbursements	The settlement in the case called In re Bextra and Celebrex Marketing, Sales Practices, and Product Liability Litigation, No. 05-CV-01669, MDL No. 1699, pending in the United States District Court for the Northern District of California, will provide a Settlement Fund of \$89 million to benefit a class of consumers and insurance companies or other en	1981	89,000,000.000
O’Gilvie v. International Playtex, 821 F.2d 1438 (10th Cir. 1987)	O’Gilvie died from Toxic Shock Syndrome after using Playtex super-absorbent tampons. The jury’s \$11.2 million verdict led to the removal from the market of Playtex’s super-absorbent tampons and addition of warnings to packaging.	1987	11,200.000
Graham v. Wyeth Labs, 666 F.Supp. 1483 (D. Kan. 1987).	Michelle Graham had a severe neurological reaction to Wyeth Labs’ DPT vaccine and suffered severe brain damage. The jury awarded \$15 million. Wyeth thereafter purified the vaccine	1987	115,000,000.000

Wyeth to pay \$134.5 M in HR law suit	As a result of a law suit filed by three Nevada, USA, women against drug major Wyeth, alleging that its hormone replacement products had been the cause of their breast cancer, the jury hearing the case found in favor of the plaintiffs, awarding damages totaling \$134.5 million	2008	135,000,000.000
State of Wisconsin various Pharmaceutical Companies	The money has come in relatively small amounts, but Wisconsin has picked up more than \$11 million in the past three years from settlements with pharmaceutical companies over alleged overpricing of prescription drugs and marketing abuses.		11,000,000.000
Businessman Exposed Problems With Quest Subsidiary's Blood Test Kits; Led to \$302 Million Settlement	The impetus for the massive federal investigation that led to today's \$302 million settlement by		302,000,000.000
DuPont Settlement Finalized	A class-action lawsuit against DuPont was finalized in February 2005, resulting in a \$108 million settlement (see EBN Vol. 13, No. 11 for more on the tentative settlement). DuPont was charged with polluting the drinking water of several Ohio and W	2005	108,000,000.000
Whistleblower Case Against New Jersey Hospital for Medicare Fraud Settles for \$1.75 Million	St. Joseph Healthcare System Inc., has agreed to pay \$1.75 million to the federal government to settle a whistleblower lawsuit that alleged the Paterson, New Jersey, hospital engaged in Medicare fraud by improperly inflating its Medicare reimbursement claims		1,750,000.000
	Products Liability: Prescription \$5,500,000 Verdict: Death		5,500,000.000

	Some 60,000 plaintiffs in the class action against the makers of Fen-Phen were given 'drop claim' settlement options. The expedited option offered \$20,000 per claim, while the grid option offered \$5,250 to \$200,000 based on the severity of their condition, plus an additional \$100,000 for clients who undergo heart-valve replacement surgery by 2010		
Wyeth Pharmaceuticals	Products Liability: Weight Loss : Heart Damage	2005	20,000,000.000
Clepper v. Wyeth, et al		2004	48,000.000
Ceballos v. Bayer A.G.; Smithkline Beecham Corp. d/b/a Glaxosmithkline; Glaxosmithkline PLC (USDC MDL 1431)	Products Liability: Prescription \$48,000 Verdict: Heart Damage		48,000.000
Lyons, Estate of v. Janssen Pharmaceutical (Circuit 94-L-324)	Products Liability: Prescription \$899,000 Settlement: Death		899,000,000.000
Wakefield, Estate of v. Warner-Lambert n/k/a Pfizer Inc. (District CJ 2000-4654)	Products Liability: Prescription 876,000 Verdict: Death		876,000.000
Sanchez v. Parke-Davis Co.	Products Liability: Prescription \$11,550,000 Verdict: Death	2008	11,600,000.000
Hunt v. DeJulian D.D.S.; Johnson D.D.S. (Superior NO67967)	Products Liability: Weight Loss Products \$8,000,000 Verdict: Avascular Necrosis	2006	8,000,000.000
Moore v. American Home Products Inc.	the FDA and the defendant were found contributorily negligent Products Liability: Prescription \$500,000 Settlement: Heart Damage	2006	237,000.000
Lovett v. Wyeth-Ayerst Laboratories; American Home Products Inc.			500,000.000
Brown, Estate of v. Glaxo Wellcome Inc.;	Products Liability: Prescription \$23,362,000 Verdict: Heart Damage	2006	23,000,000.000
Arkansas v. Bayer	Products Liability: Prescription \$1,907,460 Verdict: Death	2005	2,000,000.000

All 50 states sued the pharmaceutical company, claiming it overcharged for a drug used in cancer chemotherapy. The \$541,495 settlement for the medical center was the largest per-capita award for a state hospital from the company. In addition, the state Department of Human Services Division of Medical Services won \$175,443 and the Arkansas Employee Benefits Division received \$64,976.

Alabama's Winning Streak Continues: Jury Hits Novartis with \$78.4 Million Verdict	CLINICAL TRIAL RESEARCH; Vioxx Settlement Announced	2005	541,000.000
Alabama's Winning Streak Continues: Jury Hits Novartis and GSK with \$114,242,233	Sandoz was the first generic drug company to face the dread Alabama home field advantage. Alabama's lead trial counsel—Jere Beasley of the plaintiffs firm Beasley, Allen, Crow, Methvin, Portis & Miles—told us that the generic industry regarded the trial as a test case, so he's expecting to step up settlement talks in the wake of the verdict. (Of the 70 drug companies sued by the state in 2005, seven have settled. Beasley told us he's in active negotiations with another 15. Another three defendants have June trial dates.)	2004	78,400,000.000
		2004	114,000,000.000

Recalled Guidant defibrillator claim settlement	<p>Attorney General Troy King today announced a second major victory in his litigation against drug companies for massive overcharges to the Alabama Medicaid Agency. A jury in Montgomery County Circuit Court returned a verdict in favor of the State of Alabama, finding defendants, GlaxoSmithKline and Novartis Pharmaceuticals Corp. liable for a total of \$114,247,233, of which \$80,989,539 is from GlaxoSmithKline and \$33,257,694 is from Novartis.</p>	2003	114,250,000.000
	<p>Plaintiffs Obtain \$240 Million Amended Settlement In Guidant Defibrillators Products Liability Litigation</p>		
		2002	240,000,000.000
"Guidant Corp. pays \$92.4 million settlement with the U.S. Dept."			92,400,000.000
	<p>Eight of 12 states that sued Eli Lilly & Co over alleged off-label promotion of its antipsychotic drug Zyprexa, have reached a settlement with the pharmaceutical company.</p>		
82 Year Old Awarded \$6 Million in SJS Lawsuit Merck, Schering Settle Vytarin Zetia Class Action	<p>While the terms of the settlements are confidential, West Virginia's settlement is reportedly worth \$2.5 million.</p>		2,500,000.000
		2002	6,000,000.000
Bausch & Lomb Lens Cleaner Settlements Top \$250 Million So Far		2000	5,400,000.000

	Bausch & Lomb has reportedly settled almost 600 lawsuits stemming from antifungal infections caused by their lens cleaner ReNu with MoistureLoc. While there are dozens more lawsuits pending, the Associated Press reports, the cost so far is upward of \$250 million.	2000	250,000,000.000
Johnson & Johnson	The pharmaceutical company, Johnson & Johnson has been fined \$4.5 million by West Virginia circuit judge Martin Gaughan for false and misleading promotion of their drugs Duragesic, a painkiller, and Risperdal, an antipsychotic.	2000	4,500,000.000
IFCO Systems Enters Into Record \$20.7 Million Settlement of Claims Related to Employment of Illegal Aliens	A record corporate settlement in an investigation of the employment of illegal aliens by IFCO Systems North America (IFCO), was announced by Andrew T. Baxter, Acting United States Attorney for the Northern District of New York; John P. Torres, Acting Assistant Secretary of Homeland Security for Immigration and Customs Enforcement (ICE); and Superintendent Harry J. Corbitt, New York State Police. IFCO, headquartered in Houston, Texas, is the largest pallet management services company in the United States. IFCO has agreed to pay \$20.7 million dollars in civil forfeitures and penalties over four years, making this the largest corporate settlement in a work site enforcement case to date .	2009	21,000,000.000
GSK Reaches Potential \$28 Million Settlement over Defective Paxil Tablets	GlaxoSmithKline has reached a tentative \$28 million settlement in a class action lawsuit over manufacturing defects in certain tablets of their best selling antidepressant Paxil.		28,000,000.000

Wyeth to Pay Amputee \$6.7 Million in Landmark Case	Diana Levine, who sued the drug maker Wyeth alleging she lost an arm to gangrene after receiving a shot of an anti-nausea medicine to treat her migraine, has won her case. The Supreme Court today upheld the award for \$6.7 million.		6,700,000.000
Johnson & Johnson	The family of a 38 year old woman, who died from an overdose of fentanyl, after using the defective duragesic pain patch, has been awarded \$16.6 million. The Chicago jury ruled that subsidiaries of Johnson & Johnson are liable.	2005	16,600,000.000
CVS, America's Largest Pharmacy Chain, Pays Nearly \$37 Million to Settle Federal and State Generic Drug Switching Charges	CVS Corporation, which claims to be America's largest pharmacy chain, has paid nearly \$37 million to settle the nation's first retail pharmacy drug switching case. CVS allegedly charged the government up to 400 percent more for Medicaid patients by illegally changing generic Zantac(R) prescriptions from tablets to higher priced capsules, according to a multi-state complaint pursued by whistleblower attorneys Michael I. Behn and Linda Wyetzner .	2008	37,000,000.000
Otsuka to Pay More Than \$4 Million to Resolve Off-Label Marketing Allegations Involving Abilify	Otsuka American Pharmaceutical Inc., the U.S. subsidiary of Japanese pharmaceutical manufacturer Otsuka Pharmaceutical Co., Ltd has agreed to pay more than \$4 million to resolve allegations that it marketed Abilify, an atypical antipsychotic drug, for "off-label" uses, the Justice Department announced.	2008	4,000,000.000
Alfred Civarelli and James Celedonia v. Mickey Burke, T/D/B/A Mickey Burke's Stables, Barry Betts, D.V.M., T/D/B/A Hickory Ridge Equin Clinic and Hood Pharmacy, A West Virginia Corporation	Plaintiffs Alfred Civarelli, 60s, business owner, and James Celedonia, 50s, business owner, each owned a racehorse, which became ill on May 19, 2000 following a customary pre-race injection of vitamin...	2006	-

CHIRON; Pharma announces settlement in HIV patent dispute with Roche	Under the terms of the settlement agreement, which covers clinical diagnostics and blood screening, Roche irrevocably stipulates to the validity and enforceability of the patent. In addition, Chiron will retain all funds paid by Roche while the matter was in dispute. Chiron will also receive a lump-sum payment of \$78 million in lieu of royalties beyond January 1, 2005. Roche may elect under the terms of the agreement to obtain a partial refund and revert to paying royalties on the sales of its products in North America.	2004	78,000,000.000
Bayer Healthcare in \$97.5 million kickback settlement	Diabetic supply maker Bayer Healthcare, a unit of Bayer AG (BAYG.DE: Quote, Profile, Research, Stock Buzz), has agreed to pay \$97.5 million to settle allegations that it paid kickbacks to several diabetic suppliers and caused them to submit false Medicare claims, the U.S. Justice Department said.	2008	98,000,000.000
Bayer Agrees To Pay U.S. \$257 Million In Drug Fraud	In the largest Medicaid fraud settlement, Bayer agreed yesterday to pay the government \$257 million and pleaded guilty to a criminal charge after engaging in what federal prosecutors said was a scheme to overcharge for the antibiotic Cipro.		257,000,000.000
GlaxoSmithKline: A \$175 million settlement	A \$175 million settlement has been reached and is pending approval in the antitrust class action lawsuit filed regarding the company's nonsteroidal anti-inflammatory product Relafen.	2004	175,000,000.000
Boston IVF. - A \$108,000 verdict	A \$108,000 verdict has been reached in the lawsuit filed by Richard Gladu of Dennis. Gladu filed the suit claiming that the clinic had violated its contract by impregnating his wife without his consent.	2004	108,000.000

Brooke Army Medical Center: An \$8.1 million settlement	An \$8.1 million settlement has been reached in the lawsuit filed on behalf of the family of Marvin Moore. The suit alleged that due to medical mistakes made by the defendant, Moore was left in a vegetative state following a car accident which occurred on March 19, 2002.	2004	8,100,000.000
X-Ray LTD et al. - A \$800,000 verdict	A \$800,000 verdict has been reached in the lawsuit filed by 37-year-old Monica Ochoa who claimed that because a cancerous growth in her breast was not properly diagnosed, it spread to her liver. The jury found that Dr. Kenneth L. Sandock and X-Ray LTD were 60% responsible, Dr. Irene Duarte and Arizona Community Physicians were 20% responsible, and that Ochoa herself responsible for the remaining 20% due to the fact that she either misunderstood or ignored instructions to follow up with her primary care doctor.	2004	800,000.000
PeaceHealth: A \$1.1 million verdict	A \$1.1 million verdict has been reached in the lawsuit filed by Lori Hughes, whose 19-year-old daughter Jill Dieringer died of bacterial meningococcal disease in February 2001 at Sacred Heart Medical Center. The jury found PeaceHealth, the owner of the medical center, to have been 100 percent negligent in "one or more of the ways claimed."	2004	1,100,000.000
CHATTEM INC: Dexatrim Claims Resolved for \$13.25M in Sept. 2008	COMPANIES: Chattem Inc. Chattem, Inc., in September 2008, resolved all Dexatrim cases pending against it for US\$13,250,000 of which US\$2,545,000 was funded from the proceeds of the Dexatrim settlement trust.	2008	13,300,000.000
Fen-Phen maker Wyeth-Ayerst Laboratories: A \$1.3 million verdict	A \$1.3 million verdict has been awarded to Deborah Hayes who alleged that use of the weight-loss drug damaged her heart. Hayes had opted out of a pending class action suit. The company still faces approximately 70,000 similar opt-out lawsuits.	2003	1,300,000.000

Colorado Department of Health Care Policy and Financing: \$10 million Settlement	A \$10 million settlement has been reached in the lawsuit filed by Kaiser Permanente. The suit alleged that the department knowingly underpaid them for care of low-income patients by the amount of \$14 million between 1996 and 2001.	2003	10,000,000.000
Dangerous Diabetes Drug - \$2,500,000 Settlement	<p data-bbox="741 370 1121 427">Dangerous Diabetes Drug - \$2,500,000 Settlement</p> <p data-bbox="741 431 1178 1097">Our pharmaceutical injury lawyers successfully recovered \$2,500,000 on behalf of a 63-year-old Sacramento woman who was prescribed a diabetes drug that resulted in liver failure and the need for a liver transplant. The drug had been approved by the FDA, but was later recalled. The drug maker initially claimed that the drug was safe. However, our attorneys were able to demonstrate that the manufacturer knew about problems with impaired liver function, but never adequately warned doctors or the public about this side effect, and limited any mention of possible liver damage to the “fine print” of its package insert. Because of the manufacturer’s failure to tell prescribing doctors about the problem, our client’s physicians were unaware that her liver failure was due to the drug – delaying an accurate diagnosis for almost six months, by which time her condition had become life-threatening.</p>	****	2,500,000.000
The Norman Regional Hospital Authority, OK. - A \$25 million settlement	A \$25 million settlement has been reached and is pending approval in the class action lawsuit filed on behalf of more than 1,000 plaintiffs. The suit alleges that the hospital, Dr. Jerry Lewis, M.D., and anesthetist James Hill helped to spread the Hepatitis virus by reusing needles when administering intravenous pain medicine to patients through heparin locks.	2003	25,000,000.000

Humana Inc. - A \$100 million settlement	A \$100 million settlement has been reached in the class action lawsuit filed on behalf of 1,900 Tri-State physicians and the Academy of Medicine. The suit was filed against four health insurers alleging that the companies had conspired to use illegal and anticompetitive practices to suppress reimbursements to local doctors.	2003	100,000,000.000
Aetna et al. – A \$400-\$450 million Settlement	Aetna. Final approval had been granted to the \$400-\$450 million settlement of the class action lawsuit filed on behalf of more than 700,000 physicians. The suit claimed that the defendants had "violated contracts and defrauded doctors in violation of the federal Racketeer Influenced and Corrupt Organization Act (RICO)". The settlement calls for improvements to physician-related business practices and a National Advisory Committee of Practicing Physicians to provide advice to Aetna on issues of importance to physicians.	2003	400,000,000.000
Intrepid of North Carolina Inc. - A \$685,000 settlement	A \$685,000 settlement has been reached in the federal lawsuit filed by the U.S. Department of Health and Human Services alleging Medicaid fraud. The settlement also requires that the company be monitored by the U.S. Department of Health and Human Services for a period of five years.	2003	685,000.000

Stanford Hospital and Palo Alto Medical Clinic - A \$70 million verdict	A \$70 million verdict has been found in the lawsuit filed on behalf of the family of 9-year-old Michael Cook. The suit claimed that the Hospital staff gave Michael a standard blood screening test for metabolic disorders when he was only 4 hours old, however in order to detect disorders, the test should not be given for 24 hours. Michael suffered brain damage and developmental disorders due to the fact that his disorder, known as phenylketonuria, or PKU, was not diagnosed immediately, and therefore treatment was delayed.	2003	70,000,000.000
HealthSouth Corp. - A \$1.4 million	A \$1.4 million jury verdict has been found in the lawsuit filed on behalf of Dr. Helen Schilling. The suit claimed that Dr. Schilling, former director of medical services at HealthSouth Houston Rehabilitation Institute, was fired after she refused to illegally drum up patients for the center. The jury found that the company violated state and federal law by asking Schilling to keep patients hospitalized when they should have been discharged, and to admit patients who didn't need treatment.	2003	1,400,000.000
Cigna Corp. – A \$540 million dollar settlement	Preliminary approval has been granted to the \$540 million dollar settlement in the class action lawsuit filed on behalf of the nation's 700,000 doctors, claiming that Cigna had chronically skimped on doctor's payments. The settlement includes \$400 million to be spent on internal changes, as well as at least \$70 million for payments to doctors for claims up to 12 years old. The settlement also allows for \$55 million to be paid in attorneys' fees and \$15 million for creating a health care foundation. The final approval hearing will be held on December 18, 2003.	2003	540,000,000.000

Cardizem - A \$21 million dollar settlement	A \$21 million dollar settlement fund has been created as part of the settlement in the class action lawsuit filed on behalf of consumers who took the heart medication Cardizem CD, or any of its generic equivalents, between 1998 and the present. Class members must file their claims by September 23, 2003 in order to be awarded settlement funds.	2003	21,000,000.000
Tenet Healthcare Corp. - A \$54 million settlement	A \$54 million settlement has been reached in the lawsuit filed against Tenet Healthcare Corp, Redding Medical Center and Tenet HealthSystems Hospitals Inc. The suit was filed by the federal government, claiming that two doctors had performed unnecessary heart procedures. The settlement will cover all unnecessary heart procedures allegedly performed at Redding Medical Center between 1997 and 2002, which that were billed to Medicare, Medicaid and the military's Tricare program.	2003	54,000,000.000
Federal Government, Touchette Regional Hospital - A \$19 million verdict	A \$19 million verdict has been found in the lawsuit filed against the federal government and Touchette Regional Hospital in Centreville, Illinois regarding deficient birth procedures at the hospital. The verdict will be paid to Kimberly Coleman of Belleville whose 5-year-old son developed brain damage and cerebral palsy as a result of a doctor improperly using a vacuum extractor while attempting to deliver her son Javan on July 19, 1998.	2003	19,000,000.000

Bristol-Myers Squibb - A \$62.5 million Settlement	<p>A \$62.5 million settlement has been reached in the class action lawsuit filed against Bristol-Myers Squibb, the manufacturer of the cancer-fighting medicine Taxol. The suit alleged that the company conspired to keep lower priced generic equivalents of the breast and ovarian cancer medication off the market. The class consists of 400,000 patients who used Taxol between 1999 and 2003, and they are expected to receive \$400 to \$2,600 back.</p>	2003	62,500,000.000
GlaxoSmithKline: \$1 Million Settlement	<p>Jul. 9--Hundreds of thousands of people nationwide who received the Lyme disease vaccine have received what lawyers labeled an impressive settlement. But if you are one of the recipients of Lymerix shots, don't bother looking for a check in the mail. The benefits from an agreement finalized last week with the vaccine's manufacturer, SmithKline Beecham Corp., now GlaxoSmithKline P.L.C., are not monetary -- unless you are one of the plaintiffs' attorneys, who will split more than \$1 million.</p>	****	1,000,000.000
Northwest Medical Center - \$1.1 million has been awarded	<p>\$1.1 million has been awarded to Roy E. Lund in the civil suit he filed against Northwest Medical Center. Lund filed the lawsuit after claiming he had been falsely imprisoned at the hospital for more than seven days in 1993. On November 23, 1993, Lund's wife called the police, alleging that Lund had threatened her life. Lund was admitted for emergency mental examination and treatment against his will. According to the suit, "the allegations which were the basis for Lund's involuntary commitment were false," and state law required that he be discharged within five days.</p>	2003	1,100,000.000

Bristol-Myers Squibb - A \$41.7 Million Settlement	A \$41.7 million settlement has been reached in the antitrust class action filed against BuSpar maker Bristol-Myers Squibb. The suit claimed that the company had conspired with a potential competitor to prevent the entry into the market of a generic version of the drug, which is used to treat Generalized Anxiety Disorder and other disorders, including Alzheimer's Disease.	2003	41,700,000.000
Guidant Corp. - \$92 million dollar settlement	A \$92 million dollar settlement has been reached in the lawsuit filed against the Guidant Corp. subsidiary EndoVascular Technologies Inc. The company pled guilty to 10 felony counts for putting a defective product, Ancure Endograft, on the market. Ancure was used to treat abdominal aortic aneurysms.	2003	92,000,000.000
Rexall Sundown, Inc. - \$12 Million Settlement	Preliminary approval has been granted in the settlement of the class action lawsuit filed against Rexall Sundown, Inc. regarding the sale of the company's anti-cellulite dietary supplement, "Cellasene", which plaintiffs claim violated state and federal laws regarding unfair competition and false advertising. The company will pay \$12 million dollars into a Consumer Redress Fund to compensate those who purchased Cellasene.	2003	12,000,000.000
Cytodyne Technologies – A \$12,536,820 Verdict	A verdict has been found in the class action lawsuit filed against Cytodyne Technologies on behalf of consumers. The court has ordered the company to pay \$12,536,820, the amount identified as "obtained by means of unlawful practice." The suit alleged that the companies advertisements for its ephedra-based Xenadrine RFA-1 diet products were deceptive.	2003	12,540,000.000

Bayer Corporation and GlaxoSmithKline - \$344 million settlement	have agreed to pay settlement amounts totalling more than \$344 million for their fraudulent conduct in a scheme involving the re-labeling of products to an HMO at deeply discounted prices, and then concealing and avoiding their obligation to pay millions of dollars in additional rebates to the Medicaid program.	2003	344,000,000.000
Brooke Army Medical Center - \$16.6 million dollar verdict	A \$16.6 million dollar verdict has been awarded to Rebecca Bowman and her family in the malpractice suit filed against Brooke Army Medical Center, and Northeast Methodist Hospital, as well as one of its doctors, Rene B. Lopez. The jury found that the defendants were liable for failing to detect Bowman's heart disorder when she was admitted to their emergency rooms in September and October 1998.	2003	16,600,000.000
\$1.86 million drug settlement to be given to Illinois clinics	A \$1.86 million settlement reached with makers of the prostate cancer drug Lupron will be distributed to 19 health clinics in the state, Attorney General Lisa Madigan's office announced Thursday. The settlement ends a 2005 lawsuit claiming the companies published fraudulent prices for the drug, causing government programs to overpay hundreds of millions of dollars.	2006	1,900,000.000
Victory Memorial Hospital - \$4.2 million dollar verdict	A \$4.2 million dollar verdict has been found in a suit filed on behalf of the family of a man who died of a heart attack at Waukegan's Victory Memorial Hospital. The family Raymond Amadei alleged that he did not receive proper care on September 22, 1999, when he went to the hospital's emergency room complaining of chest pains.	2003	4,200,000.000

concluded that pharmaceutical company Lederle Laboratories was responsible for the injury to a man who contracted polio from a vaccine 30 years ago, and ordered it to pay him \$22.5 million.

Dominick Tenuto became infected with polio in 1979, shortly after his daughter received a vaccine made by Lederle from a live polio virus. Tenuto alleged that he had been exposed to the live virus while changing his daughter's diaper.

According to the Centers for Disease Control and Prevention, a total of 144 people in the United States became infected with polio from live vaccines between 1980 and 1998. While the majority of these were the vaccine recipients themselves, the number includes 51 who contracted the disease upon contact with a vaccinated individual.

Tenuto became paralyzed from the disease and ended up spending months in intensive care, breathing through a hospital ventilator. Even after two years of rehabilitative therapy, he remained partially paralyzed and to this day cannot get around without a wheelchair. Because the Wall Street office Arkansas will get \$802,000 as part of a legal settlement with a pharmaceutical company, Attorney General Mark Pryor announced Friday.

Polio Vaccine Victim Wins \$22.5 million Lawsuit Against Big Pharma

Attorney General's office recovers \$802,000 in drug company settlement

The money is part of a national \$100 million settlement with Mylan Laboratories.

22,500,000.000

2001

802,000.000

	<p>Woman wins \$43 million medical lawsuit Leg cramps, breast pain and yeast infections. Those were the side effects listed on Arlene Rowatt's bottle of Premarin, a drug she started using in 1991 to treat menopause symptoms. But almost a decade later she developed breast cancer, and a chronic fear of doctors and pills.</p>		
	<p>Two weeks ago a jury found in favor of Rowatt and two other Nevada women, and issued a \$134 million judgment against pharmaceutical giant Wyeth. The \$43 million in compensatory and punitive damages the jury awarded Rowatt can't bring back her health. But, she says it can send a message to any women who may still be on the combination estrogen progesterone pill, now called Prempro.</p>		
Wyeth		2007	43,000,000.000
	<p>GlaxoSmithKline Plc and Novartis AG should pay Alabama as much as \$814 million for inflating drug prices paid by its Medicaid program, a lawyer for the state said at the close of a civil fraud trial. Glaxo and Novartis are among 70 drugmakers sued by Alabama to go to trial in state court in Montgomery.</p>		
Glaxo, Novartis Should Pay \$814 Million, Alabama Says	****		814,000,000.000
<p>Amgen Enhanced Coverage LinkingAmgen -Search using: Company Dossier News, Most Recent 60 Days Company Profile and Ortho Biotech Settle Antitrust Suit</p>	<p>Under terms of the agreement, Amgen will pay Ortho Biotech \$200 million and the pending litigation in New Jersey District Court will be dismissed with prejudice. Amgen continues to deny that its challenged conduct was unlawful, and admits to no wrongdoing as part of the settlement agreement.</p>	2008	200,000.000
<p>Brochu v. Ortho Pharmaceutical Corp., 642 F.2d 652, Prod. Liab. Rep. (CCH) 8914 (1st Cir. N.H. 1981)</p>	<p>Mrs. Brochu used this brand of oral contraceptive until November 14, 1971; the next day she suffered a cerebral thrombosis that initially left her totally paralyzed on her left side.</p>	1981	600,000.000

Skill v. Martinez, 91 F.R.D. 498, 8 Fed. R. Evid. Serv. (Callaghan) 1372 (D.N.J. 1981)	Products liability-medical malpractice action, Mrs. Skill suffered a cerebral vascular accident (CVA), commonly known as a stroke, resulting from her ingestion of an oral contraceptive pill (Ortho Novum), manufactured by the defendant, Ortho Pharmaceutical Corporation (Ortho).	1981	250,000.000
Watkins v United States US Dist Ct, D SC, No 81-1029-1 (June 27, 1984) 27 ATLA L Rep 462 (Dec 1984) [\$152,740]; Holcomb v United States SD WV, No 79-2376 (Feb 15, 1982) 25 ATLA L Rep (Dec 1982)		1982	2,100,000.000
Timm v. Upjohn Co., 624 F.2d 536, Prod. Liab. Rep. (CCH) ¶8753 (5th Cir. La. 1980), cert. denied 449 U.S. 1112, 66 L. Ed. 2d 840, 101 S. Ct. 921		1980	310,000.000
Givens v. Lederle, 556 F.2d 1341, 2 Fed. R. Evid. Serv. (Callaghan) 387 (5th Cir. Fla. 1977)		1977	250,000.000
Reyes v. Wyeth Laboratories, 498 F.2d 1264, 19 Fed. R. Serv. 2d (Callaghan) 174 (5th Cir. Tex. 1974)		1974	200,000.000
Stavro v Upjohn ED Mich, No 77-1761 (March 17, 1982) 25 ATLA L Rep 323 (Sept 1982)		1982	500,000.000
Needham v. White Laboratories, Inc., 639 F.2d 394, Prod. Liab. Rep. (CCH) ¶8875, 7 Fed. R. Evid. Serv. (Callaghan) (7th Cir. Ill. 1981)		1981	800,000.000
Sterling Drug, Inc. v. Yarrow, 408 F.2d 978 (8th Cir. S.D. 1969)		1969	180,000.000
Boutte v United States US Dist Ct, MD Fla, No 79-643 Civ T-H (Dec 6, 1983) 27 ATLA L Rep 462 (Dec 1984)		1984	978,000.000

Stevens v. Parke, Davis & Co., 9 Cal. 3d 51, 107 Cal. Rptr. 45, 507 P.2d 653, 94 A.L.R.3d 1059 (1973) [jury verdict against both drug manufacturer and prescribing physician	1973	400,000.000
Morris v Roseville Community Hosp Cal, Placer Cty Super Ct, No 49251 (July 27, 1982) 25 ATLA L Rep 375 (Oct 1982)	1982	7,000.000
Glass v Phillips Roxane Cal, Los Angeles County Super Ct, No C-270-762 (Dec 12, 1983)	1983	500,000.000
Mahr v. G. D. Searle & Co., 72 Ill. App. 3d 540, 28 Ill. Dec. 624, 390 N.E.2d 1214, Prod. Liab. Rep. (CCH) ¶8636 (1st Dist. 1979)	1979	100,000.000
Wooderson v. Ortho Pharmaceutical Corp., 235 Kan. 387, 681 P.2d 1038, Prod. Liab. Rep. (CCH) 10100 (1984),	1984	10,000.000
White v Merck & Co Mich, Crawford Cty Cir Ct, No 76-003-068- No (Jan 1982) 26 ATLA L Rep 467 (Dec 1982)	1982	110,000.000
Mooney v Parke, Davis & Co Mich, Berrien Cty Cir Ct, No 77-355-NPZ (Dec 12, 1979) 23 ATLA L Rep 87 (March 1980)	1980	2,400,000.000
Krug v. Sterling Drug, Inc., 416 S.W.2d 143 (Mo. 1967)	1967	125,000.000
Goldberg v Smith Kline Corp D NJ, No 81-2653(HLS) (May 11, 1982) 25 ATLA L Rep 375 (Oct 1982)	1982	100,000.000
Santiago v Bristol Laboratories NY, New York Cty Sup Ct, No 19835/72 (Oct 31, 1980) 24 ATLA L Rep 135 (April 1981)	1981	800,000.000

Zuyus v Lederle Laboratories NY, New York Cty Sup Ct, No 04743/75 (March 26, 1980) 23 ATLA L Rep 378 (Oct 1980)		1980	147,000.000
Shand v Ortho Pharmaceutical Corp Vt, Chittenden Cty Super Ct, No S742-77CNC (Sept 20, 1981) 24 ATLA L Rep 467 (Dec 1981)		1981	275,000.000
McNeary v Lederle Laboratories Wash, King Cty Super Ct, No 86- 3881 (April 15, 1982) 25 ATLA L Rep 323 (Sept 1982)		1982	1,100,000.000
	Jury returned a verdict in favor of plaintiffs for \$8,279,300, including \$7.8 million in punitive damages for failing to warn of risk of compulsive behaviors, including pathological gambling, from the Parkinson's drug Mirapex. After the verdict, Michael Ciresi and Tara Sutton engaged in settlement negotiations with the defendants and confidentially settled all of the firm's remaining Mirapex cases. The firm represented more than 280 clients injured by Mirapex.		
Charbonneau v. Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer, Inc.		2008	8,290,000.000
	Plagued by probes into its questionable sales and marketing practices, Bristol-Myers Squibb has agreed to pay \$499 million to settle up with the Justice Department and the U.S. Attorney for Massachusetts. Bristol- Myers has also agreed to sign a corporate integrity agreement with the feds but will not face criminal charges. Final details of the agreement still have to be worked out.		
Bristol-Myers agrees to pay \$499M to settle probes		2008	499,000,000.000

New York State and New York City to Pay Record \$540 Million to Settle Allegations of False Claims for Medicaid Funds	U.S. Department of Justice. *The state of New York and New York City have agreed to pay \$540 million to settle allegations that they knowingly submitted, or caused to be submitted, false claims for reimbursement for school-based health care services, primarily speech therapy and transportation, provided to Medicaid eligible children from 1990 to 2001, the Justice Department announced. The settlement is a record federal recovery by the Justice Department for the Medicaid Program (see also U.S. Department of Justice).	540,000,000.000
Johnson & Johnson Fined \$4.5 Million	The pharmaceutical company, Johnson & Johnson has been fined \$4.5 million by West Virginia circuit judge Martin Gaughan for false and misleading promotion of their drugs Duragesic, a painkiller, and Risperdal, an antipsychotic.	2009 4,500,000.000
\$10.1 Billion Tobacco Verdict Paves Way for Philadelphia Counsel	Illinois Judge ordered Philip Morris USA to pay \$10.1 billion in the first "light cigarette" consumer fraud class-action lawsuit to come to trial alleging a tobacco company committed consumer fraud in its advertising of light cigarettes. The verdict will pave the way for Freedland & Russo in a similar lawsuit filed in Florida. (Note: While not being a Big Pharma example, this case has had such an impact on the consumer, I included it in this report.)	2003 10,100,000.000
Over \$100 Million in Settlements in Pharmaceutical Drug Litigation	Attorneys Michael Freedland and Raymond Valori and their litigation team have secured in excess of \$100 million dollars in Pharmaceutical Drug Litigation settlements. The most recent resolution received final judicial approval in early 2008.	100,000.000

<p>Bristol-Myers Squibb Co. ("BMC"), and its subsidiary, Apothecan, agreed to pay \$515 million to settle allegations relating to pricing practices and drug marketing.</p>	<p>According to the government, BMS paid illegal kickbacks to physicians from 2000 to mid-2003, in order to get the physicians to promote BMS drugs. These payments were in form of consulting fees and other programs, of which some involved travel to extravagant resorts.</p>	<p>2008</p>	<p>515,000,000.000</p>
<p>McKesson Corporation to Pay Over \$13 Million to Settle Allegations It Violated Federal Reporting Requirements.</p>	<p>Without admitting liability, McKesson Corporation, a national distributor of prescription medications, has settled a claim for violating federal reporting requirements related to the sale of prescription medications. McKesson has agreed to pay \$13,250,000 in civil penalties under an agreement between McKesson and multiple U.S. Attorney's Offices, including the District of Maryland. Continue reading "McKesson Corporation to Pay Over \$13 Million to Settle Allegations It Violated Federal Reporting Requirements"</p>		<p>13,300,000.000</p>
<p>Pharmacy owner faces up to 130 years in prison for his part in \$3m Medicare fraud.</p>	<p>A Miami jury found Gustavo Smith, 43, guilty of all 17 counts charged against him in the September 2007 indictment, including: conspiracy to defraud the U.S. government, to commit health care fraud, and to submit false claims to the Medicare program; seven counts of health care fraud; seven counts of submitting false claims to the Medicare program; conspiracy to commit money laundering; and one count of money laundering. Sentencing has been scheduled for July 2, 2008.</p>		<p>3,000,000.000</p>

Alabama AG announces \$6.75mm settlement	Alabama Attorney General Troy King announced January 9, 2008 that the State has settled claims against pharmaceutical manufacturers Dey, LP and Takeda Pharmaceuticals North America, Inc.	6,750,000.000
BMS - Settlement awards \$11.3 million to U.S. government for Medicaid expenses	Resolving a massive lawsuit filed 4 years ago by the U.S. government, major breast implant manufacturers Bristol-Myers Squibb, Baxter Healthcare Co., 3M, Union Carbide, and other parties have agreed to pay \$11.3 million to reimburse expenses paid out to women injured by silicone gel breast implants.	2004 11,300,000.000
Doctor Settles Medicare Fraud Case for \$2 Million	A Massachusetts based doctor, Philip Chiotellis, has agreed to pay nearly \$2 million to settle allegations by the Department of Health & Human Services that he over-billed Medicare. Continue reading "Doctor Settles Medicare Fraud Case for \$2 Million" June 04, 2006 By Sara Vann	2,000,000.000
Medco to settle for \$163 million	Medco Health Solutions, Inc. is a pharmacy benefits manager that has long been under scrutiny for possible False Claims Act violations. Medco will be settling three whistleblower lawsuits.	163,000,000.000
Matria Settles False Claims Act Lawsuit for \$9 Million	Matria Healthcare, Inc., a Georgia company, has agreed to pay \$9 million to the United States to settle allegations of Medicare fraud relating to its former subsidiary, Diabetes	9,000,000.000

Bayer Reaches Settlement With 27 Attorneys General Over Misleading Birth Control Ads	German pharmaceutical company Bayer on Monday agreed to conduct a \$20 million corrective advertising program for its oral contraceptive Yaz and submit future television advertisements to FDA for approval as part of a settlement between the drug maker and 27 state attorneys general.	2009	20,000,000.000
Eli Lilly Pays \$18M To Settle Contract Squabble	Eli Lilly & Co. has agreed to pay \$18 million to settle a biotechnology company's claims that the pharmaceutical giant stole technology which converts injectable-only drugs into pills that can be taken orally.	2007	18,000,000.000
Medicis Pharmaceutical - \$9.8 million settlement	Medicis sales reps targeted pediatricians in an effort to sell a topical skin ointment, Loprox, as a treatment for diaper rash. The problem: the Food & Drug Administration (FDA) did not approve Loprox for use on children under the age of 10. This was an instance of off-label marketing. The company settled at \$9.8 million. Through Medicaid, the government paid millions of dollars for Loprox prescriptions that would not have been reimbursed if government authorities had known that prescriptions resulted from the company's off-labeling marketing campaign.	2009	9,800,000.000
Abbott	Centocor Ortho Biotech Inc. announced today that a federal jury has returned a verdict of \$1.67 billion against Abbott Laboratories in a patent infringement suit.	2009	1,670,000,000.000
Wyeth to Pay Amputee \$6.7 Million in Landmark Case	stopped the wrongful use of a prescription ointment on young children.		6,700,000.000

In another case involving off-label marketing, Jazz Pharmaceuticals agreed to a \$20 million settlement after a sales representative for the company filed a lawsuit on behalf of the U.S. The drug's active ingredient, GHB, also known as a "date rape" drug, was sold as safe to use on children and the elderly and a compensated psychiatrist advised doctors how to conceal the off-label prescriptions to ensure insurers would pay them. The company also admitted that it relied on a psychiatrist to give talks around the country promoting the unapproved uses, while paying him tens of thousands of dollars for speaking engagements.

Jazz Pharmaceuticals - \$20 million settlement

2006 20,000,000.000

Morgado v. Warner-Lambert, Case No.: 403243-01 in the Supreme Court of the State of New York , County of New York - pharmaceutical injury trial - Rezulin, \$2 million verdict - March 3, 2003 Etek

2003 2,000,000.000

Jury issues \$43 million verdict against Warner-Lambert in Rezulin diabetes drug case. woman who said her liver was destroyed by Pfizer Inc.'s recalled diabetes drug, Rezulin, still faces the prospect of a liver transplant and a long medical battle.

Sanchez v. Parke Davis District Court of Nueces County, Texas, Case No.00-6523-F - pharmaceutical injury trial - Rezulin Verdict \$43,000,000.00 - Dec. 21, 2001

2001 43,000,000.000

<p>\$89 Million Settlement Proposed for Bextra, Celebrex Marketing Class Action</p>	<p>Consumers and Third-Party Payors that wish to remain in the Settlement and file a claim will be bound by the Court's orders and will give up the right to sue the defendants on their own.</p>	<p>2008</p>	<p>89,000,000.000</p>
<p>New Jersey Hospital to Pay \$3.85 Million to Resolve Allegations of Inflating Charges to Obtain Higher Medicare Reimbursement</p>	<p>Cooper University Hospital in Camden, N.J., has agreed to pay the United States \$3.85 million, plus interest, to settle allegations that it defrauded Medicare, the Justice Department announced (see also Medicare and Medicaid).</p>	<p>2008</p>	<p>3,850,000.000</p>
<p>San Mateo County, California, to Pay U.S. \$6.8 Million to Resolve False Claims Allegations</p>	<p>the United States \$6.8 million to resolve allegations that the San Mateo Medical Center (SMMC) submitted false claims to the United States in connection with payments from the Medicare and Medicaid</p>	<p>2009</p>	<p>6,800,000.000</p>
<p>Bernie Dusich and Josh Tuhscherer Minor v. Neonatologist and Hospital</p>	<p>Despite complications with an ulnar arterial line placed in the right hand of a premature baby, hospital staff failed to remove the line, resulting in the loss of the child's fingers and thumb.</p>		<p>4,000,000.000</p>
<p>R.H. as Parent of S.S. v. Health System</p>	<p>An 18-year-old who had been in a car accident suffered severe brain injury after physicians failed to perform additional neurological status checks, relying on a prior CT scan and neurological assessment from the hospital from which he had transferred.</p>		<p>2,400,000.000</p>

L.B. v. Dr. Deborah Johnson, et al.	A 74-year-old woman suffered multiple strokes and was left partially paralyzed when an anesthesiologist placed a line for intravenous feedings into the woman's carotid artery.	1,100,000.000
In Re Estate of Doris Matson	An elderly woman died less than 24 hours after ingesting an incorrectly compounded pain medication that was eight to 10 times stronger than the prescribed dosage.	1,100,000.000
North Dakota Plaintiff v. U.S. Pharmaceutical Company	After taking a recalled drug, a 49-year-old woman suffered heart valve regurgitation and increased pulmonary pressure.	1,000,000.000
Wyeth	All the cases involve the drugs Premarin, an estrogen replacement, and Prempro, a combination of estrogen and progestin. Both drugs remain on the market and carry the approval of the U.S. Food and Drug Administration, and both continue to be prescribed annually to hundreds of thousands of women to alleviate symptoms of menopause	2008 52,800,000.000

The parties have entered into a Settlement Agreement and a Manufacture and Supply Agreement to resolve both lawsuits and all claims between the parties. The terms of these agreements require the dismissal of all pending legal actions between the parties, a cross licensing of various patents between the two companies, the payment of \$2.5 million by Synergetics to Iridex Enhanced Coverage Linking Iridex -Search using:

Company Profile

News, Most Recent 60 Days

on April 16, 2007 and \$800,000 annually over the next five years. Under the Manufacture and Supply Agreement, Synergetics obtained the right to manufacture and supply various laser disposables, which could result in approximately \$3.0 million in revenue for Synergetics over the next five years

Synergetics Announces Settlement of Patent Litigation

2007

2,500,000.000

GlaxoSmithKline has reached a tentative \$28 million settlement in a class action lawsuit over manufacturing defects in certain tablets of their best selling antidepressant Paxil.

The suit alleged that Paxil "controlled release" (CR) tablets made between April 1, 2002 and March 4, 2005, contained a manufacturing defect that caused the tablets to split apart.

The settlement, if approved, would reimburse patients and insurers who paid for the drug. The amount each class member will receive will depend on how many defective pills they bought, to a maximum of \$150 per person. For a pill to be "defective" under the settlement, it must have split before it was removed from the container.

Class members who choose to exclude themselves from the settlement must do so by May 15. Those who wish to object to the settlement terms must do so by July 1. A final approval hearing will be held on July 10, 2009.

GSK Reaches Potential \$28 Million Settlement over Defective Paxil Tablets *MARCH-27-09: Parties Settle Paxil, "Split Pill" Class Action [CONSUMER AFFAIRS: PARTIES SETTLE PAXIL SPLIT PILL CLASS ACTION*

28,000,000.000

GlaxoSmithKline (GSK) has reached an agreement with Eliot Spitzer, New York Attorney General to settle claims that it deceptively tried to delay competitors from releasing the generic versions of its star anti-depressant drug Paxil.//

GSK was allegedly involved in a shady enterprise to keep the generic producers of Paxil in a bind of using frivolous patent-infringement lawsuits, thus managing to keep the cost of the drug in the high range. However, even after reaching the agreement, GSK denied the allegations, "We made the decision that settling was appropriate to avoid the expense and distraction of protracted litigation," a company spokeswoman said. But said Jay Nixon, Missouri Attorney General said, "GSK used the courts to hold onto a monopoly for a popular drug and the end result was that consumers - including Medicaid - paid more than they should have." The settlement of \$14 million will go towards covering Paxil purchases by Medicaid, the state and federally funded medical programme for low-income patients.

GlaxoSmithKline Agrees To Settle
Paxil Claims For \$14 million

14,000,000.000

Hagens Berman: Eleven Defendants
Settle a \$125 million Suit

Today eleven major pharmaceutical companies, including Abbott Laboratories and Watson Pharmaceuticals , agreed to a \$125 million nationwide settlement in the average wholesale price (AWP) litigation filed in 2002 by consumers and insurance companies, which claimed the defendants intentionally inflated reports of the average wholesale prices on certain prescription drugs.

125,000,000.000

Minnesota Hospitals Pay \$2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty	Three HealthEast hospitals in the St. Paul, Minnesota, area have agreed to pay the federal government a total of \$2.28 million to settle a whistleblower ("qui tam") lawsuit alleging Medicare fraud involving a certain type of spinal surgery known as kyphoplasty.	22,800,000.000
Alabama-Based Hospice Company Pays U.S. \$24.7 Million to Settle Health Care Fraud Claims	They admit patients to hospice care who did not qualify and to bill Medicare for that care. This resulted in taxpayers bearing inappropriate costs. Today's settlement evidences the Department of Justice's efforts to both protect the public monies and safeguard Medicare beneficiaries," said Alice H. Martin, U.S. Attorney for the Northern District of Alabama.	24,700,000.000
Pennsylvania Hospital Pays \$1.9 Million to Settle Medicare Fraud Case Brought by Whistleblower	St. Vincent Health System Inc., based in Erie, Pennsylvania, has agreed to pay \$1.9 million to the federal government to settle a whistleblower lawsuit that alleged the hospital submitted reimbursement claims to Medicare that greatly exceeded its actual costs.	1,900,000.000
Pfizer, Pharmacia Found Guilty of Medicaid Fraud - \$153 Million Bayer Settles Diabetes Marketing Kickback Case for \$97.5 Million	Pharmacia, a subsidiary of the pharmaceutical company Pfizer, was found guilty by a Wisconsin jury yesterday of repeatedly committing Medicaid fraud with the state.	2009 153,000,000.000 2008 97,500,000.000

Hydrochlorofluorocarbons (HCFCs) as refrigerants. When leaked into the air, HCFCs deplete ozone in the earth's stratosphere, which protects it from dangerous amounts of cancer-causing ultraviolet (UV) rays. Excessive UV exposure is linked to increased incidents of cataracts and poses risks to human immune systems and plant and animal life. The company has agreed to change over the seventeen units to use only non ozone-depleting refrigerants. Combined, the measures that the company is performing will remove over 6,350 pounds of harmful HCFCs from their operations. Further, the company will take additional steps to assure compliance with the EPA regulations at thirteen of its facilities and pay \$127,000 in civil penalties.

Bristol-Myers Squibb
Agrees to Clean Air Act Upgrades

2008

-

Three Florida residents who took Accutane as teens and developed inflammatory bowel disease (IBD) have been awarded \$12.89 million by a jury in Atlantic City. The jury found that the makers of Accutane, Hoffman-La Roche, failed to provide adequate warning of the possible condition to three patients who began taking the drug as teenagers and shortly thereafter developed severe forms of IBD. The jury awarded compensatory damages to be apportioned among the 3 individuals, now aged in their mid-to-late 20s.

Accutane IBD Victims Awarded
\$12.9 Million

12,900,000.000

The family of a 38 year old woman, who died from an overdose of fentanyl, after using the defective duragesic pain patch, has been awarded \$16.6 million. The Chicago jury ruled that subsidiaries of Johnson & Johnson are liable.

In October, a jury in Florida awarded the family of another woman who died from a duragesic overdose more than \$13 million.

NOV-19-08: Jury Awards \$16.6 Million
[NY TIMES: \$16.6 MILLION
DURAGESIC SETTLEMENT]

\$16.6 Million Awarded in Duragesic Case

16,600,000.000

Pfizer Reaches Tentative Bextra and Celebrex Settlements of \$894 Million

Pfizer Reaches Tentative Bextra and Celebrex Settlements of \$894 Million

2008

894,000,000.000

Eli Lilly Settles Zyprexa Investigations for \$62 Million

Eli Lilly has settled Zyprexa lawsuits with 32 states and Washington DC, for a reported \$62 million, putting an end to investigations into the company's marketing practices of the antipsychotic medication.

62,000,000.000

CORONA, Calif., March 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Elan Corporation, Plc on outstanding patent litigation related to Watson's generic version of Naprelan(R) (naproxen sodium) tablets. Under the terms of the agreement, Watson will pay Elan \$18 million in full settlement of all disputes related to Watson's development, manufacturing, marketing and sale of its naproxen sodium product. Watson also has agreed not to market or sell its naproxen sodium product until the expiration or final finding of invalidity or unenforceability of U.S. Patent No. 5,637,320. Other details concerning the settlement have not been disclosed.

About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

Watson Pharmaceuticals and Elan
Settle Lawsuit For \$18 Million

18,000,000.000

GlaxoSmithKline (GSK) has agreed to \$40 million to settle a long-running lawsuit over Paxil, its beleaguered antidepressant. The settlement will go to insurers to reimburse health plans that covered the use of the drug in children and adolescents.

In an earlier Paxil class action suit the drug maker paid \$64 million to consumers regarding its off-label use in children and teenagers.

OCT-02-08: Glaxo settles U.S. Paxil lawsuit for \$40 mln [REUTERS: \$40 MILLION PAXIL SETTLEMENT]

Glaxo to Pay \$40 Million in Paxil Settlement with Insurers

40,000,000.000

The two largest universities in West Virginia will receive nearly \$8 million in unclaimed funds from a class action suit settled with Warner-Lambert Co. and Parke-Davis. The suit was over the company's diabetes drug Rezulin, which can have severe side effects. The universities will use the money to fund medical research, with \$2.25 million going to Marshall's Joan C. Edwards School of Medicine Rural Health Program, and \$5.67 million to WVU's Department of Pediatrics.

Unclaimed \$8 Million From Rezulin Class Action to Benefit Medical Research

8,000,000.000

Proposed \$21.8 Million Settlement of Drug Pricing Class Action	<p>Preliminary approval of a Proposed Settlement related to the average wholesale prices of certain prescription drugs has been granted by the District Court for the District of Massachusetts. In the lawsuit, plaintiffs claimed that drug manufacturers unlawfully inflated the published average wholesale price of certain drugs, increasing what certain consumers and others paid. The defendants deny any wrongdoing. The Proposed Settlement includes approximately \$21.8 million for payments to consumers who file valid claims.</p>	21,800,000.000
Proposed Settlement In Abbott's Norvir Class Action: \$37.5 Million Settlement	<p>Abbott Laboratories has agreed to pay a \$10 million and \$27.5 million, depending on pending court rulings, to settle nationwide consumer claims of being overcharged for Abbott's HIV/AIDS drug Norvir.</p> <p>The proposed settlement attempts to get the Court of Appeals to resolve this and several other legal issues, and to tie the amount of the settlement to the decisions of the Court of Appeals.</p>	2008 37,500,000.000
Amerigroup Settles with Medicaid for \$225 Million	<p>Amerigroup has agreed to pay \$225 million to settle allegations by federal and Illinois state authorities that Amerigroup's health plans denied coverage to pregnant women and people with health ailments in the Illinois Medicaid program.</p>	2008 225,000,000.000

Gary Charbonneau has been awarded \$8.2 million in damages stemming from claims that Mirapex, a drug used to treat Parkinson's Disease, caused him to gamble compulsively. This is the first trial against Pfizer and Boehringer Ingelheim, makers and distributors of Mirapex, and could be an indicator of decisions to come. A second trial began yesterday.

\$8.2 Million Awarded to Compulsive Gambler on Mirapex

2008

8,200,000.000

(FDA) has reached a settlement with California hearing device manufacturer Advanced Bionics LLC and its president and CEO Jeffrey Greiner over alleged violations of federal law. The alleged violations involved the failure to notify the FDA of a change of outside supplier or vendor, which may have exposed patients to unnecessary health risks, such as device failure and surgery.

Under the terms of the settlement, agreed to on July 14, 2008, Advanced Bionics will pay a civil money penalty of \$1.1 million. Greiner will pay \$75,000.

On July 7, 2003, Advanced Bionics received FDA approval to market the HiRes90k Implantable Cochlear Stimulator, an implant surgically placed under the skin behind the ear to treat profound hearing loss in some adults and children. The FDA regulates cochlear implants as Class III devices—the most stringent regulatory category for medical devices.

Advanced Bionics and Greiner agreed to settle the complaint without admitting liability, and must remit payment to the U.S. Treasury within 10 days of settlement. Advanced Bionics LLC, is based in Sylmar, Calif.

2008

1,100,000.000

Advanced Bionics Settles with FDA:
\$1.1 million. Greiner will pay
\$75,000

Bristol-Myers Squibb Co. has settled with the State of California for \$23 million, in a settlement against charges of prescription drug pricing fraud. This is a large recovery for the state. There are approximately 15 companies with settlements pending, in what has been an extensive investigation of drug pricing. Some drugs were found to be priced as much as 1000 percent over cost.

BMS Settles with California for \$23
Million

23,000,000.000

Vioxx Advertising: \$58 million Settlement	<p>The suit, brought by AZ Attorney General Terry Goddard, stated that owing to aggressive marketing through direct-to-consumer television ads that began in 1999, hundreds of thousands of consumers acquired Vioxx prescriptions before doctors had a chance to understand the side effects. The suit also accused the company of "ghostwriting," a practice in which academic scientists were allegedly paid to take credit for positive research articles prepared by company-hired medical writers. As part of a settlement reached in the suit, the company agreed to pay \$58 million to resolve the multistate allegations. Additionally, the company will also submit all new TV commercials for its drugs to the Food and Drug Administration for review before they can be aired.</p>	58,000,000.000
Drug Pusher – \$24.6 Million	<p>US Attorney Michael Sullivan's office brought a lawsuit against Biovail Pharmaceuticals Inc., a NJ, based subsidiary of Biovail Corp., alleging that the company illegally paid doctors so that they would prescribe Cardizem LA, a blood pressure drug. The suit alleged that Biovail Corp. paid thousands of physicians and others up to \$1,000 each, to induce them to either prescribe or recommend Cardizem LA.</p>	2008 24,600,000.000

Bankruptcy, Mail Fraud – Forfeits \$10 Million in Cash	Federal officials brought a lawsuit against Leiner Health Products Inc., over the production, control and distribution of certain over-the-counter drug products at the company's now defunct South Carolina facility. In a recent announcement, the nutritional supplements maker stated that it will plead guilty to one count of mail fraud and forfeit \$10 million in cash in lieu of a fine.	2008	10,000,000.000
Hospital Gives Overdose - \$5.1 Million Settlement	<p>A lawsuit was filed on behalf of John Weatherspoon III against San Francisco General Hospital, alleging that the hospital's negligence resulted in the 40-year-old man's needing medical attention round the clock. The suit stated that Weatherspoon III was at the hospital in 2005 seeking treatment for a fever and cough, when hospital staff gave him sedatives for what they thought was renal failure. Hospital records testify that Weatherspoon then suffered cardiorespiratory failure after the staff allegedly failed to monitor following successive doses of sedatives he was given. He also suffered anoxic brain injury that now requires 24-hour care.</p> <p>As part of a settlement reached in the medical negligence lawsuit, city supervisors recently approved a \$5.1 million settlement payment that sources say will be used to pay for home care for the remainder of Weatherspoon's life.</p>	2008	5,100,000.000

The US Attorney General's office brought a medical malpractice lawsuit against Dr. Ralph A. Digiacomo, a Warwick rheumatologist, alleging that he failed to adequately account for his inventory of the narcotic pain reliever hydrocodone, known as Vicodin. Digiacomo admitted that he ordered 1,200 Vicodin pills every two to three weeks, stating that it was for his own use, negligently violating federal law that requires a physician to maintain complete and accurate records of the receipt and disposition of controlled substances.

As part of the settlement agreement, Digiacomo agreed to pay \$50,000 to resolve the allegations. The state Board of Medical Licensure and Discipline allowed Digiacomo to resume his medical practice recently, nearly a year after he turned in his license during the investigation of his prescribing practices. As per further terms of agreement, he is being monitored for five years by the Physicians Health Committee of the Rhode Island Medical Society and will not be allowed to order or prescribe narcotics for another year.

Doctor Gets Probation – Pays
\$50,000

2008

50,000.000

<p>Illegal Kickbacks – Doctor to pay Over \$2 Million</p>	<p>A federal lawsuit was brought against Dr. Patrick Chan, 43, a Searcy neurosurgeon, accusing him of bribery and fraud. Sources indicate that Chan admitted he demanded and received kickbacks, and has been sentenced by US District Court Judge Susan Webber Wright to three years probation. Additionally, the decree ordered him to pay \$59,000, that would include a fine of \$25,000, \$23,000 reimbursement to the Federal Bureau of Investigation for the cost of the investigation, and \$11,000 in probation fees for his illegal activities. County.</p>	<p>59,000.000</p>
<p>Drug Warnings Omitted - \$15 Million Settlement</p>	<p>After trial in Superior Court in Anchorage on March 3, 2008, sources revealed that the company reached a settlement, in which it agreed to pay \$15 million and would guarantee that Alaska will be treated as favorably as any other state that may resolve with the company in the future over similar claims.</p>	<p>2008 15,000,000.000</p>
<p>Hospital Management – Hospital to Pay \$2.8 Million</p>	<p>Natchez, MS: (Mar-19-08) Hale Hospital, a city-owned hospital in Haverhill, MA, brought a lawsuit against Quorum Health Resources, alleging that the health resources company significantly overstated financial statements and omitted losses in financial records. Haverhill's City Council President alleged that Quorum did not make the city council fully aware of the hospital's financial problems and the city had no opportunity to correct them.</p>	<p>2008 2,800,000.000</p>

Healthy Lungs – Drug Company to Pay \$500,000	<p>A class action lawsuit was brought against OSI Pharmaceuticals Inc., over its lung-cancer drug, Tarceva. The class action was filed in December 2004, accusing OSI of making false and misleading statements about Tarceva's potential to increase survival from lung cancer. In a recent development in the case, company officials announced that the company has agreed to settle the lawsuit with a \$500,000 payout.</p> <p>Company sources said that the full preliminary settlement amount is \$9 million, but the company will only pay \$500,000, as the insurance provider will cover the rest.</p>	2008	9,000,000.000
<p>Watson and GlaxoSmithKline Enhanced Coverage LinkingGlaxoSmithKline -Search using: Company Dossier News, Most Recent 60 Days Company Profile Settle Lawsuit Over Wellbutrin XI</p>	<p>Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, announced that it has reached a settlement with GlaxoSmithKline on outstanding patent litigation related to Wellbutrin XL(R) (bupropion hydrochloride) extended-release tablets 150mg.</p> <p>A class action lawsuit was brought against Airborne alleging that the drug's labels and ads falsely claimed that the product cures and prevents colds.</p>	2007	35,000,000.000
Airborne Settlement: \$23.3 million			23,300,000.000

Unsuitable Blood - \$19 Million In Fines	<p>The US Food and Drug Administration brought charges against the Red Cross, alleging that it distributed unsuitable blood products. The FDA made a formal announcement stating that it reviewed 113 recalls of blood products by the Red Cross from April 2003 to April 2006. The recalls involved the release of an estimated 4,094 unsuitable blood components. FDA sources claimed that having to conduct a recall shows that safety protocols were breached.</p> <p>As part of a settlement reached, the FDA fined the Red Cross an additional \$4.6 million, bringing penalties against the organization to more than \$19 million in recent years.</p>	2008	19,000,000.000
Medicare Fraud - \$7.5 million	<p>The federal government filed charges against Warren Hospital of Phillipsburg, alleging that the facility bilked the government by inflating costs on Medicare claims.</p>	2008	7,500,000.000
Medicaid Fraud - \$1.9 million payout to resolve allegations	<p>The State and Federal Governments brought charges against Harris Methodist Hospital in Bedford, alleging that the hospital submitted improper Medicaid and Medicare claims. Sources stated that the claims listed in the lawsuit were over orthopedic-related services between March 15, 2004, and Sept. 1, 2005.</p>	2008	1,900,000.000

Five lawsuits were brought against Mitsubishi Tanabe Pharma Corp., a Japanese pharmaceutical company, alleging that customers who used Fibrinogen, which is used to stop bleeding, ended up victims of hepatitis virus-tainted blood products. Mitsubishi Tanabe, a newly merged firm that incorporates the producer of the medical product under state license, said it had agreed to reach a settlement in five lawsuits filed over the disease.

As part of the settlement agreement, the company agreed to pay 2.1 billion yen (\$18.17 million) to resolve the case. The government and the company estimate at least 10,000 Japanese people have been infected with potentially fatal hepatitis C after being administered with Fibrinogen. Sources stated that Fibrinogen was widely used at Japanese hospitals until 1988, mostly during surgeries or after women gave birth, even though the US government had warned the public of its danger in 1977. The company is being targeted for its failure to respond to requests by victims for information disclosure and to swiftly notify people who might have contracted the disease.

Fibrinogen Hepatitis - \$18.17
Million to Settle

18,200,000.000

The family of Alycia Brown, a resident of Lacrosse, brought a lawsuit against Johnson & Johnson, alleging that the 14-year-old girl died after using the company's Ortho Evra birth control patch. The suit claimed that the girl suffered two blood clots in her lungs on May 7, 2004, after using the patch for several weeks. J&J, the world's largest maker of health care products, faces lawsuits by 2,400 of the 5 million women who used the patch. Sources claim that Johnson & Johnson settled dozens of cases before trial without releasing financial details.

As part of a settlement reached, the company agreed to pay \$1.25 million to resolve the lawsuit. It is claimed that the Brown agreement offers the first glimpse into how much money the company paid to resolve a case and avoid a trial that might air details of the company's safety concerns about the drug before it came to market in 2001.

Ortho Evra Death - \$1.25 Million to
Resolve the Lawsuit

2007

1,250,000.000

Biotape Fraud - \$2.5 million in
consumer refunds and return \$86,000
From Sales

Washington, DC: (Sep-19-07) The Federal Trade Commission brought charges against Smart Inventions, Inc. and Jon Nokes, two marketers of the alleged pain relief product called Biotape, accusing them of deceptively claiming that Biotape, an adhesive tape, provided significant, permanent relief from severe pain and that it was superior to other pain-relief products. As part of a settlement reached, Smart Inventions and Nokes agreed to provide up to \$2.5 million in consumer refunds. Additionally, a federal district court ruled that a third defendant, Darrell Stoddard, the inventor of Biotape who appeared in the product's nationally televised infomercial, violated federal law and must give up the \$86,000 he received from infomercial sales. Further, the FTC's settlement bars them from claiming that Biotape, or any other substantially similar purported pain-relief product, produces significant or permanent relief from severe pain or is superior to other products and treatments in eliminating or relieving severe pain.

2,500,000.000

Oregon Attorney General Hardy Myers's Office led a multistate probe against Boston Scientific Corp. over flawed heart defibrillators sold by Guidant Corp. Boston Scientific inherited substantial legal liability when it bought the firm last year for \$27 billion. Myers claimed investigators found Guidant continued to sell devices it knew were flawed. Although the company knew about a wiring problem with the implanted defibrillators, it continued to sell remaining inventory in 2002 and 2003, that hadn't undergone modifications to fix a flaw that could cause short-circuiting.

Boston Scientific Corp. - \$16.75 million to settle state investigations

In a settlement reached, Boston Scientific Corp. agreed to pay \$16.75 million to settle state investigations.

16,800,000.000

Enforcement Administration brought charges against Broadway Long Term Care Pharmacy Inc., an Oak Park pharmacy, and its owners, alleging that the business kept poor records of how it dispensed drugs. The pharmacy was accused of failing to account for about 30,000 tablets of hydrocodone or Vicodin and 10,000 tablets of Clonazepam or Valium between June 27, 2003, and Aug. 3, 2004. An accountability audit by investigators for that period also uncovered more than 2,800 record keeping deficiencies according to a report compiled by the Drug Enforcement Administration.

As part of a settlement reached, the pharmacy agreed to a \$325,000 civil settlement with the government rather than continue to fight allegations that their business kept poor records of how it dispensed drugs. The pharmacy did not admit to the allegations while entering into the settlement agreement. The settlement agreement identified the former owners as Reilly, Aldo Angoletta and David Carroll. Reilly, however, said there was a fourth co-owner, Frank Cable, but he was not mentioned in the settlement agreement. The pharmacy has been under new ownership since December 2005, although Reilly still works there in a senior management position. Biotechnology company Cephalon Inc. had a second quarter loss after reserving \$56 million for a settlement over alleged illegal marketing for the anticancer drug Trisenox.

Broadway Long Term Care Pharmacy Inc. - \$325,000 civil settlement

325,000.000

Cephalon Inc. - \$56 million for a settlement

2007

56,000,000.000

By Christopher Rowland, Globe Staff | July 10, 2004

Drug maker GlaxoSmithKline yesterday said it will pay \$92 million to settle lawsuits accusing it of patent maneuvering aimed at protecting its Augmentin prescription antibiotic.

The Boston-based Prescription Access Litigation project brought one of the handful of antitrust lawsuits filed against GlaxoSmithKline in 2002. The group, which has filed class-action lawsuits against a raft of drug companies over marketing and patent allegations, said it will reap \$29 million of the total settlement amount.

GlaxoSmithKline to pay \$92m to settle lawsuits

92,000,000.000

lawsuits were filed against University of California, Irvine, Medical Center (UCI), after a federal report found that more than 30 people died over a two-year period while awaiting transplants at the hospital. The controversy, which first came to light in late 2005, led to resignations among top officials at the hospital, a federal criminal investigation, and calls for a state inquiry. An investigation launched by federal health care regulators revealed that UCI's program had a one-year survival rate of 68% to 70% between July 2001 and June 2004, far below the federal requirement of 77%. In 2004, university officials met with regulators from the United Network for Organ Sharing. The officials told the network they had hired a new transplant surgeon and persuaded the network to allow UCI's program to continue. Sources claim that between 2004 and 2005, however, 33 more patients died while waiting for livers, even as the hospital turned down scores of organs that might have saved some of them. UCI received 122 liver offers between August 2004 and July 2005, but transplanted just 12. The federal scrutiny came, in part, because of a \$50,000 settlement the hospital made with Elodie Irvine, a woman who waited four years for a transplant before going elsewhere.

University of California, Irvine,
Medical Center - \$7.5 million to
settle allegations

7,500,000.000

Merck & Co. - Reserve to \$810 million to settle lawsuits

Asbury Park, NJ: (Jul-23-07) Several lawsuits have been filed against Readington-based Merck & Co., the third-largest US drug maker, by customers claiming injuries from using the company's Vioxx painkiller. In a recent filing with the US Securities and Exchange Commission, the company stated that it has added \$210 million to increase the reserve to \$810 million as of June 30, 2007. The reserve represents the best estimate of costs to be incurred through 2008. Merck faces 26,950 lawsuits in the US over Vioxx, which was withdrawn in September 2004 after a study found long-term users had a higher risk of heart attacks and strokes. The company has spent \$258 million so far this year defending the drug in suits worldwide. Last year's costs totaled \$500 million. Reports show that Merck has won nine cases that have come to trial over the drug since May 2005 and lost six, and that about 10 cases are scheduled for trial before the end of 2007. So far Merck has refused to pursue a global settlement and hasn't established a reserve for potential damages.

810,000,000.000

A series of over 4,000 lawsuits were filed against Guidant Corp. over the company's manufacturing of faulty heart defibrillators. The spate of lawsuits was brought against Guidant, which has a cardiac rhythm management unit based in Arden Hills. The company ultimately recalled more than 100,000 defibrillators, a move that contributed to a downturn in the market for the devices. Boston Scientific Corp. inherited the legal troubles when it acquired Guidant last year for \$27.5 billion.

In a settlement reached, Boston Scientific agreed to pay upwards of \$195 million to settle the more than 4,000 claims. Boston Scientific, which makes medical devices, said in August 2006, that it had set aside \$381 million to cover legal expenses related to the charges.

Boston Scientific Corp. - \$195 million to settle

2007

195,000,000.000

<p>Jazz Pharmaceuticals Inc. - \$20 million to settle</p>	<p>of Justice, the US Attorney's Office for the Eastern District of New York, the Office of the Inspector General of the United States Department of Health and Human Services, the United States Office of Personnel Management, and the United States Department of Tricare Management Activity brought charges against Jazz Pharmaceuticals Inc., alleging that the company misbranded a pharmaceutical product by its subsidiary, Orphan Medical Inc. The investigation centered on promotion of Xyrem, a pharmaceutical product approved in the United States for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy. Investigators said some Orphan employees conspired to defraud the United States with the goal of expanding the market for Xyrem by promoting the drug for off-label indications that included chronic pain, weight loss, depression, bipolar disorder, fibromyalgia, insomnia, movement disorders such as Parkinson's disease, fatigue, and EDS not associated with narcolepsy. In a settlement reached, the Palo Alto-based company agreed to pay about \$20 million over five years to the government agencies.</p>	<p>20,000,000.000</p>
---	---	-----------------------

<p>Houston, TX: Court Orders State To Pay Over \$700</p>	<p>Lawmakers cut Medicaid reimbursement rates in 2003, when the state was facing a \$10 billion shortfall in its two-year budget. Children's health care advocates have since complained the rates were so low doctors were increasingly choosing not to participate in Medicaid, making health care options difficult to find in many rural parts of the state. As part of the settlement, the judge ordered that more than \$700 million will be spent to satisfy the terms of the settlement.</p>	<p>700,000,000.000</p>
--	--	------------------------

New York, NY: (Jun-19-07) A lawsuit was filed against the two Johnson & Johnson subsidiaries after Adam Hendelson died while wearing the company's Duragesic pain patch. Hendelson was in a automobile accident and was suffering from persistent hip pain. He wore a Duragesic narcotic painkiller patch on his right arm to help with the constant pain. Duragesic is the brand name of a transdermal patch and contains a gel form of the drug fentanyl, which is up to 100 times stronger than morphine.

On December 17, 2003, Hendelson died at the age of 28. His family sued Janssen Pharmaceutica Products and ALZA Corp. for allegedly knowing about the patch's deadly side effects. More than one year after Hendelson's death, the defendants issued new health warnings about the use of Duragesic in June 2005.

A jury for the US District Court for the Southern District of Florida awarded the family a \$5.5 million settlement.
[TRADING MARKETS: DURAGESIC DEATH]

Janssen Pharmaceutica Products and ALZA Corp. - a \$5.5 million settlement

5,500,000.000

<p>Accutane - \$2.5 Million Verdict</p>	<p>Newark, NJ: (Jun-19-07) Andrew McCarrell, 36, filed a lawsuit against the makers of Accutane, Roche, after undergoing multiple surgeries, including having his colon removed, after taking the drug in 1995. A New Jersey Superior Court jury recently awarded over \$2.5 million to the Alabama man who claimed that the company's acne drug caused his inflammatory bowel disease. The case is the first of the nearly 400 US lawsuits involving Accutane. The jury awarded McCarrell \$2.5 million in damages and \$119,000 to cover medical expenses. From 1982 to May 2000 the FDA had determined that Accutane was associated with 147 suicides and hospitalizations for depression. By 2002, the FDA had confirmed 173 cases of suicide among persons taking Accutane, since its introduction in 1982.</p>	<p>2007</p>	<p>2,500,000.000</p>
<p>Pharmos Corp</p>	<p>Iselin, NJ: (Jun-07-07) Pharmos Corp. announced that its counsel entered into an agreement with plaintiffs' legal counsel to settle several class action lawsuits commenced in January 2005 and currently pending in the US District Court for the District of New Jersey. The lawsuits relate to statements purportedly made by Pharmos and its officers regarding the effectiveness of dexanabinol in treating traumatic brain injury.</p>	<p>2007</p>	<p>7,000,000.000</p>
<p>Bristol-Myers Settles Plavix Securities Suit For \$125M Leigh Kamping-Carder Securities Law 360. July 23, 2009</p>	<p>Bristol-Myers Squibb Co. has reported a \$125 million settlement in a securities class action that accuses the drugmaker of duping shareholders and causing a stock drop when it failed to properly disclose a patent deal for a generic version of its blood-thinning drug Plavix.</p>	<p>2009</p>	<p>125,000,000.000</p>

GlaxoSmithKline - \$64 Million Settlement	<p>St. Luis, IL: (May-24-07) A settlement has been reached with Britain-based GlaxoSmithKline over a 2004 lawsuit which claimed that the drugmaker promoted the drug, Paxil, to children while withholding information about negative side effects, including increased suicidal behavior. The company agreed to a \$64 million class action deal to settle claims. Parents who bought the antidepressant drug, Paxil, for their children may begin seeking reimbursements, provided they furnish proof that they bought GlaxoSmithKline PLC's Paxil and Paxil CR, a controlled-release version of the drug. Parents who no longer have pharmacy records or receipts can get up to \$100 refunded by signing a claim form. In agreeing to the settlement, GlaxoSmithKline denies claims that it misled consumers about the medication's safety. [CHICAGO SUN TIMES: PAXIL SETTLEMENT]</p>	2007	64,000,000.000
UnitedHealthCare: \$650,000 Fine	<p>The Nebraska Department of Insurance filed charges against UnitedHealthCare, alleging that the company violated 18 Nebraska insurance laws more than 800 times, mostly for its handling of claims, from July 1, 2003, through June 30, 2004. UnitedHealthCare handles insurance for about a quarter million Nebraska residents.</p>	2007	650,000.000

Purdue Pharma LLC - \$19.5 Million Settlement	<p>In a lawsuit filed by the Attorney General Richard Blumenthal and state Consumer Protection Commissioner Jerry Farrell Jr. against Stamford-based Purdue Pharma LLC, the maker of the painkiller OxyContin, they alleged that the company propagated illegal marketing practices that led to greater abuse of the highly addictive painkiller. The suit claimed that Purdue Pharma also violated FDA rules by encouraging doctors to prescribe the drug to be administered every eight hours rather than every 12 hours, which has led to misuse, diversion and abuse of Oxycontin by increasing the amount of the drug in circulation. In a settlement reached with 27 states, Purdue agreed to pay \$19.5 million as well as not to market the drug for off-label purposes, that is uses other than those approved by the US Food and Drug Administration.</p>	2007	19,500,000.000
Medicis Pharmaceutical Corp. - \$9.8 Million Settlement	<p>The US Department of Justice filed charges against Medicis Pharmaceutical Corp., alleging that it promoted its anti-fungal cream Loprox for unapproved uses. The suit claimed that the drug company had allegedly promoted Loprox, a medication typically used for fungal skin conditions such as athlete's foot, among pediatricians as a treatment for diaper rash from about November 2001 through April 2004. The US Food and Drug Administration had only approved Loprox, known chemically as ciclopirox, as a fungicide for patients over 10 years of age. In a settlement reached, Medicis Pharmaceutical agreed to pay the Department of Justice \$9.8 million to settle allegations. I</p>	2007	9,800,000.000

Two lawsuits filed against the DuPont Co. claimed that the fungicide Benlate caused birth defects in children. The lawsuits were filed in 1997 on behalf of children in Britain and New Zealand who were born without eyes or with abnormally small eyes, and defects. The lawsuit reached a settlement according to a filing with the Securities and Exchange Commission. The plaintiffs alleged that the birth defects were the result of the children being exposed in the womb to Benlate. According to DuPont, the settlement involves not only the six families named as plaintiffs in the lawsuits, but 26 other claimants. In the settlement reached, DuPont agreed to pay \$9 million to settle claims. DuPont, which began manufacturing Benlate in the 1950s, decided to halt production in 2001 in the face of mounting crop damage claims.

DuPont Co. - \$9 Million Settlement

2007

9,000,000.000

Mason County, IA (1/12/07) Mason County Associate Judge Ralph Mendelsohn approved and amended the national pediatric Paxil class settlement which will provide more payment to people who paid for Paxil to use by a minor.

Since GlaxoSmithKline's (GSK's) original \$63.8 million settlement with Korein Tillery and Swedlow and Associates on October 6, 2006, lawyers who did a large amount of work on similar class actions in MN and CA and their clients, objected to the settlement as being unfair to the consumers in the other classes and to their lawyers, whose litigation efforts improved amendments to the terms of the settlement and greatly contributed to the original settlement.

The firms who filed the objections to the original settlement on behalf of client, Colin Connare (Baum Hedlund of Los Angeles, Pendley, Baudin & Coffin of Plaquemine, LA, Strange & Carpenter of Los Angeles and Larson King of St. Paul, Minnesota) argued that the settlement proposal had a loophole that prevented adequate payment to a considerable number of consumers. One of the problems with the original settlement was the perceived problem of reimbursement to consumers who could not provide proper documentation. They were only to receive \$15, but under the new approved terms consumers who cannot provide proof will receive \$100. These

GlaxoSmithKline - \$63.8 million settlement

2007

64,000,000.000

Cell Therapeutics - \$10.5 million Settlement	<p>Seattle, WA: (Apr-17-07) The US government filed charges against Seattle biotechnology company, Cell Therapeutics, accusing it of promoting an anti-cancer drug, Trisenox, for uses that were not approved by the Food and Drug Administration. The suit stated that Cell Therapeutics subverted a regulatory system designed to assure that patients receive only those drugs that have been proven to be effective for their illness.</p>	2007	10,500,000.000
Pfizer Inc. - \$34.7 Million Settlement	<p>The Department of Justice began an investigation into the off-label marketing of Pfizer's human-growth hormone brand, Genotropin, alleging that a unit of the company made kickbacks to an outside vendor in order to increase its sales. Pfizer admitted that Pharmacia, one of its acquired companies improperly promoted Genotropin between January 2000 and March 2003 for anti-aging purposes, improved athletic performance, and enhanced appearance. In a settlement reached, Pfizer agreed to pay \$34.7 million to end the investigation.</p>	2007	35,000,000.000

Syntho Group – \$3.1 million Settlement	<p>Scivanta Medical Corporation brought charges against Syntho Pharmaceuticals Inc. and its principal owner, Muhammed Malik, known as the Syntho Group, regarding Scivanta Medical Corporation's exclusive right to distribute the hormone replacement therapy drug, Syntest. In a settlement reached between the parties, the Syntho Group agreed to pay Scivanta Medical an aggregate of \$3.1 million of which \$250,000 was paid in connection with the execution of the settlement agreement. Scivanta Medical will use the proceeds from the settlement for working capital purposes and to fund the development of the Hickey Cardiac Monitoring System, a minimally invasive two-balloon esophageal catheter system used to monitor cardiac performance.</p>	2007	3,100,000.000
US Nursing Corp. - \$235,000 fine	<p>The New Jersey Division of Consumer Affairs filed charges against US Nursing Corp. of Greenwood Village, CO alleging that the temporary nursing firm skipped required background checks on many nurses, among other violations. The company supplied nurses to replace union nurses on strike last year at Englewood Hospital and Medical Center and Robert Wood Johnson University Hospital in New Brunswick. The company also supplied nurses to at least 16 other hospitals in New Jersey from 2004 through 2006. The number of nurses that did not have the mandatory criminal background checks, professional license status, and malpractice insurance could not be provided. Though the company did not admit to wrongdoing, it resolved the allegations with a \$235,000 fine agreeing to follow the state's personal services regulations.</p>	2007	235,000.000

<p>Avanir Pharmaceuticals and GlaxoSmithKline Consumer Healthcare - \$2.1 Million Settlement</p>	<p>A nationwide lawsuit was filed against Avanir Pharmaceuticals and GlaxoSmithKline Consumer Healthcare in San Francisco in 2002, accusing them of false claims in their advertising. The suit alleged that the advertisements for the cold sore medication Abreva claimed that it cut healing time in half, though there was no research to show or prove the claim. Though the company did not admit any wrongdoing, the ads were stopped. In the settlement reached, they will pay up to \$1 million for research projects on cold sores approved by an expert panel, and \$1.2 million to the plaintiffs' lawyers.</p>	<p>2007</p>	<p>2,100,000.000</p>
<p>Merck & Co. – A \$47.5 million Verdict</p>	<p>Frederick Humeston filed suit against drug- maker Merck after suffering a heart attack while on the arthritis pill Vioxx. The 61- year-old man suffered a heart attack in 2001 while taking Vioxx, several months before Merck put a stronger warning about the drug's cardiovascular risks on the package insert. The suit accused the drugmaker of negligence and not providing adequate warning about the risks before Humeston's heart attack. In a settlement reached, the jury ordered Merck to pay the Boise postal worker and his wife a sum of \$47.5 million in compensatory and punitive damages.</p>	<p>2007</p>	<p>48,000,000.000</p>

Patients with potentially fatal, idiopathic pulmonary fibrosis have been using a drug manufactured by InterMune Inc. The drug, Actimmune, was not approved for the disease, but had been promoted for that use by InterMune Inc. The federal government booked InterMune Inc. over allegations of promoting off-label use of Actimmune. The claims were settled with InterMune Inc. paying a fine of \$36.9 million. InterMune has now announced that it was abandoning efforts to develop the product as a treatment for idiopathic pulmonary fibrosis because results from a late-stage clinical trial showed the drug did not prolong lives. The drug is already federally approved to treat two other rare conditions.

InterMune Inc. - \$36.9 Million Fine

2007

37,000,000.000

James D. Dotson v . Pfizer, Inc.
Case Number: 07-1979
Judge: Cacheris

Description: This case reaches the Court after a full trial on the merits in the Eastern District of North Carolina. James Dotson ("Dotson") brought suit against his employer, Pfizer, Inc. ("Pfizer"), for violations of the Family and Medical Leave Act of 1993, 29 U.S.C. § 2601, et seq. (the "FMLA"). The jury awarded Dotson \$1,876.00 on his FMLA interference claim and \$331,429.25 on his retaliation claim. The district court awarded Dotson \$333,305.25 in statutory liquidated damages, \$375,000.00 in attorneys' fees, and \$14,264.88 in costs.

2009

723,000,000.000

Judge approves DuPont settlement

Company agrees to pay at least \$107.6 million over use of chemical C8

2005

108,000,000.000

<p>State of Missouri v. Schering-Plough Corp. d/b/a Warrick Pharmaceuticals Corp. Case Number: 22054-01216 Judge: David L. Dowd</p>	<p>Description: The State of Missouri sued Warrick Pharmaceuticals Corporation, Schering-Plough Corporation and others on a Medicaid fraud claiming that the drug companies inflated reported prices for Medicaid reimbursement, costing the state about \$15 million over 11 years.</p> <p>Defendants denied wrongdoing. Outcome: Plaintiff's verdict for compensatory damages of \$7 million.</p>	<p>2008</p>	<p>7,000,000.000</p>
<p>John Doe v. PR Pharmaceuticals, Steven Howard and Dr. Patrick Bols</p>	<p>Description: Class action against PR Pharmaceuticals ("PRP") and its President, Steven Howe, and CEO, Dr. Patrick Bols Colorado investors, including all minority shareholders, for breach of fiduciary duties that controlling officers and directors of a company owe to the minority shareholders not to run the company for the majority shareholders own benefit, to the detriment of the minority shareholders whose investment is at their mercy.</p>	<p>2008</p>	<p>1,600,000.000</p>
<p>U.S. ex rel. Thompson et al. v. Walgreen Co. Case Number: 05-SC-759</p>	<p>Description: Illinois-based national retail pharmacy chain Walgreens has paid the United States and four participating states \$9.9 million to resolve allegations of falsely billing the Medicaid program. Walgreens submitted claims to Medicaid agencies in four states for prescription drugs dispensed to persons covered both by Medicaid and by private third-party insurance. The retail pharmacy chain allegedly charged the four state Medicaid programs the difference between what the private insurance companies paid for the drugs and what the state Medicaid programs would have paid for the drugs in the absence of private insurance.</p>	<p>2008</p>	<p>9,900,000.000</p>

Verex, Inc. v. PR Pharmaceuticals,
Inc., et al.
Case Number: 2003CV2629
Judge: J. Mark Hannen

Description: Verex, Inc. sued PR
Pharmaceuticals, Inc., Steven Howe and Dr.
Patrick Bols on breach of fiduciary duties
theories.

The defenses asserted by defendants are not
available.
Outcome: Plaintiff's verdict for
compensatory and punitive damages of \$1.3
million.

2008

1,300,000.000

Tod R. Flemke v. CVS Pharmacy
Case Number:
502006CA013156XXXXMBAH
Judge: Unknown

Tod Flemke sued CVS Pharmacy on a
premises liability negligence theory for the
injuries and damages that she sustained
when he fell and injured his lower back and
had to undergo surgery to repair herniated
discs. The Plaintiff slipped and fell over a
plug in a CVS store located in Lake Worth,
Florida. The CVS Pharmacy store did not
place caution or warning signs in the aisle to
alert customers to the fact that they were
cleaning, despite it being an unwritten
policy to place caution signs in front of
outlets. Plaintiff claimed that CVS failed its
own store policies.

CVS asserted the defense of Open and
Obvious and did not believe the incident
actually happened. CVS did not accept or
admit to any liability during the trial.

Outcome: The jury rendered a verdict of
\$500,000 for the Plaintiff, but split liability
between the Plaintiff with 23% liability and
87% of the fault with the Defendant

500,000.000

<p>United States of America ex rel Internal Revenue Services v. GlaxoSmithKline</p>	<p>GlaxoSmithKline (NYSE: GSK; LSE) announces that it has settled its transfer pricing tax dispute with the US Internal Revenue Service (IRS). This settlement resolves all the issues which were in dispute in this case. Under the agreement the final net cash cost to GSK will be approximately \$3.1 billion which covers federal, state and local taxes, interest and also the benefit of tax relief on the payments made.</p>	<p>2006</p>	<p>3,100,000,000.000</p>
<p>Invamed, Inc. and Apothecon, Inc. v. Barr Pharmaceuticals, Inc.</p>	<p>Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its Barr Laboratories, Inc. subsidiary has entered into an agreement to settle litigation claims made by Invamed, Inc. and Apothecon, Inc., both of which have since been acquired by Sandoz, Inc., a subsidiary of Novartis AG (NYSE: NVS), regarding the raw material source for Warfarin Sodium. The agreement terminates the on-going litigation between the parties.</p>	<p>2006</p>	<p>22,500,000.000</p>
<p>Ariad Pharmaceuticals Inc. v. Eli Lilly & Co. Case Number: 1:02-cv-11280-RWZ Judge: Rya W. Zobel</p>	<p>Ariad Pharmaceuticals Inc. sued Eli Lilly & Co. on a patent infringement theory claiming that Defendant infringed Plaintiff's patent covering methods of treating disease by regulating "cell-signaling activity." Plaintiff further claimed that Lilly's drug Evista and septic-shock drug Xigiris used Ariad's patent. Defendant's defenses are not available at this time. Outcome: Jury verdict for \$65.2 million in damages based on its determination that Lilly should pay a 2.3% royalty rate to the plaintiffs for U.S sales of Evista and Xigris.</p>	<p>2006</p>	<p>65,200,000.000</p>

State of Maryland, et al. v.
GlaxoSmithKline
Case Number: 2:06-cv-01298-JP
Judge: John R. Padova

Outcome: Settled for \$124 million. 2006 124,000,000.000

State of Missouri v. King
Pharmaceuticals Inc.

Description: Attorney General Jay Nixon today presented the Missouri Department of Social Services with a check for the state's share of a \$124 million nationwide settlement with a pharmaceutical company. The company, King Pharmaceuticals Inc., incorrectly reported prices for its generic drugs, resulting in the underpayment of rebates to the state Medicaid program. 2006 124,000,000.000

Ohio State Teachers Retirement
System v. Medco Health Solutions
Inc. and Merck & Co.

The Ohio State Teachers Retirement System sued Medco Health Solutions Inc. and Merck & Co. for fraud claiming that the defendants overcharged for medications provided to the plaintiff's members. Medco provided pharmacy benefit services for the teachers retirement system until 2001. Medco denied that it breached its contract with the plaintiffs.
Outcome: Plaintiff's verdict finding Medco liable for constructive fraud and awarded \$6.9 million in damages plus \$915,000 for STRS. 2005 7,800,000.000

Wyeth Pharmaceuticals – A \$3 Million Verdict	<p>New York, NY: (Feb-20-07) Jennie Nelson filed a lawsuit against the maker of Prempro after she was diagnosed with breast cancer. Wyeth was ordered to pay \$3 million in damages after a jury found the company's menopause treatment was linked to a woman's breast cancer. The verdict found Wyeth failed to provide an adequate warning regarding the link between Prempro and breast cancer. The award included \$2.4 million in compensatory damages for Nelson, 67, and \$600,000 for her husband, Lawrence Nelson, 79. Over 5,000 lawsuits have been filed against the drug maker.</p>	2007	3,000,000.000
Bayer Corporation - \$8 million Settlement	<p>Florida Attorney General Bill McCollum announced that Florida and 29 additional states have reached an \$8 million settlement with Bayer Corporation, resolving an investigation into the marketing of a drug to lower cholesterol. The settlement was part of a consumer protection enforcement action initiated over concerns that Bayer failed to adequately disclose safety risks associated with Baycol. The investigation, initiated by the states in 2004, alleged that while Bayer informed the US Food and Drug Administration about these adverse effects, the company failed to adequately warn consumers.</p>	2007	8,000,000.000

GlaxoSmithKline - \$63.8 million class action settlement	<p>Edwardsville, IL: A class action lawsuit was filed against the pharmaceutical company for allegedly promoting its antidepressant drug Paxil for use by children and adolescents while withholding negative information about the medication's safety and effectiveness. The class includes all US residents who bought Paxil or Paxil CR for their children. Madison County Associate Judge Ralph Mendelsohn has approved a \$63.8 million class action settlement. GlaxoSmithKline denies the lawsuit's claims, but has agreed to pay to settle the claims.</p>	2006	63,800,000.000
Glaxo Pays \$40 Million in (Another) Paxil Settlement	<p>GlaxoSmithKline is shelling out another \$40 million to deal with the fallout over the use of its antidepressant Paxil in kids. This time, the money is going to insurers who paid for the drug to be used in children and adolescents.</p> <p>A class-action lawsuit argued that Glaxo had promoted the drug for use in children, while withholding evidence that the drug was neither safe nor effective in kids. Glaxo denied those charges and told the WSJ it settled to “avoid the costs, burdens and uncertainties of ongoing litigation.”</p>	****	40,000,000.000

Parents who bought the antidepressant Paxil for their children can begin seeking reimbursements under a \$64 million class-action deal settling claims that the drug's maker misled consumers about the medication's safety.

Under the deal, announced in April and granted final approval last week by a judge in Madison County, Ill., parents with proof that they bought GlaxoSmithKline PLC's Paxil and Paxil CR, a controlled-release version of the drug, can recoup out-of-pocket expenses.

Parents who no longer have pharmacy records or receipts can get up to \$100 refunded by signing a claim form that carries penalties for lying.

Claim forms, which must be filed by Aug. 31, are available online at www.paxilpediatricsettlement.com.

In settling the 2004 lawsuit, Britain-based GlaxoSmithKline denies claims it promoted the drug to children while withholding information about negative side effects, including increased suicidal behavior.

\$64 Million Paxil Settlement OK'd

64,000,000.000

Philadelphia - Jennie Nelson took Prempro for six years and developed breast cancer. As a result of the cancer, she underwent a mastectomy and chemotherapy and radiation therapy. She filed a lawsuit against Wyeth claiming it was negligent in the testing, manufacture and marketing of its hormone replacement therapy drug Prempro. A jury awarded Nelson \$1 million and her husband \$500,000 in compensatory damages after finding that Wyeth's Prempro was a cause of her breast cancer. The Philadelphia Court of Common Pleas jury may award additional punitive damages if it finds Wyeth failed to warn of the dangers of Prempro.

Prempro - \$1.5 Million Verdict

2006

1,500,000.000

Novartis AG - \$19 million to settle	<p>London - Acambis and Novartis were in a dispute over an experimental vaccine for yellow fever. The dispute arose over non-performance from a 1999 deal by predecessor companies acquired by Novartis. Acambis had US sales rights to the Arilvax vaccine and had previously completed Phase 3 clinical trials with a view to applying for a license in the US. Novartis has agreed to pay \$19 million to settle the dispute over the Arilvax yellow fever vaccine.</p>	2006	19,000,000.000
Merck & Co. Inc. - \$51 Million Settlement	<p>Gerald Barnett took Vioxx for 33 months before suffering a heart attack in September 2002. The former FBI agent filed a lawsuit against Merck for compensatory and punitive damages. A New Orleans jury ruled Merck was negligent for failing to adequately warn doctors about the risks associated with the drug. The jury also found that Merck knowingly misrepresented or failed to disclose information about Vioxx to the doctors of 62-year-old Gerald Barnett. Merck has been ordered to pay Barnett at \$51 million settlement.</p>	2006	51,000,000.000
Merck & Co. - \$32 Million Verdict	<p>In April 2001, within one month of taking Vioxx, Leonel Garza had fatal heart attack. The 71-year-old's family filed a lawsuit against the drug manufacturer alleging wrongful death. A South Texas jury has ordered the company to pay \$7 million in compensatory damages and \$25 million in punitive damages.</p>	2006	32,000,000.000

Merck & Co. - \$13.5 Million Verdict	<p>John McDarby used Vioxx for five years until 2004, when he suffered a heart attack. The 77-year-old man filed a lawsuit against the drug manufacturer for allegedly misleading the U.S. Food and Drug Administration about the painkiller's heart risks. A jury ordered Merck & Co. to pay \$9 million in punitive damages. A New Jersey Superior Court jury also found Merck violated the New Jersey consumer fraud law by failing to properly warn consumers of Vioxx's cardiovascular risks. The jury awarded McDarby \$4.5 million in compensatory damages.</p>	2006	13,500,000.000
NVE Pharmaceuticals - \$260,000 settlement	<p>A lawsuit was filed against the company claiming it misled consumers by making false and misleading claims about the safety and effectiveness of its products. The lawsuit claimed NVE violated the New Jersey State Consumer Fraud Act through ads that exaggerated the benefits and minimized the risks of Stacker-2 and other Ephedra based supplements. The settlement requires NVE and its president Robert Occhifinto to pay a \$260,000 settlement to the state of New Jersey.</p>	2006	260,000.000
Kaiser Permanente – 45 Million Settlement	<p>The California Department of Managed Health Care found that the health maintenance organization's Northern California kidney transplant program imperiled hundreds of patients. In some cases, critical surgeries were delayed and other patients were lost track of altogether. Kaiser has agreed to pay a \$2 million fine and spend an additional \$3 million for outreach programs to encourage organ donation.</p>	2006	45,000,000.000

Tenet Healthcare - \$900 Million Settlement	<p>Tenet Healthcare Corp. allegedly defrauded Medicare, including manipulating the Medicare outlier system, up-coding Diagnosis Related Groupings (DRGs) and paying kickbacks to physicians. The Dallas based healthcare company, which owns 68 hospitals, has agreed to pay more than \$700 million under a global settlement with the Justice Department. Tenet will pay \$450 million in cash immediately and an additional \$275 million over three years beginning in November 2007. The remaining \$175 million of the settlement will come from Medicare payments that Tenet has agreed not to collect.</p>	2006	900,000,000.000
Highmark Inc. - \$10 Million Settlement	<p>A class action lawsuit, which affected 300 ambulance companies in 29 Western Pennsylvania counties, alleged that from 1999 through March 31, 2002 Highmark Inc. determined that non-contract ambulance companies should be reimbursed for transporting enrollees in Highmark's SecurityBlue program at the Medicare-approved rate and not for their full charges. Highmark Inc. has agreed to settle the lawsuit for \$10 million. The health care insurer admits no wrongdoing regarding its reimbursements.</p>	2006	10,000,000.000

Saint Barnabas Health Care System - \$265 million to settle	Saint Barnabas, New Jersey's largest health care provider, allegedly cheated Medicare out of more than half a billion dollars over the past eight years by inflating charges for patients with serious illnesses. Prosecutors claimed that Saint Barnabas hospitals deliberately inflated charges under the Medicare program that increased reimbursements to hospitals that care for people with medical complications. The hospitals will pay \$265 million to settle the allegations and must accept an outside monitor that will track and supervise Medicare billings for the next six years.	2006	254,000,000.000
Catholic Healthcare West – Over \$1.3 Million Settlement	In 2005, a class action lawsuit brought about by Consejo de Latinos Unidos, claimed that Catholic Healthcare West overcharged uninsured patients compared with what it charges those who have insurance.	2006	1,300,000.000
Dr. Joseph Rudolph - \$565,000 to Settle	Dr. Joseph Rudolph was accused by the federal government of illegally benefiting from a federal prescription drug program. The allergist imported prescription drugs from Canada, thus providing discounts to his patients, until the government ordered him to desist. Prosecutors accused him of illegally selling discounted medicines to doctors nationwide from January 2004 to August 2005. A deadlocked jury in May led to the attorney's office deciding not to retry him. Dr. Rudolph agreed to pay \$565,000 to settle the civil lawsuit.	2006	565,000.000
Baxter Healthcare - \$8.5 million Settlement	The Texas attorney general filed a lawsuit against Baxter Healthcare in 2004 for alleged Medicaid fraud. The lawsuit claimed a scheme falsely reported wholesale prices of I-V fluids and injectible medications prescribed for Medicaid patients. Baxter denied any wrongdoing but agreed to pay the state an \$8.5 million settlement	2006	8,500,000.000

<p>Ortho Evra Settlement Reported for \$1.25 Million H.D. Smith Wholesale Drug Co. - pay a \$2.2 million settlement</p>	<p>Johnson & Johnson has agreed to pay \$1.25 million to settle one Ortho Evra birth control patch lawsuit. The details of the confidential agreement were made public after the news agency received a copy of settlement documents from a court clerk. Although it was known that other cases have settled, this is the first public report about the amount paid on any individual Ortho Evra settlement</p>	2007	1,250,000.000
	<p>H.D. Smith Wholesale Drug Co. - pay a \$2.2 million settlement</p>	2006	2,200,000.000
<p>Owens Corning - a \$5.2 Billion Settlement</p>	<p>Thousands of lawsuits were filed on behalf of people sickened by asbestos and in 2000, the fiberglass insulation maker filed for Chapter 11 bankruptcy protection. Asbestos was used as insulation and fire retardant, until the 1970's when scientists found its inhaled fibers could cause cancer and other diseases. Owens Corning has reached a \$5.2 billion settlement to resolve current and future asbestos claims.</p>	2006	5,200,000,000.000
<p>Schering Plough KK - \$8 Million Settlement</p>	<p>SciClone Pharmaceuticals, Inc. filed a lawsuit against Schering regarding a dispute concerning clinical trials conducted in Japan with ZADAXIN, SciClone's lead compound. Schering has agreed to pay SciClone an \$8 million settlement.</p>	2006	8,000,000.000

Bayer AG - \$10 Million Settlement	<p>A class action lawsuit was filed against the German drug maker on behalf of unions, employers and health plans for money spent on the recalled cholesterol drug Baycol. Bayer recalled Baycol in 2001 after it was allegedly linked to more than 100 deaths. Major health insurers, employers and unions purchased Baycol before the recall that could not be used after the drug had been withdrawn from the market. A Philadelphia Court of Common Pleas Judge has approved a nationwide class action settlement which may provide class members with as much as \$10 million.</p>	2006	10,000,000.000
Matrixx Corp. - \$12 Million Settlement	<p>More than 300 people filed a class action lawsuit against the makers of the cold remedy Zicam alleging the zinc nasal spray caused a loss of sense of smell and taste. Millions of people have used the zinc gluconate nasal spray without problems, but hundreds of other users felt an intense burning sensation in their nose, and subsequently lost their sense of smell and/or taste. Only 30% of the latter had some sense of smell return. Matrixx has agreed to pay a \$12 million class action settlement.</p>	2006	12,000,000.000
Diageo PLC - \$150 million (GBP) Financial Settlement	<p>During the 1960s the pharmaceuticals division of the Distillers Company distributed thalidomide throughout the United Kingdom. Pregnant women taking the drug began to produce babies with deformities including stunted arms and legs. The drug was withdrawn in 1961. Diageo has finalized a \$150 million (GBP) financial settlement with Thalidomide Trust's National Advisory Council and Thalidomide UK set up for those affected by the drug.</p>	2005	150,000,000.000

Kroger Co. - \$7 Million Settlement	The Drug Enforcement Agency audited seven King Soopers pharmacies and discovered multiple violations of the Controlled Substances Act. The Drug Enforcement Agency filed charges against the nation's largest retail grocery chain and two of its subsidiaries, King Soopers and City Market. Kroger Co. has agreed to pay a \$7 million settlement as well as start a corporate wide compliance program to improve their pharmaceutical controls.	2005	7,000,000.000
Medirate Professional Pharmacy Inc. - Pay a \$450,000 settlement	The wholesale closed door pharmacy dba Medicate Long Term Pharmacy distributes controlled substances to customers in nursing homes and prisons. Medirate informed the Drug Enforcement Administration that 300,000 doses of several controlled substances went missing from their pharmacy. Charges were filed against the company for lack of security. Several former employees have been charged with felonies related to diverting controlled substances and Medirate has agreed to pay a \$450,000 settlement.	2005	450,000.000
PAL & AFSCME DC 37 announce \$24 million settlement with Serono in case alleging illegal promotion of AIDS drug Serostim	The Prescription Access Litigation Project (PAL) and PAL member AFSCME District Council 37 Health and Security Plan (DC 37) today announced a settlement in a nationwide class-action lawsuit brought by DC 37 and others against EMD Serono, Inc. and Merck Serono International S.A.		25,000,000.000
J&J Pays \$1.25 Million to Settle Suit Over Death of 14-Year-Old	Johnson & Johnson agreed to pay \$1.25 million to settle a lawsuit over the death of a 14-year-old girl who used the company's Ortho Evra birth-control patch, according to court records.		1,250,000.000

DuPont Settlement to Fund Test of Potential Toxics	Last month, DuPont, the largest manufacturer of perfluorocarboxylates, agreed to spend \$5 million to assess one aspect of the possible risk of exposure to these chemicals as part of a settlement with the U.S. Environmental Protection Agency.	2006	5,000,000.000
DuPont Settlement — \$38.5 Million	Michael Gordon received the highest honor of the Association of Trial Lawyer's of America – New Jersey (ATLA-NJ), its ATLA Gold Medal. The honor came to Michael in recognition of his four year long efforts in securing a \$38.5 Million		39,000,000.000
Walgreen Co. - \$1.3 million settlement.	The Drug Enforcement Administration, the Federal Bureau of Investigation, and others were investigating the retail drugstore chain for allegedly breaking federal laws by failing to monitor sales of cold medicines used to make methamphetamine. A Denton Walgreen store sold more than 53,000 tablets in one day to one person. New legislation requires stores to sell cold medicines behind the pharmacy counter and requires consumers to show a photo ID and sign a log. They are limited to 7.5 grams, or about 250 30-milligram pills, in a 30-day period. Computer tracking will prevent customers from exceeding the limit by shopping at multiple stores. Walgreen has agreed to pay a \$1.3 million settlement.	2005	1,300,000.000
Walgreens Pays U.S. \$9.9 Million to Settle Medicaid Prescription Drug Allegations	Illinois-based national retail pharmacy chain Walgreens has paid the United States and four participating states \$9.9 million to resolve allegations of falsely billing the Medicaid program, the Justice Department announced (see also Medicare and Medicaid).	2008	9,900,000.000

Boston Scientific - \$74 million settlement	<p>The U.S. Justice Department filed a lawsuit against the company claiming it illegally continued to make and sell systems for implanting stents in 1998 even after learning that a significant percentage of them were defective. In the summer of 1998 Boston Scientific began shipping large amounts of stents from Medinol that Boston Scientific attached to its balloon catheters. Boston Scientific received evidence within days of its first shipments that some of the balloons had pinholes; a defect that caused them to burst before they had finished fully expanding. The company continued shipping the devices even after they discovered the device was failing to meet the product's advertised specifications. The company has agreed to a \$74 million settlement with the Justice Department.</p>	2005	74,000,000.000
Wyeth Pharmaceuticals - \$2.2 million award	<p>Four Utah women sued the drug company after they allegedly suffered heart valve damage as a result of taking Pondimin, one of the drugs used in the fen phen slimming cocktail. Pondimin and Redux, were recalled in 1997 after being linked to heart valve problems and a highly fatal lung condition called primary pulmonary hypertension. The women have recently been awarded \$2.2 million.</p>	2005	2,200,000.000
Wyeth Pharmaceuticals - \$200 million in damages	<p>A Pennsylvania jury has awarded two former fen-phen users \$200 million in damages for heart problems caused by the diet drug. In February, Wyeth offered class action plaintiffs a 'drop claim' settlement option of up to \$100,000. Even though the weight loss medication is still on the market, Margie Paul and Elaine Karician were awarded \$100 million each</p>	2005	200,000,000.000

Jury Awards Louisiana Women \$2 Million Against Health Insurer	<p>A Louisiana jury awarded Ms. Christiane Hymel \$2 million against Blue Cross Blue Shield for causing the delay in discovery of a spinal tumor. The jury awarded \$2,000,000 for loss of enjoyment of life; \$50,000 for physical injuries; \$70,000 for unpaid past due medical bills; \$70,000 penalty based on those medical bills and the wrongful failure to pay them; \$15,000 in future medical expenses; and \$101,000 in attorney fees. (Feb-14-05) Ms. Hymel presented to her doctors complaining of back pain. Her doctors recommended a MRI, but BCBS refused to pay for it. Subsequently, the MRI was delayed by four months as Ms. Hymel raised the money to pay for the MRI on her own. As a result in the delay in diagnosis, she requires extensive physical therapy in order to walk again, and suffers irreparable numbness from the chest down.</p>	2,000,000.000
Dr. Rami Geffner - \$75,000 Fine	<p>The Ocean County physician has agreed to pay a \$75,000 fine to settle allegations that he failed to properly secure his prescription pads. The pads were stolen and used fraudulently to obtain health-insurance benefits by filling forged prescriptions.</p>	2005 75,000.000
Pfizer Inc. - \$4 million settlement	<p>The state of Texas, as well as 18 other states, has settled with Pfizer over allegations that the company was misleading people over the effectiveness of its ear medicine Zithromax. The company has agreed to pay a sum of \$4 million to all of the states involved in the case, although it admitted no wrongdoing. Pfizer also agreed to spend around \$2 million on commercials explaining how antibiotics combat ear infections, the illness Zithromax is used against.</p>	2005 4,000,000.000

Gambro Healthcare Laboratory Services – A \$53 million settlement	<p>The company, as well as another related company in Florida and the parent company in Colorado, have settled with federal authorities over allegations of Medicare/Medicaid fraud. The government alleges that two laboratories in Florida were improperly servicing people suffering from end stage renal disease, essentially kidney failure and incurable without dialysis or transplant. The two labs in question agreed to pay a combined total of \$53 million to the government, one of the largest Medicare/Medicaid fraud settlements ever received. Both laboratories were run by Colorado-based Gambro Healthcare, which is owned by the Swedish company Gambro Group, based out of Stockholm. The company did not fight the allegations any further after the settlement, and accepted responsibility for its actions.</p>	2000	53,000,000.000
Wyeth Pharmaceuticals - \$21.1 million to resolve litigation	<p>Two Utah residents had filed a class action lawsuit against the company for cardiovascular damages from the diet drug phen-fen. A jury decided the plaintiffs should be awarded \$5.5 million in damages. Phen-fen has been withdrawn from the market and Wyeth has set aside \$21.1 billion to resolve litigation.</p>	2005	21,100,000.000

Beth Israel Medical Centre - \$3.2 million settlement

Beth Israel Medical Centre in Boston has agreed to pay \$3.2 million in a settlement stemming from allegations that the hospital incorrectly billed Medicare for various procedures, in particular certain cardiac procedures. The suit was filed against six other hospitals, as well as Beth Israel. The suit claims that the Medicare program was charged for cardiac procedures not deemed safe by government agencies that were carried out between 1986 and 1995. A former salesman of medical equipment originally blew the whistle on Beth Israel and many other hospitals. The total amount of money recovered in settlements like this is \$40 million. As well as Beth Israel Medical Centre, other hospitals were included in the settlement. There were two from New Jersey; General Hospital Centre in Passaic and Hackensack University Medical Centre; two from California; Daniel Freeman Hospital in Los Angeles and Good Samaritan Hospital in Santa Clara; and one in Utah; LDS Hospital in Salt Lake City. The other five hospitals combined for roughly an additional \$2.3 million.

2002

3,200,000.000

<p>Santa Barbara-based Tenet Healthcare Corp. settlement worth \$30.75 million</p>	<p>Santa Barbara-based Tenet Healthcare Corp. has reached a settlement worth \$30.75 million with the U.S. Department of Justice, as well as some civilian lawsuits. The settlement resolved an inquiry by the Department into the hiring practices of a Tenet-run hospital in Florida, as well as a more generalized scrutiny of the company itself. The majority of the settlement, \$22.5 million is going towards the investigation of the Florida hospital, which was under investigation because of its contracts with some of its physicians, as well as other issues. The rest will go to settle the civilian claims, all of which were filed due to problems with Medicare claims. As well as paying the money, the Florida hospital will have to meet the terms of a corporate integrity agreement, which will force it to abide by federal laws and regulations. Tenet is the second-largest hospital company in the U.S.</p>	<p>2004</p>	<p>30,750,000.000</p>
<p>Wyeth Pharmaceuticals</p>	<p>Some 60,000 plaintiffs in the class action against the makers of Fen-Phen were given 'drop claim' settlement options. The expedited option offered \$20,000 per claim, while the grid option offered \$5,250 to \$200,000 based on the severity of their condition, plus an additional \$100,000 for clients who undergo heart-valve replacement surgery by 2010. Two-thirds rejected the offer and will continue fighting.</p>	<p>2005</p>	<p>2,200,000.000</p>

Wyeth Pharmaceuticals: \$2.2 Million award	Four Utah women sued the drug company after they allegedly suffered heart valve damage as a result of taking Pondimin, one of the drugs used in the fen phen slimming cocktail. Pondimin and Redux, were recalled in 1997 after being linked to heart valve problems and a highly fatal lung condition called primary pulmonary hypertension. The women have recently been awarded \$2.2 million.	2005	2,200,000.000
Wyeth Ordered To Pay 134.5 Million In Hormone Therapy Lawsuit	Various US press agencies have reported that a jury in Nevada has instructed Wyeth Pharmaceuticals Inc to pay 134.5 million dollars in compensatory damages to three women who claimed the company's hormone therapy drugs caused their breast cancer.		135,000,000.000
J&J Units Must Pay \$16.6 Million for Pain-Patch Death (Update4)	Nov. 17 (Bloomberg) -- Two units of Johnson & Johnson must pay \$16.6 million to the family of a Chicago-area woman who died after using a Duragesic pain-patch, a state jury found, dealing the company its fourth defeat in as many trials since 2006.		16,600,000.000
Mississippi jury awards five people \$150 million in fen-phen trial	Mississippi judge set aside a \$150 million award given to five people who claimed their health problems could be traced to the controversial diet drug cocktail known as fen-phen.	1999	150,000,000.000
<i>Related:</i> \$2.5 million settlement	Johnson & Johnson in July 2007 agreed to pay the family of a Florida man \$2.5 million to resolve claims that Adam Hendelson, 28, had died after using one of the patches, three people with knowledge of the accord said. A jury had awarded the plaintiffs \$5.5 million one month earlier.		2,500,000.000
<i>Related:</i> \$772,500 verdict	In July 2006, a state court jury in Houston ordered Janssen and Alza in July to pay \$772,500 to the family of a Texas woman who died after her patch leaked. The companies appealed that verdict.		773,000.000

University of Pennsylvania and the Children's National Medical Center - \$1 Million Award	At the age of 18, Jesse Gelsinger joined a gene therapy experiment intended to cure his nitrogen processing disorder. After an injection, just four days into the study, Gelsinger died. His family sued the two institutions for fraud, alleging their son was misled concerning potential risks. The Gelsinger family was awarded \$1 million for the death of their son.	2005	1,000,000.000
UK Insurance Industry - \$10 Million pound Settlement	A high court judge ruled in favor of thousands of asbestos exposed workers who developed pleural plaques. Up to 10 million pounds will be paid out over the next 40 years with a maximum compensation to each worker of 7,000 pounds.	2005	10,000,000.000
Torrington-Winsted Pediatric Associates and Pediatric & Adolescent Healthcare - \$500,000 Settlement	Torrington-Winsted Pediatric Associates and Pediatric & Adolescent Healthcare and its former owner, Dr. William Silberberg, have agreed to pay federal and state government over \$200,000 and pay private insurers \$300,000. The two Connecticut based pediatric practices offered free vaccines to children but billed Medicaid. A multi-million dollar settlement has been reached as is pending approval in the class action lawsuit filed on behalf of consumers who claim they were injured by the company's Metabolife 356 pill. The pill, which contains a combination of caffeine and the herbal stimulant ephedra, has been linked to strokes, heart attacks and, in some cases, death.	2005	500,000.000
Metabolife International - A multi-million dollar settlement		2005	45,000,000.000

Bayer - \$9 million settlement	The parties have reached a tentative nationwide \$9 million settlement in a class action filed against Bayer, Inc. on behalf of Canadians who live in any province other than British Columbia, and who were prescribed the anti-cholesterol drug Baycol (cerivastatin) and family members of deceased Canadians who took the drug. The suit alleged that the plaintiffs contracted rhabdomyolysis, a muscle disease, after taking the drug.	2004	9,000,000.000
Bayer reaches \$8 million settlement over drug disclosure	Bayer Corp. will pay \$8 million to 30 states, including \$200,000 to Texas, as part of a settlement requiring the company to fully disclose when drugs pose risks for patients with specific health conditions. ****		8,000,000.000
DuPont Pharmaceuticals Co: A \$44.5 million settlement	A \$44.5 million settlement has been reached in the class action lawsuit filed on behalf of consumers who purchased the blood-thinning medication, Coumadin. The suit alleged that the company disseminated false and misleading information about generic versions of Coumadin.	2004	46,000,000.000
Servier Canada Inc. et al: \$25 million settlement	The \$25 million settlement has been granted court approval in the class action lawsuit filed on behalf of Canadians (excluding those residing in Quebec) who ingested the diet drugs, Ponderal and Redux and suffered from Valvular Heart Disease ("VHD") or Primary Pulmonary Hypertension ("PPH").	2004	25,000,000.000
TAP Pharmaceutical Products: A \$150 million settlement	A \$150 million settlement has been reached in the class action lawsuit filed in May 2001 on behalf of anyone who purchased the drug Lupron after Jan. 1, 1985. The suit alleged that the company artificially inflated the price of the drug, which is primarily used to treat prostate cancer, but is also prescribed for endometriosis in women and premature puberty in children.	2004	150,000,000.000

Organon USA Inc. & Akzo Nobel N.V. - A \$36 million settlement	A \$36 million settlement has been reached in the nationwide class action lawsuit filed on behalf of the consumers, state purchasers, and other end payors of the antidepressant drug, Remeron. The suit alleged that the company improperly listed a new "combination therapy" patent with the U.S. Food and Drug Administration in order to unlawfully extend its monopoly.	2004	36,000,000.000
University of Illinois: A \$3 million settlement	A \$3 million settlement has been reached in the lawsuit filed on behalf of the family of Brandon and Patricia Reyes, twins who were born at the University hospital in early 1998. The suit alleged that the hospital was wrong to discharge the babies, who were just over three pounds apiece when they were discharged, without ordering breathing monitors and around-the-clock nursing care.	2004	3,000,000.000
Medtronic Sofamor Danek - A \$400 million verdict	A \$400 million verdict has been reached in the patent infringement lawsuit filed on behalf of Dr. Gary Michelson, a spinal surgeon and inventor, and Karlin Technology, Inc. The suit alleged that that Medtronic materially breached purchase and license agreements between the parties, engaged in wrongful conduct, infringed six patents owned by Dr. Michelson, and intentionally underpaid royalties.	2004	400,000,000.000
Bristol-Myers Squibb Co., Baxter International Inc.'s healthcare unit, 3M Co., Dow Chemical Co.'s Union Carbide Corp. unit et al: An \$11.3 million settlement	An \$11.3 million settlement has been reached with the U.S. government as medical reimbursement for women injured by silicone breast implants. The suit was filed four years ago by the Department of Justice.	2004	11,300,000.000

UnitedHealth Group: A \$9.95 million settlement	A \$9.95 million settlement has been reached in the class action lawsuit filed on behalf of 250,000 class members. The suit alleged that some pharmacies collected higher copayments than they should have under UnitedHealth care prescription drug plans.	2004	10,000,000.000
GlaxoSmithKline PLC. - A \$2.5 million settlement	A \$2.5 million settlement has been reached with the State of New York. The lawsuit alleged that the company had misrepresented data on prescribing its antidepressant drug Paxil to children.	2004	2,500,000.000
Merck Pays More Than \$400 Million to Settle Federal, State Medicaid Fraud Investigation Sparked by Qui Tam Whistleblower Case Detailing Marketing Schemes for Vioxx(R), Zocor(R), Several Other Drugs	One of the world's largest drug manufacturers, Merck & Co., Inc. ("Merck"), has agreed to pay more than \$400 million to the U.S., 49 states and the District of Columbia to settle qui tam whistleblower-led allegations that the pharmaceutical giant illegally defrauded Medicaid and other public healthcare programs across the U.S., according to a federal settlement Agreement unsealed today. Merck employed four schemes to grab or maintain market share for drugs including Vioxx(R), Zocor(R), Cozaar(R), Fosamax(R), Maxalt(R), and Singulair(R), according to qui tam whistleblower lawyers Steven H. Cohen, Mark Kleiman and BethAnne Yeager, who represent the whistleblower, a former Merck district sales manager.		400,000,000.000
HealthSouth and Physicians Pay \$14.9 Million to Settle Health Care Fraud Claims	The HealthSouth settlement also resolves allegations that the company paid kickbacks to, and entered into improper financial relationships with, other physicians, including a group in Los Angeles, in an apparent attempt to induce the referral of patients.		15,000,000.000

Parkway Hospital and Leben Home for Adults: A \$7 million settlement	A \$7 million settlement has been reached in the lawsuit filed on behalf of 24 mentally ill residents. The suit alleged that the plaintiffs were coerced into unnecessary prostate operations in 1998.	2004	7,000,000.000
Interplastic Corp. - A \$4.75 million settlement	A \$4.75 million settlement has been reached in the class action lawsuit filed on behalf of an estimated 1,000 Latonia, KY residents. The suit alleged that since the 1990's, the plant has frequently been releasing chemical fumes which have led to illnesses and property damage for the plaintiffs.	2004	4,800,000.000
California fertility specialist Dr. Steven Katz: \$1 Million Settlement	A \$1 million settlement has been reached in the lawsuit filed by Susan Buchweitz, a California woman who was implanted with the wrong embryos.	2004	1,000,000.000
Inverness Medical Innovations, Inc.	A proposed settlement has been reached in the class action lawsuit filed on behalf of all persons in the United States who have purchased an ovulation predictor kit manufactured, marketed, sold or distributed by Inverness Medical Innovations, Inc., Inverness Medical, Inc., Unipath Diagnostics, Inc., Unipath Online, Inc. and Unipath Ltd. during the period from April 7, 1999 through May 10, 2004.	2004	not reveal (as many settlements, as part of the agreement, do not disclose dollar amounts)
Educators Mutual - A \$2.86 million settlement	A \$2.86 million settlement has been reached in the lawsuit filed in regards to allegations of Medicare fraud. The federal suit alleged that the insurance group violated the Medicare Secondary Payer law by making Medicare the primary payer for kidney transplants and dialysis services.	2004	2,860,000.000
Banner Health - A \$6.1 million settlement	A \$6.1 million settlement has been reached with the federal government in Wyoming. The suit was filed regarding allegations that the company submitted false Medicare claims.	2004	6,100,000.000

Pfizer Inc. - A \$60 million settlement	A \$60 million settlement has been reached and is pending approval in the class action lawsuit filed in regards to the company's sale of Warner-Lambert's diabetes drug, Rezulin. The suit was filed on behalf of purchasers of Rezulin who reside in Illinois.	2004	60,000,000.000
Metabolife - A \$7.4 million verdict	A \$7.4 million verdict has been reached in the lawsuit filed by Rhea McAllister, a 35-year-old woman who suffered a stroke as a result of taking the now banned supplement which contains the drug ephedra.	2004	7,400,000.000
GlaxoSmithKline. A \$75 million settlement	A \$75 million settlement has been reached in the consumer lawsuit filed regarding charges that the company illegally blocked generic versions of its arthritis drug Relafen in the United States.	2004	75,000,000.000
Bethesda Memorial Hospital: A \$63 million verdict	A \$63 million verdict has been found in the lawsuit filed by Derik and Jennifer Korzeniowski and their 61/2-year-old son Luke. The suit claimed that Luke suffered severe brain damage after he was delivered with forceps, a practice which was determined to be medically unsound decades ago.	2004	63,000,000.000
Johns Hopkins University: A \$2.6 million settlement	A \$2.6 million settlement has been reached in the lawsuit filed on behalf of the National Institutes of Health. The suit alleged that the hospital overbilled for addiction research and other projects, and came after an employee revealed that researchers had inflated the amount of time required to carry out studies on therapies for drug dependence.	2004	2,600,000.000
Rush University Medical Center, Rush North Shore Medical Center, Dr. Bennett Braun, psychologist Roberta Sachs, and Dr. Corydon Hammond: A \$7.35 million settlement	A \$7.35 million settlement has been reached in the Chicago medical malpractice lawsuit filed by a woman who alleged that she was put under drug-induced hypnosis and then convinced she was part of a satanic cult.	2004	7,350,000.000

Dow Corning: \$24.2 million Settlement	A settlement of about \$24.2 million has been reached in the class action lawsuit filed on behalf of between 2,000 and 3,000 Canadian women who claim their silicone breast implants have caused them health problems.	2004	24,000,000.000
Taxol: \$62.5 million in settlement	Bristol-Myers Squibb Co. will distribute \$62.5 million in settlement checks to cancer patients who took the chemotherapy drug Taxol. As part of a settlement agreement with Bristol-Myers Squibb for unlawfully monopolizing the manufacture and sale of the anticancer drug Taxol and its generic form paclitaxel.		62,500,000.000
University of Washington: A \$35 million settlement	A \$35 million settlement has been reached in the lawsuit filed regarding a whistleblower lawsuit which alleged that doctors from the University's medical school and two other hospitals systematically overbilled Medicaid and Medicare and that documents were destroyed to hide the practice.	2004	35,000,000.000
Behavioral Health Care Associates et al. - A \$3.5 million settlement	A \$3.5 million settlement has been reached in the class action lawsuit filed on behalf of patients. The suit alleged invasion of privacy based upon the phony psychiatrist's accessing and reviewing the patient's medical records, and learning their identities as mental health patients.	2004	3,500,000.000
Parkland Medical Center in Derry, Progressive Women's Healthcare: A \$2.3 million verdict	A \$2.3 million verdict has been reached in the malpractice lawsuit filed by Derek and Melissa O'Donnell. The suit alleged that due to a complicated delivery two years ago, the O'Donnell's daughter Ashley suffered nerve damage so severe that she will probably never have full use of her right arm.	2004	2,300,000.000

Dow Corning. - The \$2.35 billion in settlement	The \$2.35 billion in settlement funds which were agreed upon nine years ago will finally be paid out, starting as soon as June 15. The suit was filed on behalf of 170,000 women in reference to damages suffered due to breast implants. Settlements will range from \$2,000 to \$330,000 per person.	2004	2,350,000.000
The University of Washington. - A \$35 million	A \$35 million settlement has been reached in the lawsuit filed regarding a claim that the school has been systematically overbilling Medicaid and Medicare and that it destroyed documents to hide the practice.	2004	35,000,000.000
Medco Health Solutions Inc. - A \$29 million settlement	A \$29 million settlement has been reached in the lawsuit filed by 20 states. The suit alleged that the company pressured doctors to change patients' medications to benefit its bottom line.	2004	29,000,000.000
Oregon Health & Science University - \$200,000 Settlement	A settlement has been reached in the class action lawsuit filed on behalf of two Oregon students. The suit was filed in regards to the controversial study of drug testing in Oregon high school athletes. (Apr-23-04) [DAILY NEWS] PORTLAND -- Two Oregon students have reached a settlement over a controversial study of drug testing in Oregon high school athletes, ending years of court challenges to the research. The settlement, approved Wednesday by U.S. District Court Judge Garr King, calls for the Oregon Health & Science University, several school districts and some employees of both to pay the plaintiffs' lawyers \$90,000.	2004	200,000.000

Mariner Post-Acute Network Inc. previous owners of the Clinton Health & Rehabilitation Center. - A \$10 million verdict	A \$10 million verdict has been reached in the class action lawsuit filed on behalf of the family of Mamie Crook who was a patient of the Rehabilitation Center from June 15, 1999, to Sept. 26, 2000. The suit alleged that the defendants were negligent in the woman's care, causing doctors to have to amputate her left leg at the knee after she developed sores due to inadequate care by the nursing home staff.	2004	10,000,000.000
Diet drug users get \$29.2 million	American Home Products will appeal a \$29.2 million award that an Oregon state court has given to two users of the company's diet drug. AHP is uninsured for the award, having exhausted relevant liability coverage limits in prior lawsuits	2000	29,200,000.000
Drug maker agrees to pay \$ 4.83 billion Fen-phen liability case one of largest in history	American Home Products Corp. resolved one of the biggest product liability cases ever Thursday by agreeing to pay up to \$ 4.83 billion to settle claims that its fen-phen diet drug combination caused dangerous heart-valve problems.	1999	4,830,000,000.000
Courtney settlement totals \$71 million	total of \$72.1 million to victims of former pharmacist Robert Courtney's drug dilution schemes, a newspaper reported. In its story for Sunday editions, The Kansas	2003	72,000,000.000
Jury orders Mylan to pay \$12 million in antitrust case	A federal jury ordered Mylan Laboratories Inc. to pay at least \$12 million to four insurance plans after finding the generic drugmaker violated antitrust laws by overcharging for two popular anti-anxiety medications.	2005	12,000,000.000
Judge cuts \$2.2 billion award for diluted drugs to \$330 million	While upholding a jury's verdict for a cancer patient who received drugs diluted by a pharmacist, a judge cut the damages from \$2.2 billion to just over \$330 million.	2003	330,000,000.000
Court affirms \$1.27 million award against Wal-Mart in drug death	Wal-Mart Stores Inc. lost its appeal Thursday of a \$1.27 million jury award to a Texas woman whose husband died after a Wal-Mart pharmacist in Arkansas gave him the wrong prescription medicine.	2003	1,270,000.000

<p>\$16 million verdict in pharmacy mistake case upheld</p>	<p>A state appeals court has upheld a judgment that Rite Aid Corp. and a pharmacist must pay \$16 million to a girl who was given the wrong medicine and suffered permanent brain damage.</p>	<p>2000</p>	<p>16,000.000</p>
<p>Wal-Mart loses appeal of \$840,000 wrong-drug verdict</p>	<p>The Arkansas Court of Appeals affirmed Wednesday an \$840,000 judgment against Wal-Mart Stores Inc. Enhanced Coverage LinkingWal-Mart Stores Inc. -Search using: Company Profile News, Most Recent 60 Days for giving a Siloam Springs man an incorrect prescription that, a jury found, caused him post-traumatic stress disorder.</p>	<p>2004</p>	<p>840,000.000</p>
<p>\$100 million award in Propulsid</p>	<p>The attorney who won a case against the makers of heartburn drug has said he doesn't expect the \$100 million jury verdict to stand. Hazlehurst attorney Jim Shannon told a legal symposium in Oxford on Friday that he expects a judge to reduce the award. In September, a Claiborne County jury ruled drug manufacturer Janseen and its parent company, Johnson & Johnson, knew or should have known about possible health risks associated with Propulsid.</p>	<p>2001</p>	<p>100,000,000.000</p>
<p>Ala. settles suits with 6 drug firms for \$89M</p>	<p>Six pharmaceutical companies have settled Medicaid drug pricing lawsuits with the state of Alabama for \$89 million, the latest in a string of drug fraud cases resulting in a financial boon to the state.</p>	<p>2009</p>	<p>89,000,000.000</p>

Lilly loses patent fight with Ariad Pharmaceuticals	<p>The U.S. District Court jury in Boston awarded Ariad and three co-plaintiffs, including the Massachusetts Institute of Technology, Enhanced Coverage Linking Massachusetts Institute of Technology, -Search using: Company Profile News, Most Recent 60 Days about \$65.2 million. The award includes a 2.3 percent royalty on future U.S. sales of Evista and Xigris until the patent expires in 2019. Last year, the two drugs had combined worldwide sales of about \$1.3 billion for the Indianapolis-based company.</p>	2006	65,200,000.000
In re Lorazepam and Clorazepate Antitrust Litigation	<p>On February 1, 2002, Judge Thomas F. Hogan of the United States District Court for the District of Columbia signed an order in the matter of In re: Lorazepam and Clorazepate Antitrust Litigation, MDL Docket No. 1290, finally approving settlements of two antitrust class actions filed on behalf third-party payors who overpaid for two anti-anxiety drugs from 1998 through 1999. The settlements established two funds totaling \$35.4 million payable to third-party payors throughout the United States.</p>	2002	35,400,000.000
Molecular Diagnostics Lab. V. Hoffman-LaRoche, Inc., et al.	<p>\$33 million settlement against two large biotechnology companies after more than four years of hard-fought litigation. The class alleged that the two companies improperly exploited and enforced a patent claiming Thermus aquaticus DNA polymerase (“Taq”), an enzyme that has been crucial to discoveries in medical diagnostics and treatment, the study of the human genomes, and criminal forensics. The court granted final approval to the settlement.</p>	2007	33,000,000.000

Mary & John Doe v. ABC Company	A woman who suffered acute renal failure after taking a prescription drug produced by defendant settled her claim against the manufacturer for \$275,000.	2003	275,000.000
Doe Family v. Roe Health Care Providers and Roe Drug Manufacturers	In 2001, approximately two months before his death, the plaintiffs' decedent, a 75-year-old male, was prescribed a cholesterol-reducing drug (Drug #1) to be taken with another cholesterol-reducing drug.	2003	1,250,000.000
Cortez Strong v. American Cyanamid Co., Georgia Santo-Jawaid	plaintiff Cortez Strong, then 4 months old, and now 18, was orally administered his second dosage of Orimune, a polio vaccine, by his pediatrician, Georgia Santo-Jawaid.	2005	8,500,000.000
John Doe v. Unnamed Drug Company, Unnamed Pharmacy, Unnamed Orthopedist and Unnamed Infectious Disease Specialist	On March 27, 2000, plaintiff John Doe, a 51-year-old welder, was injured in an industrial accident on the job. He suffered significant internal injuries and a severely comminuted left lower extremity ...	2006	125,000.000
Katherine and David King as legal representatives of Mary Ellen King v. Secretary of the Department of Health and Human Services	A girl who suffered crippling seizures and eventual brain damage after receiving a diphtheria-tetanus-pertusis (DTP) vaccination received \$4.69 million from a federally administered compensation fund	2002	4,690,000.000
State of Alabama v. Sandoz Inc.	In January 2005, the state of Alabama filed an action against the Germany-based pharmaceutical company Sandoz Inc., alleging that it fraudulently misrepresented and concealed the costs of prescription	2009	78,400,000.000
People of the State of California v. CVS Pharmacy Inc., a Rhode Island Corporation	Homolka, both attorneys, entered an agreement with attorneys Michael Miller, Nancy Armstrong, Joel Gatlin, and the firms of Miller & Associates, Armstrong & ...	2009	975,000.000
John J. Orzel and Sylvia E. Orzel, guardian v. Scott Drug Co. and Abbott Laboratories	Plaintiff went to the Figure Eight Weight Loss Clinic and received a prescription from the clinic doctors for a drug called Desoxyyn, which is an amphetamine used for weight control. Plaintiff filled ...	1988	3,600,000.000

Estate of Lewis M. Conn and Irene, Peter and Deborah Conn v. Nationwide Pharmacy, John Newcomb and Rose Somerville	Decedent entered Defendant Nationwide Pharmacy to purchase a prescription of penicillin. After making his purchase, decedent asked for a cup of water to take one of the penicillin pills. Defendant c... Defendant Drug Emporium's store in Marietta. Defendant's pharmacist allegedly gave plaintiff hypertension medication instead of medication for migraine headache...	1990	845,000.000
Janet M. and Richard C. Miller v. Drug Emporium	defendant pharmacist filled the prescription with the wrong dosage.	2002	850,000.000
Santos v. DeVillers, individually and d/b/a DeVillers Pharmacy	Plaintiff alleged that defendant was negligent in failing to exercise reasonable In January 1995, Defendants dispensed the steroid Prednisone to Plaintiff, a 36-year-old electrician. Plaintiff claimed that Defendants failed to properly label the prescription, Plaintiff was taking several prescription medications which had been filled by defendant drugstore. On the third day of taking the medications, she allegedly suffered a seizure and uncontrolled body m...	1994	143,000.000
John and Rose Marie Oliver v. Evkin Pharmacy Corp., Ralph Ekstrand, and Vincent Conte	March 14, 1998, plaintiff, a 30-year-old female sales rep for Pitney Bowes, filled a prescription for Dexamethasone at defendant Rite Aid Pharmacy located in the City of West Los Angeles. She had been...	1999	1,000,000.000
Anonymous 49 Year Old Female v. Anonymous Drugstore	Plaintiff, a 5 year old male, was prescribed Adderall for attention deficit hyperactivity disorder (ADHD). His aunt had an Adderall prescription filled at defendant pharmacy and began administering th...	2000	200,000.000
Tina Hartounian v. Thrifty Payless, Inc. dba Rite Aid	John Kilgore and Kelli Ann Kilgore v. Wal-Mart Stores, Inc.	2000	72,000.000
Anonymous 5 Year Old Male v. Anonymous Pharmacist		2002	840,000.000
John Kilgore and Kelli Ann Kilgore v. Wal-Mart Stores, Inc.			

Jane Doe, Age 45 v. Anonymous Pharmacy	A patient being treated for Wilson's Syndrome overdosed as a result of a pharmacist error in preparing the prescribed medication. The woman settled her claim against the pharmacist for \$650,000.	2003	650,000.000
Concepcion Morgado v. Warner Lambert Co., Parke-Davis & Co., and Pfizer, Inc.	In May 1998, plaintiff Concepcion Morgado, 51, a dressmaker, began using the diabetes drug Rezulin. A blood test taken shortly thereafter was read as normal. In August 1998, Morgado, a type-2 diabetic...	2003	2,000,000.000
Vivian Collins; Emir Hernandez; and Amelia J. Ceballos, individually and as Personal Representative of the Estate of Palmira I. Rodriguez v. Bayer A.G.; SmithKline Beecham Corporation, d/b/a Glaxosmithkline, and Glaxosmithkline, PLC.	Plaintiff Vivian Collins, 58, had a history of hyperlipidemia, hypertension and peripheral vascular disease. In December 2000, she was prescribed 0.8 mg of Baycol, a statin that is used to lower chole...	2003	2,100,000.000
Doe Family v. Roe Health Care Providers and Roe Drug Manufacturers	In 2001, approximately two months before his death, the plaintiffs' decedent, a 75-year-old male, was prescribed a cholesterol-reducing drug (Drug #1) to be taken with another cholesterol-reducing dru...	2003	1,300,000.000
Donna Kubitz, individually and as personal representative of the estate of Bruce K. Kubitz, deceased v. David B. Winkles, individually, and as David B. Winkles d/b/a Winkles Pharmacy	Plaintiffs' decedent Bruce Kubitz, 40, was prescribed butlabital and Darvocet (propoxyphene) for headaches and stomach problems. Both drugs are highly addictive and linked to depression. His doctor fi...	2003	800,000.000
Ronald Gunderson, as administrator of the estate of Mary Margaret Gunderson, et al. v. Sandoz Pharmaceuticals Corporation, now Novartis Pharmaceuticals Corporation, and the estate of Dr.	The plaintiff is the estate of Mary Margaret Gunderson, who died at age 32.	2004	19,000,000.000

Rodger and Claudia Price v. Walgreen Co	In May 1996, plaintiff Roger Price, a 56-year-old photo lab worker, was diagnosed with a severe case of peripheral vascular disease resulting in the occlusion of two of the three arteries feeding his ...	2004	1,200,000.000
Jerry Coffey, Individually and as Representative of the Estate of Cynthia Cappel-Coffey, Deceased and as Next Friend of Rachel Coffey, Sarah Coffey and Jennifer Coffey, Minors v. Wyeth, f/k/a American Home Products Corporation; Wyeth Pharmaceuticals, f/k/a Wyeth-Ayerst Laboratories Division of American Home Products Corporation; A.H. Robins Company; and Kevin Tyrrell, Jointly and Severally	From November 1996 through June 1997, plaintiffs' decedent Cynthia Cappel-Coffey was prescribed the diet drug Pondimin, also known as fenfluramine hydrochloride in combination with phentermine. Dr. Ca... A pharmacist who acknowledged having made a mistake in compounding a prescription medication agreed to settle the injury claim of a man who was totally disabled after ingesting the medication. The amo...	2004	1,000,000,000.000
Anonymous Plaintiff v. Anonymous Pharmacist	On Feb. 9, 1999, plaintiff Alexandra Gerhke, who was 7-months-old, was given what her mother, Tracey Gerhke, thought was Phenobarbital, an anti-seizure medication, by William Zaeske, a pharmacist at W...	2004	1,400,000.000
Tracey Gerhke, individually, and as mother and next friend of Alexandra Gerhke, and David Gerhke vs. Walgreen Company d/b/a Walgreens and William Zaeske	In 1997, plaintiff Miguel Valverde, 25, a truck driver, sustained a hemorrhagic stroke due to a ruptured aneurysm. He alleged that, 11 hours earlier, he had taken Alka-Seltzer Plus for cold symptoms, ...	2004	21,000,000.000
Miguel Valverde v. Bayer Corp.	Plaintiff Larry Hines, 56, was prescribed Pondimin, a diet drug that serves as an appetite suppressant, by his physician in 1996. He took Pondimin for eight months, until early 1997 when he discontinu...	2004	400,000.000
Larry Hines v. Wyeth Pharmaceuticals		2004	115,000.000

Susan Rives, Lorraine Gordon, Sonia Jones v. Wyeth Pharmaceuticals	Va., Lorraine Gordon, 46, of Harrisonburg, Va., and Sonia Jones, 50 of Oxon Hill, Md. all took Pondimin (fenfluramine) for a period of months in 1996.	2005	2,500,000.000
Edward Guardiola and Nadine Guardiola v. Basinger's Pharmacy, Inc., an Illinois corporation, d/b/a Basinger's Marycrest Pharmacy; Basinger's Pharmacy City Center and Dr. Harish Bhatt	On Feb. 3, 2000, plaintiff Edward Guardiola, 52, a paint tester, went to Basinger's Marycrest Pharmacy, which is located at 2130 West Jefferson St. in Joliet. He requested a refill of a prescription f...	2005	1,000,000.000
Anonymous Female v. Anonymous Pharmacist, Anonymous Pharmacy, Anonymous Residential Home, Anonymous Physician and Anonymous Psychiatrist	A mentally retarded woman died from an overdose of lithium that was allegedly not recognized by any of her medical providers for one month. Defendants pharmacist, pharmacy and residential home settled...	2006	1,000,000.000
Barbara Pepe and Owney Pepe v. Septodont, Inc. and Deproco, Inc.	On May 29, 2001, plaintiff Barbara Pepe, 46, a telephone company worker, was injected with Septocaine, a prescription local anesthetic, for a root canal, but the numbness did not wear off.	2006	305,000.000
Stephanie Henderson, Individually and as Personal Representative of the Estate of Darryl A. Henderson, Sr., and Darryl A. Henderson, Jr., and Chelsea Henderson, a Minor, by Stephanie Henderson, Parent, Next of Friend, and Natural Guardian v. Bayer Corporation	On the afternoon of Feb 21, 2001, plaintiffs' decedent Darryl Henderson, 37, was upstairs sitting in bed watching television when his son, plaintiff Darryl Jr., came home from school. He asked the bo...	2006	2,000,000.000
John McDarby, Irma McDarby and Thomas Cona v. Merck & Company	On June, 9, 2003, plaintiff Thomas Cona, 57, owner of a medical-testing company, was playing golf when he suffered a heart attack. He claimed it was caused by Vioxx, which he took daily for 22 months....	2006	14,000,000.000

Heineman v. Walgreens	A drugstore was found negligent for incorrectly filling a prescription.	2006	120,000.000
Adam W. Mason v. John Doe	In the mid-1990s, plaintiff Adam Mason, 20s, occupation not given, was prescribed Accutane, a drug that is given to patients with severe acne. Accutane is prescribed for patients who suffer from sever...	2007	2,800,000.000
Anonymous Male v. Anonymous Hospital	A settlement was reached under the Federal Tort Claims Act after a pharmacy allegedly gave an 80 year old patient the incorrect dosage of blood clotting medication. Plaintiff was rendered a paraplegic	2007	1,000,000.000
Next of Kin of Justin Young, a Minor, and Julie and John Young, Individually v. XYZ Corp. and John Doe	was severely injured when he received a potentially lethal dosage of potassium while being given total parenteral nutrition (TPN) at home through an intrav...	2009	7,500,000.000
Mace v. Hoffmann-La Roche Atlantic Co., N.J.; Super. Ct.; No. ATL-L-199-05 (12/10/08)	Three plaintiffs claimed acne medication led to inflammatory bowel disease and that drug's maker warned doctors but not patients. Defense challenged causal link of plaintiffs' illness.	2008	13,000,000.000
\$58 MILLION MERCK SETTLEMENT TO CHANGE DECEPTIVE TV DRUG ADVERTISEMENTS	California Attorney General Edmund G. Brown Jr. today announced a "groundbreaking settlement" with Merck & Co. which requires the pharmaceutical manufacturer to obtain Federal Drug Administration approval before running any television drug advertisements for new pain medications.	2008	58,000,000.000

Merck paying \$671M to settle case over drug rebates, marketing	<p>In one of the biggest U.S. health care fraud settlements ever, Merck & Co. will pay \$671 million to settle claims it overcharged the government for four popular drugs and bribed doctors to prescribe its drugs, federal prosecutors said Thursday.</p> <p>The alleged overcharges, dating back to the mid-1990s, involved Medicaid programs in the District of Columbia and every state but Arizona, as well as federal health-insurance programs at agencies including the Department of Defense and Veterans Administration.</p>	2008	671,000,000.000
Reaches \$2.3 Billion Tax Settlement With IRS	<p>New Jersey-based Merck has reached a \$2.3 billion settlement with the Internal Revenue Service related to three separate tax disputes from 1993 to 2006, the Wall Street Journal reports. The largest dispute involved a 1993 transaction under which Merck transferred patents for the drugs Zocor and Mevacor to a subsidiary in Bermuda. Merck said that the settlement is actually for \$2.9 billion, but \$1.2 billion is tax-deductible interest and \$200 million already has been paid to the government.</p>	2007	2,300,000,000.000
MERCK-MEDCO: MERCK OFFERS \$42.5M TO SETTLE BENEFITS SUIT	<p>Merck yesterday offered to pay \$42.5 million to settle "long-running" class-action lawsuits alleging that its pharmacy benefit manager subsidiary Medco Health Solutions</p>	2002	43,000,000.000
DuPont Merck: \$ 22 M for overpricing affair	<p>DuPont Merck Pharmaceutical Enhanced Coverage Linking DuPont Merck P</p>	1998	22,000,000.000

\$176M Settlement in Drug Price Suit	Nineteen drug companies will pay more than \$176 million to settle a class-action lawsuit alleging they overcharged for medicine sold at independent pharmacies in California, the San Francisco Chronicle reported today. In addition, the companies will have to pay \$27 million in fees to attorneys who represented the plaintiffs in the suit brought on behalf of California's 32 million consumers.	1999	176,000,000.000
BAYER TO PAY \$20 MILLION TO CORRECT AD MISINFORMATION	Enhanced Coverage LinkingPharmaceutical giant Bayer -Search using: News, Most Recent 60 Days Company Profile	2009	20,000,000.000
Competition Bureau fines Bayer \$3.65M over price-fixing conspiracies	Enhanced Coverage LinkingBayer AG, - Search using: News, Most Recent 60 Days Company Profile	2007	3,600,000.000
Bristol-Myers SquibbEnhanced Coverage : Second drug company to pay more than \$1 billion in fines Here is a list of aggregated fines paid by a few drug companies to the Justice Depatment, SEC and FDA over the last few years due to marketing fraud, accounting fraud, and bad manufacturing:		2007	1,000,000.000

Bristol-Myers Squibb	Bristol-Myers Squibb Enhanced Coverage Linking Bristol-Myers Squibb Co. and a subsidiary have agreed to pay more than \$515 million to settle federal and state investigations into their drug marketing and pricing practices, U.S. Attorney Michael Sullivan announced today. Last year, on June 8, 2006, the Securities and Exchange Commission announced that BMS would pay \$750 million which would be distributed to compensate shareholders injured by fraudulent earnings management at Bristol-Myers Squibb	2007	515,000,000.000
----------------------	---	------	-----------------

Here is a list of aggregated fines paid by a few drug companies to the Justice Department, SEC and FDA over the last few years due to marketing fraud, accounting fraud, and bad manufacturing:

Schering-Plough	1,200,000,000.000
GlaxoSmithKline 563	563,000,000.000
Bristol Myers Squibb	1,200,000,000.000
Pfizer 514	514,000.000
Takeda-Abbott	875,000,000.000
Eli Lilly 36	36,000,000.000
Bayer 271	271,000,000.000
AstraZeneca 355	355,000,000.000
Abbot 482	482,000,000.000

The following information was released by the United States Attorney's Office for the District of Massachusetts:

MEDICAL DEVICE
MANUFACTURER AND ITS
PRESIDENT SENTENCED FOR
CONSPIRING TO DISSEMINATE
ADULTERATED COMPUTER
SOFTWARE DEVICE

A Clinton Township, Michigan medical device manufacturer and its President were sentenced today in federal court after pleading guilty to conspiring with others to disseminate, without first obtaining approval from the U.S. Food and Drug Administration (FDA), adulterated computer software devices for use in interpreting bioelectrical impedance analysis (BIA) test results in order to promote diagnoses of AIDS wasting and to increase sales of an AIDS wasting drug.

RJL and LIEDTKE admitted that, commencing in September 1996, they and others, including Serono Labs, conspired to introduce three BIA computer software packages into interstate commerce for use in calculating body cell mass and diagnosing AIDS wasting. These software devices were adulterated in that neither RJL, LIEDTKE, nor others had obtained premarket approval from the FDA before disseminating them. LIEDTKE was sentenced to 3 years probation and a \$10,000 fine.

LIEDTKE

10,000.000

Executive sentenced in Serono fraud case

On Wednesday, prosecutors asked U.S. District Judge Edward Harrington to sentence Liedtke to a prison sentence of just less than 3 1/2 years. But Harrington refused, citing the case of Dr. Norma Muurahainen, who worked as a medical director for Serono and pleaded guilty to disseminating an adulterated device, but does not face prison time.

Halcion maker found partly liable in killing	A Dallas jury, in the first verdict of several civil suits against the makers of Halcion, Thursday found the USA's most popular sleeping pill partly responsible for a killing. The jury awarded up to \$ 2.15 million to the family of ex-Fort Stockton, Texas, police officer William Freeman, who blamed Halcion for his 1987 killing of his close friend.	1992	2,150,000.000
Tylenol Verdict Puts Spotlight On Drug Labels	As doctors and drug-makers measured the effects yesterday of a jury verdict awarding \$ 8.8 million to a Fairfax County man who lost his liver after he took Tylenol and drank wine, medical specialists said the case apparently was the first in which serious injury resulted from moderate amounts of the medication and alcohol.		8,800,000.000
Md. Woman Upheld on Appeal Over Birth Defects Tied to Drug	Oxendine, 18, a young girl when litigation began, convinced a D.C. Superior Court jury in 1983 that her mother's use of Bendectin during pregnancy had been responsible for the deformity of her right arm at birth. That verdict, the first in the nation to go against Merrell Dow, won her \$ 750,000 in compensatory damages.		750,000.000
WYETH IS ORDERED TO PAY \$1 BILLION IN DIET-DRUG CASE	Texas jury awards \$1 billion to the estate of a deceased woman after finding that Pondimin, a diet drug from Wyeth caused her death; about \$100 million was actual damages, while the remainder was punitive damages; the verdict is the first in a case alleging that a Wyeth diet drug caused a rare disease called primary pulmonary hypertension (M)	2004	1,000,000.000
Dalkon	The first case to reach a jury verdict results in an award of \$85,000 in damages in Wichita, Kan.	1975	85,000.000

Dalkon	A Colorado jury awards \$6.2 million in punitive damages and \$600,000 in compensatory damages in the largest verdict in a shield case.	1984	6,200,000.000
Dalkon	A settlement reportedly for around \$38 million is announced and called the largest non-class action settlement in the nation's history.	1984	38,000,000.000
Jury awards \$15 million in DPT case	A federal jury awarded \$15 million Wednesday to a couple who claimed their daughter suffered permanent brain damage after receiving a DPT vaccination seven years ago.	1987	15,000,000.000
WARNER-LAMBERT CO PLEADS GUILTY TO NOT REPORTING EPILEPSY DRUG'S FLAWS	with federal regulators over its epilepsy drug Dilantin; pleads guilty to a felony charge of failing to notify FDA about problems with the drug, and agrees to pay a \$10 million fine .		10,000,000.000
Georgia Receives \$5 Million in Drug Settlement	Georgia Department of Community Health (DCH) announced that the state will receive \$5 million in a drug settlement from Bristol-Myers Squibb Company	2008	5,000,000.000
Two Chicago clinics benefit from drug settlement	A The Ark clinic and the CommunityHealth clinic willreceive \$100,000 and \$275,000 respectively to buy pharmaceuticals for poor patients.	2009	375,000.000
Amgen Plans Charge to Cover Drug Settlement	Amgen Inc. said it will take a third-quarter charge of 35 cents a share to pay Johnson & Johnson a \$96-million settlement over Amgen's marketing of a drug.	1997	96,000,000.000
Colorado gets \$3.5 million from drug settlement	Colorado will receive \$3.5 million as part of two settlements with drug manufacturer Pfizer	2009	3,500,000.000

ATTORNEY GENERAL ANNOUNCES CANCER DRUG SETTLEMENT	Attorney General Mark Shurtleff announced today that the manufacturer of a prostate cancer drug has offered to reimburse \$35,000 to Utah for defrauding the state's health care programs. TAP Pharmaceutical Products, Inc. has also agreed to pay a total of \$875 million to resolve criminal charges and civil liabilities for fraudulent drug pricing and marketing.	2001	910,000,000.000
Utah receiving payment from drug settlement	The state is receiving a second payment from drug manufacturer Bristol-Myers Squibb as part of a settlement over the anti-anxiety drug BuSpar. The Utah Attorney General's Office announced Friday that the most recent payment of \$565,192 will be divided between the University of Utah Medical Plan, the state Medicaid office, the Utah Developmental Center, Utah State Hospital, the Public Employees Health Program and the Attorney General Antitrust Litigation Fund.	2005	565,000,000.000
Mass. gets nearly \$4.7M in drug settlement	The Massachusetts attorney general's office says Pennsylvania drug maker Cephalon Inc. has agreed to a nearly \$4.7 million payment to the state to settle allegations of off-label marketing of three pharmaceutical products.	2008	4,700,000.000
Washington to get \$2.7 million from drug settlement	Attorney General Rob McKenna says Washington state will collect about \$2.7 million from a settlement with makers of the painkiller OxyContin.	2007	2,700,000.000
Colorado gets \$100K in national drug settlement	Colorado receives \$100k in a settlement with drug makers in a dispute over two cholesterol medications	2009	100,000.000
Nevada to get \$1.1 million in drug settlement	Settlement with Eli Lilly	2008	1,100,000.000

AG says Vermont received \$725,000 drug settlement	Vermont Attorney General William Sorrell said Monday the state received more than \$700,000 from an August settlement with Schering-Plough	2007	725,000.000
Arizona to get part of drug marketing settlement	Attorney General Terry Goddard says Arizona will receive at least \$804,888 from a settlement with Pfizer Inc.	2009	804,000.000
Ranbaxy and the Scottish government have reached a one million pound settlement.	Ranbaxy and the Scottish government have reached a one million pound settlement. The agreement follows accusations by the former of anti-competitive cartel conduct, in connection with drugs that were supplied to the NHS.	2008	-
Banner Health Systems settlement money being distributed	Money from a \$1 million settlement with Banner Health Systems is being distributed to long-term care centers, Attorney General Wayne Stenehjem says	2004	1,000,000.000
The \$30.7 million settlement came in a lawsuit filed on behalf of consumers who purchase the drug Hytrin, which doctors prescribe to treat hypertension and enlarged prostates. Abbott Laboratories manufactures the name brand drug, while Geneva Pharmaceuticals makes its generic version, called Terazosin.	According to the lawsuit, Abbott wrongfully paid Geneva to delay introduction of its generic version of Hytrin and took other steps to delay competitions from the lower-priced versions of its product. The complaint alleges those moves hurt consumers, who paid higher prices for the drug as a result.	2005	30,700,000.000
Synthroid Lawsuit Settled	Settlement in the thyroid drug Synthroid case for those who purchased the drug between January 1, 1990 and October 21, 1999, settles for \$87.4 million.	2003	87,400,000.000

Texas Personal Injury Attorney Wins \$19.4 million Defective Drug Settlement For Remicade User	Texas jury ruled that Remicade manufacturer Centocor failed to warn doctors and their patients about adverse reactions associated with the arthritis drug and therefore was at fault for the personal injury illnesses Hamilton suffered due to her use of Remicade. The Texas personal injury award for the defective drug claim included \$16 million in punitive damages against the Pennsylvania bio medicine company.		19,400,000.000
Walgreens agrees to \$35M drug-switching settlement	Walgreen Co. has agreed to pay \$35 million to the U.S. Department of Justice to resolve allegations that it had switched patients to more expensive drugs to boost its Medicaid reimbursement. In the settlement,	2008	35,000,000.000
MADIGAN ANNOUNCES \$7.2 MILLION SETTLEMENT IN DRUG PRICING CASE	Attorney General Lisa Madigan today announced that her office has brokered a \$7.2 million settlement agreement with Amgen Inc., and its wholly-owned subsidiary, Immunex Corporation, to settle allegations that the drug companies inflated the wholesale price index used for setting Medicaid reimbursements. The funds from Madigan's settlement have been deposited into the State of Illinois' General Revenue Fund for use in paying Medicaid bills for Illinois' neediest patients.	2009	7,200,000.000
STATE RECEIVES SETTLEMENT MONEY IN DRUG PRICE-FIXING CASE	Montana Attorney General Mike McGrath said Wednesday that 644 Montana residents will split more than \$149,000 as part of a settlement in a drug price-fixing case.	2002	149,000.000

	<p>Five leading drugmakers swallowed a bitter pill last week. In a surprise move, they offered to pay \$120 million to settle treble-damage claims against them for allegedly rigging the price of a widely used antibiotic, tetracycline. While proposing the settlement, the five companies—American Cyanamid, Chas. Pfizer, Bristol-Myers, Upjohn and Squibb Beech-Nut—asserted that they "have not violated the antitrust laws."</p>		
<p>Drugs: The \$120 Million Settlement</p>		<p>1969</p>	<p>120,000,000.000</p>
<p>KING PHARMACEUTICALS TO PAY U.S. \$124 MILLION FOR MEDICAID REBATE UNDERPAYMENTS & OVERCHARGING FOR DRUG PRODUCTS</p>	<p>King Pharmaceuticals has agreed to pay \$124 million plus interest to resolve allegations that it underpaid rebates owed under the Medicaid program and overcharged various federal and state governmental entities for its drug products, the Justice Department announced today. Attorney General Richard Blumenthal today announced a national Medicaid fraud settlement of \$6.15 million that will go to Connecticut. Cephalon, Inc., resolving an investigation into illegal off-label drug marketing that endangered patients, causing serious side effects, addiction and even death.</p>	<p>2005</p>	<p>124,000,000.000</p>
<p>Connecticut Attorney General Announces \$6.15 Million Settlement For Illegal Drug Marketing</p>	<p>Hawaii expects to receive about \$165,000 out of a proposed \$80 million settlement of an antitrust lawsuit filed by state attorneys general involving the heart medication Cardizem CD.</p>	<p>2008</p>	<p>6,150,000.000</p>
<p>Article: Heart drug settlement may net state \$165,000</p>		<p>2003</p>	<p>165,000.000</p>
<p>ADERIS PHARMACEUTICALS: \$1M milestone payment received for initiation of Binodenoson trial</p>	<p>receipt of a \$1 million milestone payment from King Pharmaceuticals, Inc., in connection with King's commencement of the pivotal phase III clinical trial program involving binodenoson.</p>	<p>2004</p>	<p>1,000,000.000</p>

Four years after Richard Scrushy was acquitted of directing accounting fraud at HealthSouth, a judge has held him accountable for \$2.876 billion, Bloomberg reports. "Scrushy was the CEO of the fraud," said the judge, who ruled without a jury. The decision "is a shot across the bow for those who engage in corporate greed and fraud in our country," said an attorney for the plaintiffs.

Shareholders suing Scrushy held that the hospital chain's founder had spent the firm's cash on real estate, 400 flights to his lake house in a HealthSouth helicopter, and breast implants for a member of a band he put together. His lawyers said he advanced money to the company for expenses, the helicopter use was in his contract, and the band member needed emergency implants because her current ones had made her sick.

HealthSouth Boss on Hook for \$2.9B
Fraud

2,900,000,000.000

A jury has awarded a former sales representative for a pharmaceutical company \$ 8.4 million after finding the company guilty of age discrimination for firing him. Ferdinand Maiorino, 67, had worked for Schering-Plough Corp. for 35 years before he was fired July 15, 1991.

Jury Awards \$ 8.4 Million in Age
Discrimination Case

Maiorino contended that he was fired because of his age; the company said it fired him because of poor performance.

1994

8,400,000.000

Besides a national class-action lawsuit by pharmacies, Eli Lilly and Co. also has settled at least two other lawsuits alleging price discrimination in its drug sales. Within the last several months, the Indianapolis drugmaker settled a separate lawsuit by 3,800 independent pharmacies accusing it and 34 other drug companies and wholesalers of antitrust violations and price discrimination, said Larry L. Braden, an Atlanta-area pharmacist who is a plaintiff in the case in federal court in Chicago. Terms of Lilly's settlement in that case are confidential, he said. In addition, Lilly agreed last year to give \$11.9 million worth of free ... The prices of more than a thousand brand name drugs are about to get a little cheaper, thanks to a huge settlement with a major drug distributor. The settlement is for more than \$350 million and ends a long court battle over an alleged drug industry scheme to boost pharmacy profits at your expense.

Indianapolis Drugmaker Eli Lilly Is Party to Two Other Pricing Settlements

2000

350,000,000.000

Vermont Attorney General William Sorrell said Monday the state received more than \$700,000 from an August settlement with Schering-Plough. The company was charged with illegal marketing practices and pled guilty to one count of conspiracy to make false statements to the government and paid a \$180 million fine. A civil penalty of \$255 million was then divvied to the state attorneys general to be put into the state's Medicaid fund.

AG says Vermont received \$725,000 drug settlement

725,000.000

<p>FIFTY-SIX ATTORNEYS GENERAL ANNOUNCE MULTIMILLION DOLLAR ANTIDEPRESSANT DRUG SETTLEMENT</p>	<p>Attorneys General from the 50 states, the District of Columbia and the U.S. territories and commonwealths announced the completion of a \$36 million settlement with drug maker, Organon USA Inc., and its parent company, Akzo Nobel N.V., over the antidepressant drug, Remeron.</p>	<p>36,000.000</p>
<p>THIRTY-TWO STATES AND THE DISTRICT OF COLUMBIA REACH \$ 100 MILLION ANTITRUST SETTLEMENT WITH PRESCRIPTION DRUG MANUFACTURER</p>	<p>Thirty-two States, the District of Columbia and the Federal Trade Commission have reached a \$ 100 million settlement with pharmaceutical giant Mylan Laboratories and other drug companies.</p>	<p>2007 100,000,000.000</p>
<p>Vioxx</p>	<p>a jury in Angleton, Texas, found Vioxx producer Merck liable for the death of fifty-nine-year-old Robert Ernst. The Brazoria county jury assessed a staggering \$253 million (\$24 million compensatory, \$229 million punitive) in damages against Merck, although Texas law will cap the punitive damages at less than \$2 million and thus reduce the total award to about \$26 million.</p>	<p>2005 253,000,000.000</p>
<p>\$4 million against McNeil Pharmaceutical. Directed verdict for Burgerman and Smith</p>	<p>Breakdown: \$1.5 million compensatory and \$2.5 million punitives. - Products Liability Product Liability - Muscle Relaxant - Fatality - Punitive Damages - Wrongful Death Facts: Plaintiff's decedent, a 75 year-old woman, was prescribed Parafon Forte DSC (chlorzoxazone), a muscle relaxant manufactured by Defendant McNeil, to treat numbness and stiffness in her hands. Defendant physicians read the drug's warnings and believed the drug to be safe. Two months thereafter decedent presented to the emergency room with a two-week history of progressively worsening...</p>	<p>4,000,000.000</p>

Bayer Agrees to \$14 Million Settlement Over Medicaid Pricing	<p>class action lawsuit was brought against OSI Pharmaceuticals Inc., over its lung-cancer drug, Tarceva. The class action was filed in December 2004, accusing OSI of making false and misleading statements about Tarceva's potential to increase survival from lung cancer.</p> <p>Hawai'i Attorney General Mark Bennett said the state will use its \$165,000 share to reimburse Hawai'i consumers and state agencies for their purchases of the drug Cardizem CD, made by Aventis.</p>	2001	14,000,000.000
Hawai'i to get \$165,000 from drug settlement	<p>Merck settled the very first nominal pricing fraud case in which the company was accused of taking kickback and violating Medicaid best price regulations for Vioxx (an arthritis drug), Zocor (a cholesterol drug), Pepcid (an acid-reflux drug), Cozaar (a hypertensive medication), Fosamax (a bone loss drug) Maxalt (a migraine medication) and Singulair (an asthma medication).</p>	2003	165,000,000.000
Merck - \$650,000 under the False Claims Act			650,000.000

Serono-- \$567,000,000 under the False Claims Act

In October of 2005, Serono agreed to pay \$704 million to settle a fraud case involving Serostim, a human growth hormone product used to fight AIDS-related wasting. The charges involved kickbacks to doctors for prescribing Serostim, kickbacks to specialist pharmacies for recommending Serostim, illegal off-label marketing of the drug, and non-FDA approved diagnosis equipment designed to spur more Serostim prescriptions. Serostim cost as much as \$20,000 for a three-month regime. Of the total \$704 million settlement, \$567 million is earmarked to settle federal and state civil claims (\$305 million federal), with \$136.9 million paid as a related criminal fine.

2005

567,000,000.000

TAP [Taketa-Abbott Pharmaceutical] Pharmaceutical Products Inc. -- \$875,000,000 under the False Claims Act

In October 2001, TAP Pharmaceutical Products Inc. agreed to pay \$875 million to resolve criminal charges and civil liabilities in connection with fraudulent drug pricing and marketing of Lupron, a drug sold for the treatment of prostate cancer. Of this amount, \$559,483,560 was recovered under the False Claims Act. In addition, TAP pled guilty to a conspiracy to violate the Prescription Drug Marketing Act and paid a \$290 million criminal fine, the largest criminal fine ever in a health care fraud prosecution. Under the Lupron scheme, TAP gave doctors kickbacks by providing free samples with the knowledge that the physicians would bill Medicare and Medicaid \$500 per dose. At the time the Lupron fraud was discovered, Lupron accounted for 10% of the money spent on prescription drugs under Medicare Part-A. As part of the settlement, TAP entered into what prosecutors called a "sweeping" corporate integrity agreement.

2001

875,000,000.000

Abbott Labs-- \$400,000,000 under
the False Claims Act

In July of 2003, a unit of Abbott Laboratories, Inc. pled guilty to obstructing a criminal investigation and defrauding the Medicare and Medicaid programs and agreed to pay \$400 million to resolve civil claims. In addition, the subsidiary of Abbott Labs, CG Nutritionals, Inc., agreed to a criminal fine of \$200 million. The Abbott/CG Nutritionals scam involved the sale of enteral products which pump special foods into the stomachs and digestive systems of patients who, because of disease or some other disorder, are not able to ingest meals in a normal manner.

2003

400,000,000.000

Fresenius Medical Care of North America (National Medical Care) -- \$385,000,000 under the False Claims Act	<p>In January of 2000, Fresenius Medical Care of North America, the world's largest provider of kidney dialysis products and services, agreed to pay the United States \$486 million to resolve a sweeping investigation of health care fraud at National Medical Care, Inc. (NMC), a kidney dialysis subsidiary owned by Fresenius. Of this amount, \$385,000,00 was recovered under the False Claims Act. Three NMC subsidiaries also pled guilty to three separate conspiracies and were levied fines of \$101 million. Fresenius has also entered into a corporate integrity agreement with the U.S. Department of Health and Human Services. The Fresenius/NMC scam involved fraudulent and fictitious blood testing claims by LifeChem, Inc., NMC's clinical blood testing laboratory, kickbacks to dialysis facilities to obtain blood testing contracts for LifeChem, and fraudulent claims submitted to Medicare for intradialytic parenteral nutrition (IDPN), a nutritional therapy provided to patients during their dialysis treatments.</p>	2000	385,000,000.000
Cephalon - \$375,000,000 under the False Claims Act	<p>In September of 2008, Cephalon settled an off-label marketing case in which the company was accused of marketing the narcotic lollipop Actiq ("fentanyl citrate") as well as Gabitril (an epilepsy medication) and Provigil (a narcolepsy medication). An additional sum of \$50 million was paid to settle criminal charges in this case.</p>	2008	375,000,000.000

<p>Bristol Myers Squib -- \$515,000,000 under the False Claims Act</p>	<p>Bristol-Myers Squibb agreed to pay \$515 million to settle allegations brought in seven qui tam cases (six in Boston and one in Florida) involved pricing and promotional activities (including kickbacks to doctors) for more than 50 drugs, including 13 drugs with a combined 2007 sales of \$10.7 billion - - a total of 69 percent of Bristol-Myers' 2007 pharmaceutical revenue. Drugs included in this settlement include the blood thinner Plavix, antipsychotic Abilify, the cholesterol treatment Pravachol, the cancer therapy Taxol, and the antidepressant, Serzone. Of the \$515 million, approximately \$328 million will be paid under the Federal False Claims Act, with the state's getting a total of \$187 million</p>	<p>515,000,000.000</p>
<p>SmithKline Beecham Clinical Laboratories Inc. doing business as GlaxoSmith Kline -- \$325,000,000 under the False Claims Act</p>	<p>In March of 1997, SmithKline Beecham Clinical Laboratories Inc. (SBCL) was ordered to pay \$325 million for filing of false claims relating to laboratory tests paid for in whole or in part by the federal government. SmithKline Beecham Clinical Laboratories also agreed to adopt a corporate compliance agreement. The multiple scams involved adding on laboratory tests not requested by doctors and which were not medically necessary, billing for lab tests that were not actually performed, giving kickbacks to doctors in order to get their business, and billing Medicare for dialysis testing already paid for by kidney dialysis centers.</p>	<p>1997 325,000,000.000</p>

HealthSouth -- \$325,000,000 under the False Claims Act	<p>In December of 2004, HealthSouth Corporation, the nation's largest provider of rehabilitative medicine services, agreed to pay the United States \$325 million to settle allegations that the company systematically defrauded Medicare and other federal healthcare programs. Said Assistant Attorney General Peter Keisler, "HealthSouth's fraud on Medicare was driven both by longstanding business practices in its outpatient physical therapy business and improprieties in its inpatient rehabilitation business."</p>	1997	325,000,000.000
National Medical Enterprises -- \$324,200,000 under the False Claims Act	<p>NME agreed to pay \$379 million in criminal fines, civil damages, and penalties for kickbacks and fraud at NME psychiatric and substance abuse hospitals in more than 30 states. Of this amount, \$33 million will be paid in criminal fines. After this settlement, NME renamed itself "Tenet". See #1 at top of this list.</p>		324,000,000.000
Gambro Healthcare -- \$310,000,000 under the False Claims Act	<p>In December 2004, Gambro Healthcare agreed to pay \$310.5 million to resolve civil liabilities stemming from alleged kickbacks paid to physicians, false statements made to procure payment for unnecessary tests and services, and payments made to Gambro Supply, a sham durable medical equipment company. The settlement also requires Gambro to allocate \$15 million to resolve potential liability with various state Medicaid programs. Gambro Healthcare has also entered into a comprehensive Corporate Integrity Agreement. The Gambro Supply Corporation, a wholly-owned subsidiary of Gambro Healthcare, has also agreed to plead guilty to criminal felony charges; admit to execution of a healthcare fraud scheme; pay a \$25 million fine; and be permanently excluded from the Medicare program.</p>	2004	310,000,000.000

Schering-Plough-- \$292,969,482
under the False Claims Act

In July 2004, Schering-Plough, a major pharmaceutical manufacturer, agreed to plead guilty to fraud in the pricing of Claritin sold to the Medicaid program. The settlement agreement included a criminal fine of \$52.5 million, \$117 million to settle state claims, and nearly \$176 million to settle federal False Claims Act claims

2004

293,000,000.000

AstraZeneca Pharmaceuticals --
\$266,127,844 under the False Claims
Act

In June 2003, AstraZeneca Pharmaceuticals LP, a major pharmaceutical manufacturer, pled guilty to health care fraud and agreed to pay \$355,000,000 to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug sold for the treatment of prostate cancer. Of this amount, \$266,127,844 was recovered under the False Claims Act, and the remainder was levied as criminal fines. AstraZeneca pled guilty to giving doctors kickbacks by providing free drug samples knowing that the doctors would then turn around and bill Medicare and Medicaid hundreds of dollars per sample.

266,000,000.000

Bayer Corporation -- \$257,200,000
under the False Claims Act

In April 2003, Bayer Corp. paid \$257,200,000 to settle Medicaid fraud charges involving a "lick and stick" scheme in which Bayer sold re-labeled products to an HMO at deeply discounted prices, and then concealed this price discount in order to avoid paying additional rebates to the government. \$143 million of the Bayer settlement went to resolve a whistleblower's allegations that Bayer defrauded the Medicaid and Public Health Service programs by relabeling products sold to a health maintenance organization at deeply discounted rates and then concealing the discounts to avoid paying rebates, in violation of the Medicaid Rebate program. In addition, Bayer paid \$108 million to reimburse state Medicaid programs for the same conduct. An additional \$5.5 million criminal fine was also levied.

2003

257,000,000.000

<p>First American Health Care of Georgia -- \$225,000,000 under the False Claims Act</p>	<p>organization and its purchaser agreed to reimburse the federal government \$255 million for overbilling and making fraudulent Medicare claims. Under the agreement, First American Health Care of Georgia, Inc., the nation's largest home health care provider, and its new owner, Integrated Health Services, Inc, agreed to reimburse the federal government for money stolen from Medicare through fraudulent billing practices. The alleged fraud was that First American billed Medicare for costs unrelated to the care of patients in their homes, including the personal expenses of First American's senior management, as well as for the company's marketing and lobbying expenses. In a related criminal action, the company's two major principals, Jack and Margie Mills, were found guilty of defrauding Medicare, and were sentenced to prison terms of 90 months and 32 months respectively for their participation in the fraud. An Epilogue: IHS never paid the Federal Government under the terms of the settlement, and IHS itself filed for bankruptcy in February of 2000. The bankruptcy courts later collected 7.5 cents on the dollar, or \$19.1 million of the</p>	<p>1996</p>	<p>225,000,000.000</p>
<p>Laboratory Corporation of America -- \$182,000,000 under the False Claims Act</p>	<p>In November 1996, Laboratory Corporation of America Holdings (LabCorp), agreed to pay \$182 million to resolve charges that it submitted false claims for medically unnecessary laboratory tests to federal and state health care programs. The fraud involved bundled lab tests that were billed to Medicare as free-standing tests, resulting in an eight-fold increase in charges to Medicare.</p>	<p>1996</p>	<p>182,000,000.000</p>

Medicaid Fraud Busts Net More Than \$20 Million In 07, Says North Carolina AG Cooper	December 17, 2007 -- Raleigh: North Carolina's Medicaid fraud investigators recovered more than \$20 million and investigated dozens of cases of fraud and patient abuse in 2007, North Carolina Attorney General Roy Cooper said today.	2007	20,000,000.000
\$634 Million FCA Settlement for OxyContin	Purdue Frederick Co. and three of its executives have pled guilty to misbranding prescription painkiller OxyContin and will pay more than \$634.5 million, including a \$276 million criminal fine, \$160 under federal and state false claims acts, and \$130 million to settle private civil claims.	2007	634,000,000.000
Quest Reserves \$241 Million	Quest Diagnostics has increased its litigation reserves to \$241 million, noting that this amount "represents the minimum expected probable loss" due to False Claims Act litigation related to the government investigation of NID, a test-kit manufacturing subsidiary closed in 2006. Settlement talks with the U.S. Government are ongoing.		241,000,000.000
\$215 Million Alabama Jury Award Sends Message on Average Wholesale Price Fraud	AstraZeneca was hit with a \$215 million judgment in Alabama over Medicaid drug pricing fraud. The jury said AstraZeneca must pay \$40 million in compensatory damages and \$175 million in punitive damages for alleged false and misleading reporting of drug prices reimbursed by the Alabama State Medicaid Agency. Remember, this is just one drug company in one state. If we scale up the compensatory award alone, based on population, AstraZeneca seems to face a potential liability of \$2.4 billion for Average Wholesale Price and Medicaid Best Price violations. AstraZeneca is just one of more than 75 drug companies in line to face similar charges in Alabama.		215,000,000.000

Alabama Jury Returns \$78.4 Million Judgment Against Drug Manufacturer	<p>against the drug manufacturer Sandoz, a subsidiary of Novartis. The Alabama lawsuit was one of more than 70 lawsuits that have been brought on behalf of the state of Alabama against various drug manufacturers. The Alabama lawsuits center around Average Wholesale Prices (AVP) that drug manufacturers were posting that were much higher than the prices doctors and pharmacists were actually paying for the drugs. Essentially, the state of Alabama is claiming that these drug manufacturers were committing a fraud upon Alabama's Medicaid program by having the state pay an average wholesale price for a drug that was actually being sold at a much cheaper rate.</p>	2009	78,000,000.000
Pfizer Loses \$38 Million Trade Secret Jury Verdict in California - Punitive Damages Phase Still to Come	<p>A Santa Clara County jury has ordered drugmaker Pfizer to pay \$38 million in compensatory damages to a leading medical research nonprofit for stealing trade secrets to develop a pain relief drug. The Superior Court jury reached the verdict Monday in a 2004 lawsuit filed against Pfizer...</p>	2008	38,000,000.000
MedQuist Announces Entry of Final Judgment Approving Settlement and Dismissing Medical Transcriptionist Class Action	<p>As part of the settlement, the Company also agreed to pay \$1.5 million, approximately \$1.1 million of which will be given to the Association for Healthcare Documentation Integrity (AHDI) to fund programs for the general benefit of medical transcriptionists and the medical transcription industry.</p>	2009	1,500,000.000

<p>AMA Claims Victory With Record Breaking Settlement in Case Against Insurer</p>	<p>The American Medical Association (AMA), along with the Medical Society of the State of New York and the Missouri State Medical Association, claims victory with the settlement agreement reached today in the lawsuit against United Health Group. Enhanced Coverage Linking United Health Group. - The \$350 million settlement marks the largest monetary settlement of a class action lawsuit against a single health insurer in the U.S (see also American Medical Association).</p>	<p>2009</p>	<p>350,000,000.000</p>
<p>GLAXOSMITHKLINE - Civil settlement reached on Zofran and Kytril</p>	<p>GlaxoSmithKline announced that it has reached a civil settlement with the U.S. Department of Justice, the U.S. Attorney's Office for the District of Massachusetts, and the Office of the Inspector General of the U.S. Department of Health & Human Services to resolve the federal government's "average wholesale price" (AWP) investigation concerning Zofran and Kytril, drugs used to treat nausea associated with chemotherapy. The company has agreed to pay the government a civil settlement of \$149 million plus certain interest. The total amount of the settlement is covered by GSK's existing legal reserve.</p>	<p>2005</p>	<p>149,000,000.000</p>

Airborne, Inc., Reaches Agreement With the Federal Trade Commission Over Older Advertising and Labeling of Products	The enhanced settlement fund of up to \$30 million (\$23.5 million for the class action settlement and \$6.5 million for the recent FTC settlement) will be divided among consumers who joined the class action and filed for refunds; the plaintiff; his attorneys, who include private practitioners in California; and the Center for Science in the Public Interest (CSPI) in Washington, D.C. A large share of the settlement will be distributed to class action attorneys. The claims administrator will approve and pay individual claims by October 15, 2008.	2008	30,000,000.000
Zimmer Announces Settlement of Federal Investigation	Zimmer Holdings, Inc. announced that it has settled with the U.S. Attorney's Office in New Jersey an ongoing federal investigation into its financial relationships with consulting orthopaedic surgeons. Under the terms of the settlement, Zimmer entered into a Deferred Prosecution Agreement, will pay a civil settlement amount of \$169.5 million and will be subject to oversight by a federal monitor appointed by the U.S. Department of Justice for 18 months.	2007	170,000,000.000

EpiCept settles Maxim securities litigation	<p>Enhanced Coverage LinkingEpiCept Corporation - (EPCT) announced the settlement of a derivative securities lawsuit filed in October 2004 by a shareholder of Maxim Pharmaceuticals Enhanced Coverage LinkingPharmaceuticals -Search using: The terms of the settlement call for EpiCept to pay \$50,000 in EpiCept common stock to cover the plaintiff's legal expenses. The settlement is subject to customary conditions such as the execution of settlement documents, the final court approval of the settlement and dismissal of the Putnam claims with prejudice.</p>	2006	50,000.000
Tenet reaches partial settlement with IRS, expects to make \$80 million payment in Q4 2006	<p>Tenet Healthcare Corporation Enhanced Coverage LinkingTenet Healthcare Corporation -Search using: Company Dossier Company Profile News, Most Recent 60 Days (THC) announced that it has reached a settlement with the Internal Revenue Service (IRS) to resolve certain disputed issues in connection with the audit of its tax returns for the fiscal years 1995, 1996 and 1997.</p>	2006	80,000,000.000
<p>Attorney General Corbett Announces \$36.7 Million Multi-State Settlement With CVS/Caremark Enhanced Coverage LinkingCVS/Caremark - Search using: Company Profile News, Most Recent 60 Days in National Dosage-Switching Investigation</p>	<p>Corbett said that Pennsylvania will receive \$495,628 from CVS/Caremark as the result of this settlement. The payment will be used to reimburse the PA Medicaid program for higher prescription payments that were generated by the switch from ranitidine tablets to capsules.</p>	2008	36,700,000.000

Dey, L.P. reaches settlement with State of Ohio on pricing litigation	<p>John Kling, senior vice president of legal affairs at DEY, stated, "We are pleased that this settlement achieves a resolution to the pricing litigation brought by the State of Ohio. The net amount of cash paid to the State of Ohio, after legal fees and the Federal government's share of the settlement, is \$952,925. In addition, Dey will donate respiratory pharmaceuticals</p> <p>Medtronic has agreed to pay the United States \$75 million to settle allegations that it caused the submission of false claims to Medicare, the Justice Department announced.</p>	2006	952,000,000.000
Medtronic		2008	75,000,000.000
Stryker Corporation	<p>Kalamazoo, Michigan-based Stryker Corporation Enhanced Coverage Linking Stryker Corporation have agreed to pay the United States \$16.6 million to settle allegations that Physiotherapy submitted false claims to Medicare and other federal health care programs, the Justice Department announced (see also Medicare and Medicaid). "Submitting false claims to our nation's health care programs is tantamount to stealing from the American taxpayer," said Peter D. Keisler, Assistant Attorney General for the Civil Division. "Today's settlement sends a strong signal that the government aggressively pursues those who engage in such conduct and makes them pay a steep price for their misdeeds."</p>	2007	16,600,000.000

<p>Repligen Announces Settlement with ImClone In Erbitux Lawsuit</p>	<p>Repligen Corporation) announced it has reached a settlement with ImClone Systems, Incorporated Enhanced Coverage LinkingImClone Systems, in the lawsuit against ImClone for infringement of U.S. Patent No. 4,663,281 based on ImClone's manufacture and sale of Erbitux(R). The settlement provides for ImClone to make a payment of \$65 million to co-plaintiffs Repligen and The Massachusetts Institute of Technology Enhanced Coverage LinkingMassachusetts Institute of Technology and will result in net proceeds to Repligen of approximately \$40 million after payment of obligations to MIT and legal expenses.</p>	<p>2007</p>	<p>65,000,000.000</p>
<p>Medtronic Resolves Marquis Defibrillator Lawsuits</p>	<p>Under terms of the settlement, Medtronic has agreed to settle 2,682 cases for \$95.6 million plus \$18.5 million in attorneys' fees. The amended settlement expands a prior agreement obtained in July 2007, which had provided for a recovery of \$195 million to settle over 5,600 claims. After additional injured patients stepped forward, the agreement was amended to provide up to \$240 million in compensation. The successful settlement mediation sessions were conducted before U.S. Magistrate Judge Arthur J. Boylan in Minneapolis over a 15-month period.</p>	<p>2008</p>	<p>114,100,000.000</p>
<p>Plaintiffs Obtain \$240 Million Amended Settlement In Guidant Defibrillators Products Liability Litigation</p>	<p>Charles S. Zimmerman</p>	<p>2007</p>	<p>240,000,000.000</p>

Synergetics Announces Settlement of Patent Litigation	<p>The parties have entered into a Settlement Agreement and a Manufacture and Supply Agreement to resolve both lawsuits and all claims between the parties. The terms of these agreements require the dismissal of all pending legal actions between the parties, a cross licensing of various patents between the two companies, the payment of \$2.5 million by Synergetics to Iridex on April 16, 2007 and \$800,000 annually over the next five years. Under the Manufacture and Supply Agreement, Synergetics obtained the right to manufacture and supply various laser disposables, which could result in approximately \$3.0 million in revenue for Synergetics over the next five years</p>	2007	3,000,000.000
<p>Novo Nordisk Agrees To Pay \$9 Million Fine in Connection With Payment of \$1.4 Million in Kickbacks Through the United Nations Oil-for-Food Program</p>	<p>Novo Nordisk A/S (Novo), a Danish corporation based in Bagsvaerd, Denmark, has agreed to pay a \$9 million penalty for illegal kickbacks paid to the former Iraqi government, Assistant Attorney General Lanny A. Breuer of the Criminal Division announced. Novo agreed to pay the fine as part of a deferred prosecution agreement with the Department. The matter is part of the Justice Department's ongoing investigation into the U.N. Oil-for-Food program (see also U.S. Department of Justice).</p>	2009	1,400,000.000

Ligand announces agreements to settle securities class action and derivative lawsuits	Under the agreements, in exchange for a release of all claims, the company will pay a total of \$12.15 million in cash. The settlement amounts and a portion of the company's total legal expenses will be funded by the company's insurance carrier while the remainder of the company's legal fees incurred will be paid by the company. As part of the settlement of the state derivative action, the company has agreed to adopt certain corporate governance enhancements.	2006	12,100,000.000
Advanced Medical Optics Enhanced Coverage LinkingAdvanced Medical Optics -Search using: Company Dossier News, Most Recent 60 Days Company Profile announces settlement with Alcon of patent infringement suits	Under the agreement, which has an effective date of June 30, 2006, Alcon will pay AMO a lump sum of \$121 million. The parties agree to dismiss all existing patent litigation and not to sue on the patents at issue, including the use of multiple viscoelastics in one surgical procedure. In addition, each company is granted a license to the patents covering its existing phacoemulsification equipment features, which allows them to market their current products without the threat of litigation	2006	121,000,000.000
Impax settles Solvay litigation	Issue: false advertising practices dating back to 1998 in connection with the marketing of 2 of the company's 10 Lipram pancreatic enzyme supplements as well as 2 discontinued pancreatic enzyme supplements. Under the settlement, IMPAX will pay \$23 million to the plaintiffs, of which \$12 million will be paid immediately from the company's cash reserves, which total approximately \$42 million currently. The balance will be paid over the next 6 years. Sales and gross profits from these two Lipram products were not material to IMPAX's results.	2006	23,000,000.000

Cynus announces settlement of Ortho-McNeil arbitration over sale of drug-delivery business	In the settlement, Ortho-McNeil has agreed to make a cash payment to Cygnus of \$4 million. The arbitration hearing had been scheduled to commence in early October 2005.	2005	4,000,000.000
Company announces settlement, license agreement with Georgetown	Digene will record a pretax charge of \$7.5 million in settlement expense in its 2005 fiscal fourth-quarter results.	2005	7,500,000.000
BRISTOL-MYERS SQUIBBE; Settlement awards \$11.3 million to U.S. government for Medicaid expenses	Resolving a massive lawsuit filed 4 years ago by the U.S. government, major breast implant manufacturers Bristol-Myers Squibb, Enhanced Coverage Linking Bristol-Myers Squibb, -Search using: Company Dossier News, Most Recent 60 Days Company Profile Baxter Healthcare Co., 3M, Union Carbide, and other parties have agreed to pay \$11.3 million to reimburse expenses paid out to women injured by silicone gel breast implants.	2004	11,300,000.000
Ceres group announces settlement of class action litigation	The company estimates these settlements will result in a charge in the third quarter ending September 30, 2004 of approximately \$2.1 million (after tax), or \$0.06 per diluted share. Although the final amount of the settlement payout may vary, the company believes that the ultimate payout will not materially exceed this amount.	2004	2,100,000.000

Kos obtains settlement for trademark infringement of Advicor	As part of this settlement, Andrx will pay Kos \$6 million and has agreed to cease using the Altacor trademark for any of its products to avoid further confusion between Andrx's cholesterol product, Altacor, and Kos' highly differentiated cholesterol product, Advicor.	2004	6,000,000.000
Hagens Berman: Pfizer Settles Lawsuits Over Prescription Pain Killers Bextra and Celebrex	Hagens Berman announced it reached an \$89 million settlement with Pfizer on behalf of purchasers of Celebrex and Bextra in a suit claiming the pharmaceutical giant launched misleading marketing campaigns for its drugs (see also Hagens Berman).	2008	89,000,000.000
Cardinal Health Resolves Controlled Substance License Suspensions	The administrative and civil settlement agreements also resolve all DEA claims related to the company's controls against the diversion of controlled substances. Without admitting any wrongdoing, Cardinal Health also agreed to pay a \$34 million settlement payment, an amount the company fully reserved during fiscal 2008. "Protecting the integrity of the pharmaceutical supply chain is a responsibility we take very seriously, and preventing prescription	2008	34,000,000.000

<p>People with flu shot twice as likely to get swine flu</p>	<p>(PRX) announced that its partner, Spectrum Pharmaceuticals, Inc. Enhanced Coverage Linking Spectrum Pharmaceuticals, Inc., has entered into a settlement agreement with GlaxoSmithKline (GSK Enhanced Coverage Linking GlaxoSmithKline) that resolves U.S. patent litigation related to GSK's Imitrex Injection, thereby eliminating the inherent uncertainty and costs of litigation. The confidential terms of the settlement, which remain subject to government review, permit Par to sell generic versions of certain sumatriptan injection products with an expected launch date during GSK's sumatriptan pediatric exclusivity period which begins on August 6, 2008, but with the launch occurring not later than November</p>	<p>2006</p>	<p>-</p>
<p>EpiCept settles Maxim securities litigation</p>	<p>EpiCept Corporation (EPCT) announced the settlement of a derivative securities lawsuit filed in October 2004 by a shareholder of Maxim Pharmaceuticals Enhanced Coverage Linking Pharmaceuticals. The terms of the settlement call for EpiCept to pay \$50,000 in EpiCept common stock to cover the plaintiff's legal expenses. The settlement is subject to customary conditions such as the execution of settlement documents, the final court approval of the settlement and dismissal of the Putnam claims with prejudice.</p>	<p>2006</p>	<p>50,000.000</p>

<p>Sanofi-aventis Enhanced Coverage Linking Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet</p>	<p>The agreement calls for payment of a civil settlement of \$182.82 million (plus interest) which includes \$172.6 million to the U.S. government to resolve all federal claims for civil damages and a \$10.22 million "opt-in" fund for states desiring to resolve any alleged Medicaid overpayment claims for Anzemet(R) relating to the same conduct. The total amount of the settlement is fully covered by existing reserves. The Group's U.S. pharmaceutical subsidiary has also entered into a five-year Corporate Integrity Agreement with the Office of the Inspector General of the Department of Health and Human Services.</p>	<p>2007</p>	<p>182,000,000.000</p>
<p>Pennsylvania Attorney General Corbett Recovers \$7.8 Million in Settlement Funds for State's Medicaid Program</p>	<p>Attorney General Tom Corbett announced that Pennsylvania has received \$7.8 million as part of a national settlement with the Schering-Plough over improper pricing and marketing practices for several of the company's prescription medications.</p>	<p>2007</p>	<p>7,800,000.000</p>
<p>Proposed Settlement Will Make Up to \$28 Million Available to Individuals Who Purchased and Companies That Reimbursed for Paxil CR®</p>	<p>If approved, the Proposed Settlement will provide up to \$28 million to settle the claims in the lawsuit. Some of this money will be paid to insurance companies and other entities that made reimbursements for (in whole or in part) Paxil CR(R) and some of this money will be paid to consumers who purchased or paid for (in whole or in part) Paxil CR(R). The recovery available to insurance companies and other Third-Party Payors ("TPPs") will be based on their number of covered lives as of December 31, 2004. Consumer class members' recovery will be based on the number of Paxil CR(R) tablets that they paid for or purchased, up to \$150, that were defective in that they were split before they were removed from the container in which they were purchased.</p>	<p>2009</p>	<p>28,000,000.000</p>

Caraco Pharmaceutical Laboratories,
Ltd.
Announces Settlement of Ethyol®
ANDA Patent Litigation

Caraco Pharmaceutical Laboratories, Ltd.
Enhanced Coverage Linking Caraco
Pharmaceutical Laboratories, Ltd.
announces that it has executed a settlement
agreement with MedImmune, stipulating the
dismissal of the lawsuits filed in the United
States District Court for the District of
Maryland regarding the submission of an
Abbreviated New Drug Application
(ANDA) for a generic version of Ethyol (see
also Generics). Under the settlement
agreement, MedImmune grants Caraco a
license to certain patents, permitting Caraco
to continue marketing a generic version of
Ethyol in the United States. The settlement
resolves the entirety of the litigations
between the parties.

The terms of the settlement are confidential.

2009

-

Ferro Announces Settlement of Litigation	<p>As a result of the settlement agreement and as part of Ferro's second quarter financial results, Ferro will record a \$6.25 million reserve for a \$5.5 million settlement payment to the direct purchasers and a \$750,000 settlement payment to PolyOne Corporation, which opted out of the class of direct purchasers and entered into a separate settlement agreement with Ferro. The settlement agreement with PolyOne Corporation did not require payment until Ferro entered into a settlement agreement with the class of direct purchasers. The impact of the reserve settlement is expected to lower net income per share for the second quarter, ended June 30, 2007, by approximately 10 cents. Previously, Ferro had indicated that it expected to earn approximately 16 to 21 cents per share in the quarter, including 4 cents for charges related to its manufacturing rationalization programs.</p>	2007	750,000.000
Ligand Pharmaceuticals and the Rockefeller University Enter Settlement Agreement and Mutual Release	<p>As part of the settlement, Ligand agreed to pay Rockefeller \$5 million upon entering into the Settlement Agreement, \$2 million in payments over the next two years, plus royalties derived from product sales including for TPO mimetic compounds licensed to GlaxoSmithKline (GSK Enhanced Coverage LinkingGlaxoSmithKline (GSK</p>	2009	5,000,000.000

<p>Synovics Pharmaceuticals Announces the Settlement of all Legal Proceedings with Nostrum Pharmaceuticals Inc., Dr. Nirmal Mulye and Anil Anand</p>	<p>Synovics Pharmaceuticals, Inc. Enhanced Coverage Linking Pharmaceuticals, Inc.(OTCBB:SYVC), a specialty pharmaceutical company, announced that on July 31, 2007, the Company together with its subsidiary Synovics Laboratories, Inc. ("Synovics Labs") settled its dispute with Nostrum Pharmaceuticals,Enhanced Coverage LinkingPharmaceuticals, -Search using: Biographies Plus News News, Most Recent 60 Days Inc. ("Nostrum"), Nirmal Mulye, Ph.D. ("Mulye") and Anil Anand.</p>	<p>2007</p>	<p>7,500,000.000</p>
<p>Otsuka to Pay More Than \$4 Million to Resolve Off-Label Marketing Allegations Involving Abilify</p>	<p>Otsuka American Pharmaceutical Inc., the U.S. subsidiary of Japanese pharmaceutical manufacturer Otsuka Pharmaceutical Co., Ltd., has agreed to pay more than \$4 million to resolve allegations that it marketed Abilify, an atypical antipsychotic drug, for "off- label" uses, the Justice Department announced (see also Pediatrics).</p>	<p>2008</p>	<p>4,000,000.000</p>
<p>Repligen Announces Settlement with Bristol-Myers Squibb Company Profile in Orencia(R) Lawsuit</p>	<p>on announced that it has reached a settlement with Bristol-Myers Squibb Enhanced in its lawsuit alleging infringement of U.S. Patent No. 6,685,941 ("the '941 patent"), based on Bristol-Myers SquibbEnhanced 's sale of Orencia(R) for the treatment of rheumatoid arthritis. The settlement provides for Bristol-Myers Squibb to make an initial payment of \$5,000,000 and to pay royalties on the U.S. net sales of Orencia for any clinical indication at a rate of 1.8% for the first \$500,000,000 of annual sales, 2.0% for the next \$500,000,000 of annual sales and 4% of U.S. annual sales in excess of \$1 billion for each year from January 1, 2008 until December 31, 2013.</p>	<p>2008</p>	<p>-</p>

Subsidiaries Reach \$34.7 Million Settlement with DOJ; Resolve Allegations of Improper Activities Prior to Acquisition by Pfizer	Pfizer announced that two subsidiaries of Pharmacia have reached separate settlements with the United States Department of Justice to address charges stemming from the off-label marketing of Genotropin -- a human growth hormone medicine -- and the inappropriate use of a vendor contract to increase the sales of other Pharmacia medicines. Both settlements cover activities that occurred at Pharmacia before that company was acquired by Pfizer in 2003. The subsidiaries have agreed to pay fines totaling \$34.7 million.	2007	34,700,000.000
Genzyme Announces Settlement of Lawsuit Concerning Consolidation of Tracking Stocks	Under the terms of the settlement, Genzyme will pay a total of \$64 million to a class of shareholders who held Genzyme Biosurgery E stock on May 8, 2003.	2007	64,000,000.000
Endocare, Inc., has reached an agreement with lead plaintiffs and their counsel in the securities class action lawsuit pending against the company and certain of its directors and former officers in the U.S. District Court for the Central District of California.	A settlement agreement has been executed and will be submitted to the court for its preliminary approval and for authorization to provide notice of its terms to class members.	2004	8,900,000.000
Enzo Biochem announces settlement agreement	Under the agreement, in exchange for a release of all claims, the company and the individuals will pay a total of \$8.95 million in cash. Enzo Biochem, Inc., (ENZ), a biotechnology company, announced that it, its wholly owned subsidiary Enzo Life Sciences, Inc., and Digene Corp. (DIGE) have entered into a settlement and license agreement, and joint stipulation and order of dismissal with prejudice related to litigation involving Enzo's U.S. Patent No. 6,221,581 (the '581 patent).The settlement involves minimum payments to Enzo of \$30.5 million .	2004	30,500,000.000

Dey, L.P. reaches settlement with State of Idaho on pricing litigation	"The net amount of cash paid to the State of Idaho, after legal fees, is \$1,072,700; the Federal government's share of the settlement will be paid out of this amount by the State of Idaho."	2006	1,000,000.000
Bristol-Myers Squibb Company	The Department of Justice announced that Bristol-Myers Squibb Company (BMS) has agreed to plead guilty and pay a \$1 million criminal fine for lying to the federal government about a patent deal involving a popular blood-thinning drug. The Department said that BMS's illegal actions threatened to reduce competition for the drug Plavix that could have reduced the cost of blood-thinning drugs sold to heart attack, stroke and other patients.	2007	1,000,000.000
Rite Aid Corporation and Subsidiaries Agree to Pay \$5 Million in Civil Penalties to Resolve Violations in Eight States of the Controlled Substances Act	In addition to the \$5 million penalty, Rite Aid and all of its subsidiaries agreed to a compliance plan with the U.S. Drug Enforcement Administration (DEA) to ensure compliance with all requirements of the CSA and applicable DEA regulations and to prevent diversion of controlled substances. The compliance plan also requires Rite Aid to implement a pseudoephedrine and ephedrine tracking system in each of its 4,915 stores that is designed to prevent the abuse of pseudoephedrine and ephedrine products, which are used to make methamphetamine.	2009	5,000,000.000

<p>Advanced Cell Technology Enhanced Coverage LinkingAdvanced Cell Technology announces settlement of patent interference action</p>	<p>Under the terms of the settlement agreement, Start agreed to pay ACT an initial payment of \$500,000 and milestone payments of up to \$750,000. Start, Geron, Exeter and Roslin each further agreed not to sue ACT or UMass under the involved Roslin patent applications. In exchange, ACT and UMass dismissed their appeals with prejudice, transferred control of related UMass patents and patent applications to Start in the non-human animal field, and ACT paid certain legal fees. Under the terms of the settlement agreement, ACT retained its rights under the UMass patents in the human field.</p>	2006	750,000.000
<p>Biosurgical-device company reports settlement of cases</p>	<p>CryoLife, Inc., (CRY), a biomaterials and biosurgical-device company, reported that on Monday, October 25, 2004, it agreed to a binding settlement of three general liability lawsuits pending in the Multnomah Circuit Court in Oregon.</p>	2009	15,200,000.000
<p>Advanced Magnetics Announces Settlement of Lawsuit with Cytogen Corporation</p>	<p>Under the terms of the settlement agreement, Advanced Magnetics will pay Cytogen a lump sum payment of \$4 million in cash and release to Cytogen the 50,000 shares of Cytogen common stock currently being held in escrow under the terms of the original license and marketing agreement.</p>	2007	-
<p>Depomed Enhanced Coverage Settles Patent Litigation Against IVAX</p>	<p>The parties have entered into a settlement and license agreement that provides for a one-time payment to Depomed of \$7.5 million, and a non-exclusive license to the asserted patents in favor of IVAX and Teva.</p>	2008	7,500,000.000

BROOKHILL-WILK 1, LLC: Intuitive Surgical settles pending litigation	Intuitive Surgical, Inc., (ISRG), a robotics company, has settled its pending litigation with Brookhill-Wilk 1, LLC. Under the terms of the settlement, Brookhill-Wilk will grant a perpetual, exclusive license and certain covenants to Intuitive in consideration of a one-time license fee in the amount of \$2.6 million.	2004	2,600,000.000
Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation	Emisphere Technologies, Inc. (NASDAQ:EMIS) has agreed to accept \$18 million from Eli Lilly and Company to settle the pending litigation between the two companies.	2007	18,000,000.000
Auriga Settles Lawsuit to Reduce Royalties Payable on Levall Product Line by Approximately \$10 Million	The new agreement reduces the initial period of time for which Auriga is obligated to make royalty payments at the rate of 50% of net sales, reducing it from the first year following the closing date of the license agreement to the date of December 31, 2006. Further, effective February 1, 2007, the royalty payment rate on all sales by Auriga is reduced to 25% of net sales until the aggregate royalty payments total \$10 million. Once the aggregate royalty payments total \$10 million, Auriga will not be required to make any further royalty payments to Athlon.	2007	10,000,000.000
MASIMO; Settlement of all existing patent litigation regarding pulse oximetry products announced	Masimo announced a settlement of all existing patent litigation with Nellcor, a division of Tyco Healthcare. Under the terms of the settlement, all pending patent litigation will be dismissed, and Nellcor has paid Masimo \$265 million for damages through January 31, 2006. In addition, Nellcor made an advance royalty payment of \$65 million related to sales of Nellcor's new products during the remainder of calendar 2006.	2006	330,000,000.000

GIFT AWARDS: Eli Lilly gives \$6 million to group that sued a year ago	<p>A medical research foundation that settled a \$100 million drug patent lawsuit against Eli Lilly and Co. a year ago found itself on the receiving end of a \$6 million gift from the drug maker April 6, 2004, with past harsh words replaced by mutual praise.</p> <p>The money to create two endowed faculty chairs in biomedical research is the largest gift in the Oklahoma Medical Research Foundation's 58-year history, said Adam Cohen, director of legal and public affairs.</p>	2004	6,000,000.000
OMRF, Eli Lilly reach settlement over Xigris	<p>OMRF alleged patent infringement, fraud, breach of contract and unjust enrichment against Lilly in a \$100 million suit. In the suit, OMRF alleged that Lilly had stopped paying for the license to use activated protein C.</p>	2003	100,000,000.000
Martek Announces Settlement of Class Action Lawsuit	<p>Martek Biosciences Corporation announced that it has entered into a tentative settlement of all claims in the securities class action litigation filed in the United States District Court for the District of Maryland alleging, among other things, violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934. The settlement will result in the dismissal of the claims against Martek and all other defendants, subject to final court approval (see also Martek Biosciences Corporation).</p>	2007	6,000,000.000

Pharmacia & Upjohn Company In	Pharmacia & Upjohn Company Inc. -- will plead guilty to a single count of offering to an outside vendor remuneration in the form of an award of a contract to manage a Genotropin patient assistance program as an inducement for recommending the purchase of Pharmacia medicines. The contract was awarded in 2000. The subsidiary, which has no operational role in Pfizer today, was assessed a fine of \$19.7 million and will be disqualified from participation in government healthcare programs.	2007	20,000,000.000
Pharmacia & Upjohn Company In	Pharmacia & Upjohn Company LLC -- has entered into a Deferred Prosecution Agreement with the Department of Justice (DOJ) that includes a fine of \$15 million to address the improper promotion of Genotropin, which Pfizer discovered and self-reported to the Department of Justice, the FDA and the Office of the Inspector General within the first month following completion of the Pharmacia acquisition. Under the agreement, no criminal charges will be filed against Pharmacia Enhanced Coverage LinkingPharmacia -Search using: News, Most Recent 60 Days Company Profile in return for compliance with the terms of the agreement.	2007	15,000,000.000
Cutera settles patent litigation with Palomar	Under the terms of the settlement, Cutera will pay Palomar for sales of its systems that contain Nd:YAG and/or ProWave770 handpieces for hair removal. A one-time estimated payment of \$22 million will be paid to Palomar for royalties due on past sales of those systems, accrued interest, penalties and reimbursement of Palomar's legal costs.	2006	22,000,000.000

A \$100,000 settlement was reached for the estate of a male who died after he was given HIV-contaminated blood products administered or manufactured by the defendants. The plaintiff contended that the defendants were negligent by failing to properly inspect the product and by failing to warn the decedent of the risks.
Biles, Estate of v. Alpha Therapeutic Corp.;

HIV Contamination Case Settles

1998

100,000.000

Bayer says it has entered into a settlement with “the vast majority” of plaintiffs in a decades-old piece of litigation brought by hemophiliacs who were infected with HIV-tainted blood transfusions in the 1980s.

The suit claimed that three companies, Alpha, Baxter and Bayer’s Cutter Biological unit:

... recruited and paid donors from high risk populations, including prisoners, intravenous drug users, and blood centers with predominantly homosexual donors, to obtain blood plasma used for the production of Factor VIII and IX.

Plaintiffs allege that these companies failed to exclude donors, as mandated by federal law, with a history of viral hepatitis. Such testing could have substantially reduced the likelihood of plasma containing HIV and/or HCV entering plasma pools.

It is not known how much the settlement is for. Bayer said in its Q2 disclosure:

Bayer and its three co-defendants have entered into an agreement with two U.S. law firms representing the vast majority of plaintiffs in the U.S. Federal Multidistrict Factor Concentrates litigation. The agreement is subject to conditions that must be satisfied before the settlement can be completed, including broad acceptance of,

<p>Attorney General of Maryland: Attorney General Gansler settles consumer protection claims against Express Scripts, Inc; Express Scripts to pay over \$9 million as part of settlement</p>	<p>Attorney General Douglas F Gansler announced today that his Consumer Protection Division, along with the offices of 28 other Attorneys General, has entered into a settlement with Express Scripts, Inc., one of the nation's largest pharmacy benefits management (PBM) companies. As part of the settlement, Express Scripts will pay \$9.3 million to the states and up to \$200,000 in reimbursement to patients who incurred expenses related to certain switches between cholesterol-controlling drugs.</p>	<p>2008</p>	<p>9,300,000.000</p>
<p>Mississippi shares in settlement over antibiotic drug</p>	<p>Mississippi has reached a settlement with GlaxoSmithKline Hood, in a statement, said the multistate settlement resolved claims that GSK delayed generic competition by fraudulently listing and prosecuting litigation that involved Augmentin, a drug that GSK manufactures and sells to fight many different types of bacteria in the body. Mississippi will receive \$103,411 from the \$3.5 million Augmentin settlement, he said.</p>	<p>2006</p>	<p>103,000,000.000</p>

West Virginia will receive part of a \$ 41.8 million multistate settlement with a pharmaceutical company accused of making false statements about its drug, Attorney General Darrell McGraw announced Wednesday.

Some 37 states were involved in the settlement with Knoll Pharmaceutical Co., which makes Synthroid, a synthetic thyroid hormone pill taken daily by more than eight million people.

West Virginia to receive part of \$ 41.8 million settlement

West Virginia will get \$ 771,500.

1999

42,000,000.000

Michigan will receive \$ 1.45 million as its part of a settlement with Knoll Pharmaceutical Co. of a deceptive and anticompetitive marketing lawsuit, Michigan's attorney general said Wednesday.

Attorney General Jennifer Granholm said 37 states reached a \$ 41.8 million settlement with the drug company and its parent company, BASF Corp., both of New Jersey, in the dispute over the marketing of Synthroid, a thyroid treatment drug

State to get \$ 1.45 million in settlement

1999

1,450,000.000

Drug company, state reach settlement in drug pricing lawsuit	<p>The state reaches a deal with one of 13 generic drug manufacturers sued for allegedly inflating drug prices. Attorney General Martha Coakley says Missouri-based ETHEX Corporation set higher prices for their drugs in reports submitted to national pricing services. The state's Medicaid program uses the reporting services to determine how much they will pay for drugs for Medicaid participants. Coakley says the inflated prices caused the Medicaid program to pay more than they should have. Under the settlement, ETHEX agrees to pay the state nearly \$575,000 over the next two years and to provide \$150,000 in free drugs.</p>	2007	725,000.000
19 drug companies settle class-action price gouging lawsuit	<p>Nineteen drug companies agreed Friday to pay \$ 176 million to settle a class-action lawsuit alleging they gouged the public for medicines sold through independent pharmacies.</p> <p>The settlement calls for the companies to provide \$ 148 million worth of brand-name drugs to 300 nonprofit medical clinics in the state that dispense drugs to the poor. "We view this to be an exceptional result," said plaintiffs' attorney Bill Bernstein. "The cost of auditing claims and distributing money would eat up so much of the benefit that we thought we could do so much public good by distributing through the public health community."</p>	1999	176,000.000

<p>DRUG SETTLEMENTS REAP \$11 MILLION STATE SUES COMPANIES, ACCUSING THEM OF INFLATING PRESCRIPTION PRICES</p>	<p>The money has come in relatively small amounts, but Wisconsin has picked up more than \$11 million in the past three years from settlements with pharmaceutical companies over alleged overpricing of prescription drugs and marketing abuses.</p>	<p>2006</p>	<p>11,000,000.000</p>
<p>April 16, 2003, Wednesday, BC cycle</p>	<p>The settlements stem from an array of lawsuits and investigations throughout the country into how pharmaceutical companies price prescription drugs, particularly drugs sold to Medicaid.</p>		
<p>Drugmakers agree to settlement on alleged Medicaid overcharges MARYLAND ATTORNEY GENERAL: Curran announces \$14 million settlement regarding the drug</p>	<p>"When these corporations violate the law, Wisconsin taxpayers lose money," said Attorney General Peg Lautenschlager.</p>	<p>2003</p>	<p>250,000,000.000</p>
	<p>Pharmaceutical companies Bayer AG and GlaxoSmithKline have agreed to pay record Medicaid fraud settlements to resolve allegations they overcharged the government insurance program for the poor. The settlement comes as prosecutors around the country clamp down on pricing and sales practices of drug makers.</p>		
	<p>German-based Bayer will pay the government more than \$250 million, and Glaxo will pay almost \$88 million for failing to give the Medicaid program the lowest price charged to any consumer, said U.S. Attorney Michael J. Sullivan.</p>	<p>2006</p>	<p>14,000,000.000</p>

Louisiana gets \$841,000; consumers get \$750,000 in settlement	<p>Louisiana consumers and state agencies are sharing in a nearly \$1.6 million settlement with a drug company that was accused of illegal price-fixing to hike the costs of two medications more than 2,500 percent. More than 3,700 Louisianians who bought the two generic anti-anxiety drugs made by Mylan Pharmaceutical began receiving checks in June from the settlement. They split \$750,000 based on the amount of the drugs they had purchased, Attorney General Richard Ieyoub said.</p>	2002	1,600,000.000
State gets \$1M in medical fraud deal	<p>Louisiana will receive \$1.05 million as part of a \$375 million national medical fraud settlement with pharmaceutical manufacturer Cephalon Inc.</p>	2009	1,000,000.000
Assistant Missouri AG lands big verdict against pharmaceutical giants	<p>In late October, a jury returned a \$7.3 million verdict for actual damages and \$100 million in punitive damages against three pharmaceutical giants: Warrick Pharmaceuticals, Schering Corp. and Schering-Plough Corp. Rather than appeal the decision, the companies eventually settled the case for \$31 million, a major victory for the state, consumer interests, Burlison and co-counsel Jan Adams from the state's Medicaid Fraud Control Unit.</p>	2008	31,000,000.000
Alabama settles suits against 5 drug companies	<p>The state of Alabama has settled Medicaid drug pricing lawsuits it filed against prescription drug manufacturer Bristol-Myers Squibb Enhanced Coverage Linking Bristol-Myers Squibb -Search using: News, Most Recent 60 Days Company Profile Company Dossier and four other companies, a lawyer representing the state confirmed Friday.</p>	2008	16,000,000.000

Court Upholds What Is Believed to
Be First Toxic Shock-Diaphragm
Verdict

The Arizona Court of Appeals on Tuesday upheld a \$1.5 million verdict in favor of a woman who claimed she suffered toxic shock syndrome caused by use of a diaphragm.

In a unanimous opinion, three justices of the state's middle-level appellate court said there was sufficient evidence presented to justify the Maricopa County Superior Court verdict against Ortho Pharmaceutical Corp., makers of the Ortho All-Flex diaphragm, which has been sold for more than 40 years.

1988

1,500,000.000

A United States judge has approved a \$242 million agreement to settle charges that seven companies fixed the prices of vitamins during a nine-year conspiracy and overcharged thousands of purchasers. The final settlement was far less, however, than the \$1.05 billion settlement the parties announced last November to settle claims from about 4,000 plaintiffs.

Plaintiffs' lawyers said last month that many of the largest companies, representing the bulk of damages, had pulled out of the deal to pursue claims on their own. A total of 224 companies representing 75 percent of the vitamins purchased have opted out, a plaintiffs' lawyer, Jonathan Schiller, said. They include big-name companies like Tyson Foods and Quaker Oats. United States District Court Judge Thomas Hogan said the remaining settlement was fair and reasonable.

Under the agreement, plaintiff companies will receive 18 percent to 20 percent of what they spent on vitamins during the time in question. They will also be entitled to additional payments if any of the opt-out companies reach larger settlements.

Settlement in Vitamin Case Is
Approved

The defendants are Roche Holding, Rhone-

2008

242,000,000.000

Norplant offers to settle side effect lawsuits	<p>The makers of the Norplant birth control device have agreed to settle lawsuits with at least 36,000 women who say the company downplayed the side effects of the contraceptive device, both sides confirmed Wednesday.</p> <p>American Home Products Corp. could end up paying more than \$ 50 million to end five years of litigation, The Dallas Morning News reported Thursday.</p>	1999	50,000,000.000
Record \$ 10 million accord on claim that drug impaired vision	<p>A 79-year-old Schaumburg man will receive \$ 10 million from a company that marketed and distributed a drug that allegedly impaired the man's vision. Kenneth A. Krutz -- a retired manufacturing facility manager -- agreed Tuesday to settle a lawsuit he brought against American Home Products Corp., and Cook County Circuit Judge James M. Varga certified the matter on Wednesday, plaintiff lawyers said.</p>	2002	10,000,000.000
5 Awarded \$150 Million In Diet-Drug Damages	<p>Five people who attributed health problems to the diet drug fen-phen were awarded \$150 million in actual damages today by a jury here.</p> <p>The jurors were still determining punitive damages. The maker of the diet drug, American Home Products, has denied wrongdoing and said it would appeal</p>	1999	150,000,000.000
Three men awarded \$170.4 million from Johnson & Johnson	<p>Three men claiming Johnson & Johnson suppressed marketing their invention to prevent it from competing with the pharmaceutical's pain-killing drugs won a \$170.4 million antitrust settlement -- the largest ever given to individuals.</p> <p>A U.S. District Court jury Thursday</p>	1981	170,000,000.000

	<p>Pfizer Inc. settled Friday with a Corpus Christi woman who had alleged in a Texas court that the diabetes drug Rezulin damaged her liver.</p> <p>About four hours earlier a jury had awarded 63-year-old Margarita Sanchez \$43 million in compensatory damages. The jurors were deliberating punitive damages when the lawyers announced a settlement. The amount was not disclosed.</p>		
Settlement reached in Rezulin suit		2001	43,000,000.000
Jury awards \$2.3M to ex-Easy Returns owners	<p>The former owners of a St. Charles pharmaceutical returns business sold after a federal Drug Enforcement Administration investigation won a \$2.3 million jury verdict against the buyer.</p>	2009	2,300,000.000
KC cancer patient wins \$2.2B vs. pharmacist	<p>Saying they wanted to "send a message out to the world," jurors in Jackson County awarded \$2.2 billion to a cancer patient who was given diluted chemotherapy drugs by pharmacist Robert Courtney.</p> <p>Georgia Hayes claimed in her pharmacist malpractice suit that the doses of chemotherapy she began receiving from Courtney's pharmacy in September 1999 worsened her ovarian cancer and affected her chance of survival.</p>	2002	2,200,000,000.000
ICN to Pay \$10 Million in Common Stock, \$4.5 Million Cash to Settle Suit	<p>ICN Pharmaceuticals Inc. said today it will pay \$10 million in common stock and \$4.5 million in cash to settle six remaining claims in a nearly 10-year-old class-action lawsuit against the company.</p>	1996	4,500,000.000

A Houston jury has awarded nearly \$13 million in damages to three women who claimed their silicone breast implants made them chronically ill without rupturing. The jury made the award Wednesday and was slated to reconvene Thursday to determine possible punitive damages in state District Judge Carolyn Marks Johnson's court.

With lawyer and court costs attached, the verdict is \$18.5 million.

Breast-implant case brings \$13 million award

1994

18,500,000.000

Award Of \$175,000 In Case Originally Involving 29 Women

A 4-month-long trial product liability trial involving the Dalkon Shield contraceptive device has ended with a \$175,000 jury award for the last of 30 original plaintiffs.

1984

175,000.000

Thousands of hemophiliacs who got AIDS from tainted blood may want to pass on \$ 100,000 settlement offers now that a jury has awarded \$ 2 million in one case.

More than 6,000 hemophiliacs with AIDS tentatively accepted the deal, which has been delayed because of a dispute over whether some of the money should be paid to the federal government as reimbursement for health benefits.

Drug company must pay \$ 2 million for AIDS-contaminated product

The jury agreed with the Barnes' lawyers that Bayer Corp.'s Cutter Laboratories division should have warned patients in the early 1980s that its product, derived from human plasma, could carry the virus that causes AIDS.

1997

2,000,000.000

Merrell Dow Pharmaceuticals Inc., the drug manufacturer, agreed last July to an out-of-court settlement, without admitting liability, to create the \$120-million fund and immediately put \$40 million into the fund to draw interest.

Merrell Dow Pharmaceuticals Inc.,

1985

120,000,000.000

federal court jury has awarded \$2.75 million to a registered nurse who said she underwent a hysterectomy as a result of injuries suffered from using the Dalkon Shield contraceptive device. Margaret Sharon Worsham, 37, testified that she had looked forward to having children and grandchildren until she suffered a ruptured ovarian abcess and peritonitis in 1978.

Nurse Wins \$2.75 Million From IUD
Maker

After a four-week trial, a federal jury on Wednesday awarded her \$1.75 million in compensatory damages and \$1 million in punitive damages from the A.H. Robins Co., which voluntarily withdrew the Dalkon Shield from the market in 1974.

1982

2,750,000.000

The holder of a patent for an instructional baseball pitching device reached a settlement in his patent infringement case against Dollar Tree Stores Inc. Enhanced Coverage Linking Dollar Tree Stores Inc. -Search using:
Company Profile
News, Most Recent 60 Days
Company Dossier
filed in U.S. District Court for the Western District of Missouri.

"We argued that the retailer could make a profit from selling other, unrelated products once a customer was in the store to buy this product," said plaintiff's attorney Kip Richards of Kansas City. Thus, he argued, the plaintiff's damages exceeded the retail price of the baseballs whose maker allegedly infringed the patent.

Dollar Tree settles patent infringement case

2007

375,000.000

Brentwood-based KV Pharmaceutical is entitled to more than \$3 million from officers and directors who backdated stock options, according to a settlement approved Sept. 2 by U.S. District Judge Henry E. Autrey.

The lawsuit, filed by two plaintiffs on behalf of KV, alleged members of the company's board of directors and its officers unjustly enriched themselves through backdated stock options.

KV directors, officers will repay \$3 million

Lawyers for both sides urged Autrey to approve the settlement.

2008

3,000,000.000

Guidant to Pay \$425 Million in Settlement	A competitor of the Johnson & Johnson unit that makes cardiac stents has been ordered to pay damages of \$425 million to the health care giant after losing a patent dispute.	2003	425,000,000.000
Warner-Lambert	Makers of an anti-epilepsy drug Friday vowed to appeal a jury verdict awarding \$7 million to a 12-year-old Brooklyn girl who was born without eyeballs. A federal jury in Brooklyn ruled Thursday the makers of the drug Dilantin should have warned doctors not to prescribe the drug to women of child-bearing age because it could cause birth defects. Ellen Alboher, mother of Elyse Alboher, 12, was prescribed Dilantin in the year before her child was born, court papers show. Mrs. Alboher and her husband, Albert, sought \$15 million from the drug's makers, Warner-Lambert Co.'s Parke-Davis division.	1983	7,000,000.000
DRUG COMPANY OFFERS \$120 MILLION IN SETTLEMENT	Merrell Dow Pharmaceuticals agreed today to set up a \$120 million fund for hundreds of people who said their birth defects were caused by Bendectin, an anti-nausea drug taken by millions of women during pregnancy.	1984	120,000,000.000
Jury Awards \$ 42 Million to 'DES Daughters'	A jury awarded \$ 42.3 million to 11 women whose mothers took DES during pregnancy, including eight who were the first to go to trial claiming the drug caused reproductive problems not related to cancer. "It's a great victory for the women's health movement," said Sybil Shainwald, the lawyer who filed the lawsuits against three small drug companies.	1994	42,300,000.000

OSI Pharmaceuticals Enhanced Coverage Linking
 OSI Pharmaceuticals to pay \$500,000 to settle Tarceva lawsuit
 Pfizer To Pay Ky. \$5.4M For Medicaid Fraud

OSI's full preliminary settlement amount is \$9 million, but its insurer is covering the remainder of the amount. Terms of the settlement are subject to court approval.

2008	9,000,000.000
2002	5,400,000.000

87,625,891,400.000

1990-91 - About 130,000 claims settled by the trust, the Dalkon Shield Claims Resolution Facility in Richmond, Va., for \$ 5,500 each or less.

1990-91

715,000.000
87,626,606,400.000

Note: in citing 724 cases, we only barely scratched the surface of the total number of similar cases. For example, the 130,000 Dalkon Shield cases that were settled were included just to show that there were multiple other such examples.

100000